Mapping cellular diversity and lineage dynamics within the developing murine and human pancreas by Wong, Daniel
UCSF
UC San Francisco Electronic Theses and Dissertations
Title
Mapping cellular diversity and lineage dynamics within the developing murine and human 
pancreas
Permalink
https://escholarship.org/uc/item/6dt2f64r
Author
Wong, Daniel
Publication Date
2019
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
  
 
 
 
by 
 
 
 
 
Submitted in partial satisfaction of the requirements for degree of 
 
 
in 
 
 
 
in the 
 
GRADUATE DIVISION 
of the 
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
______________________________________________________________________________ 
       Chair 
 
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
Committee Members 
 
 #
!!%"&"#$((#'$$& !%"
%!"#
	
	



 (#$%
%$ 
"
 ii	
  
 iii	
Contributions 
Experiments and analyses for this dissertation were performed in the laboratory of Dr. 
Julie Sneddon at the University of California, San Francisco. Chapter 2 is work published as a 
manuscript in Nature Communications with myself and Dr. Lauren Byrnes as co-first authors. 
Co-authors of this published manuscript include Meena Subramaniam, Nathaniel Meyer, 
Caroline Gilchrist, Sarah Knox, Aaron Tward, Chun J. Ye, and Julie Sneddon. I wrote this 
manuscript with both Drs. Lauren Byrnes and Julie Sneddon. I performed all embryonic 
dissections, dissociations, and FACS-sorting of cells for single-cell RNA-sequencing. I also 
performed immunostaining and in situ hybridization for single-cell RNA-sequencing validation 
and genetic lineage tracing experiments. Dr. Lauren Byrnes prepared single-cell RNA-seq 
libraries and performed all bioinformatics analyses and qRT-PCR experiments on hESC-derived 
beta cells. Meena Subramaniam assisted with single-cell RNA-sequencing analysis. Nathaniel 
Meyer performed the directed differentiation of hESCs to beta cells. Caroline Gilchrist helped 
perform immunofluorescence on the Fev-Cre; Rosa26mTmG lineage traced pancreas. Human 
fetal pancreas was obtained from Dr. Sarah Knox. Drs. Aaron Tward and Chun J. Ye guided 
bioinformatics analyses. Chapter 3 contains work not yet published. Dr. Zhe Liu helped with 
human fetal tissue dissociation. Jacquelyn Bouza and Reed McMullen performed the directed 
differentiation of hESCs to beta cells. Theodore Roth guided all FEV knock-in construct designs 
and CRISPR/Cas9-mediated genomic editing. Gabriel Peixoto assisted in cloning of the FEV 
knock-in constructs and verification of clonality of all FEV knock-in and knock-out lines. I 
performed all remaining experiments and analyses in both chapters and wrote this dissertation.  
 
 
  
 iv	
Mapping cellular diversity and lineage dynamics within the developing murine and 
human pancreas 
Daniel Wong 
 
Abstract 
 The pancreas is a highly branched, compound gland whose development requires the 
diversification of many distinct cell lineages. Cells in exocrine compartment of the pancreas 
synthesize and secrete digestive enzymes required for food digestion, whereas cells in the 
endocrine compartment are responsible for maintaining glucose homeostasis through the 
production of various hormones. In this work, we sought to characterize the diversity of cell 
types present in the developing pancreas and chart their differentiation through multiple 
developmental stages. We start in Chapter 2 by identifying novel and known cell populations 
within the mesenchymal and epithelial compartments of the developing murine pancreas and 
mapping their developmental progress across multiple embryonic stages using single-cell RNA-
sequencing. We uncover significant cellular diversity within the mesenchymal compartment and 
utilize single-cell transcriptomic data to reconstruct lineage relationships among the developing 
pancreatic mesothelium and several previously uncharacterized mesenchymal populations in 
mouse pancreatic development. In the epithelial compartment, we uncover a novel endocrine 
progenitor stage defined by high expression of a transcription factor named Fev. Through 
genetic lineage tracing, we demonstrate that this Fev+ progenitor population is derived from 
Ngn3+ endocrine progenitors and that all hormone-expressing endocrine lineages of the murine 
pancreas transit through a Fev-expressing cell stage. Through in silico reconstruction of 
endocrine lineages, we identify candidate regulators of alpha and beta lineage allocation 
expressed during this novel Fev+ progenitor stage. In Chapter 3, we apply our findings of 
endocrine lineage dynamics in murine pancreatic development to that of human and uncover 
similar FEV-expressing endocrine progenitor populations in human pancreatic development. We 
 v	
map the transcriptional dynamics of human endocrine cell differentiation and identify novel 
candidate lineage regulators of human alpha and beta lineage allocation. We subsequently 
identify major disparities between the developmental paths that human endocrine cells follow in 
vivo versus in vitro during directed differentiation of hESCs towards the beta lineage. Our 
analysis reveals a lineage that may be mis-differentiated as hESC-derived progenitors 
differentiate towards a beta cell fate. Blocking the generation of this mis-differentiated lineage 
during in vitro beta cell differentiation represents a powerful solution in making in vitro beta cell 
differentiation more robust. Finally, given that FEV+ progenitors constitute a major stage in 
human endocrine cell differentiation, we have generated novel tools to study both the function of 
FEV and FEV-expressing cells in in vitro beta cell differentiation. Our work forms a foundation 
on which improvements to in vitro beta cell differentiation can be made to more closely reflect 
proper endocrine cell development in vivo, thereby increasing beta cell yield at the end of this 
process and generating beta cells that are functional.  
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Chapter 1 
Introduction 
  
 2	
Disease burden of diabetes mellitus 
 
 In 2017, there were an estimated 425 million people affected by diabetes mellitus in the 
world, representing a large global unmet need (The International Diabetes Federation). The two 
most prevalent types of diabetes mellitus are type 1 and type 2 diabetes (T1D and T2D). In both 
T1D and T2D, the function of the beta cell, the endocrine cell type housed within the pancreatic 
islets of Langerhans that responds to dynamic blood glucose levels by secreting insulin, is either 
lost or impaired. The hormone insulin is a critical signal that instructs many of the body’s cells to 
import glucose from the blood to be used for energy (Tokarz et al., 2018). Without insulin, this 
regulated process of systemic energy homeostasis goes awry. In T1D, beta cells are destroyed 
by the host immune system, removing the only endogenous source of insulin in the body (Yoon 
and Jun, 2005). In T2D, insulin resistance in peripheral tissues causes beta cells to upregulate 
their insulin production and secretion, leading to their eventual metabolic exhaustion and the 
inability to meet this increased demand for insulin throughout the body (Prentki and Nolan, 
2006). Fortunately, the production of insulin for human use was achieved in 1922 (Gilchrist et 
al., 1923). Although the administration of exogenous human insulin to patients with diabetes 
mellitus serves as an effective tool to manage this disease, patients with diabetes still develop 
life-threatening comorbidities, such as retinopathy, nephropathy, neuropathy, and 
macrovascular complications (Trikkalinou et al., 2017). This is because exogenous insulin 
administration only serves as a disease management tool and is not a curative treatment 
(Zheng et al., 2018). Additionally, even with exogenous insulin administration, patients with 
diabetes experience a diminished quality of life with the ongoing demands of diabetes 
management, including continually monitoring blood glucose levels, injecting insulin, abiding to 
a strict diet plan, carefully planning meals, and exercising (Huang et al., 2007). Thus, there is a 
significant need for new treatments that release patients with diabetes mellitus from 
dependence on exogenous insulin.   
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Therapeutic strategies for diabetes mellitus  
 
 Current strategies for insulin independence for patients with diabetes involve beta cell 
replacement, either in the form of solid pancreas or pancreatic islet transplantation (Sneddon et 
al., 2018). In both cases, pancreatic tissue comes from cadaveric donors, and thus, there is a 
limited supply of donor material that constrains these transplantation procedures from being 
made available to all patients with diabetes. Instead, solid pancreas or pancreatic islet 
transplantation is often performed as a last resort for patients with poorly controlled diabetes 
encompassing severe glycemic instability and worsening secondary complications such as renal 
failure (Giorgakis et al., 2018). The first case of insulin independence through solid pancreas 
transplantation was achieved in 1966 through transplantation of pancreatic tissue from a 
cadaveric donor into a 28-year-old recipient with T1D (Kelly et al., 1967). Successful pancreatic 
islet transplantation arrived in 2000 through what is now referred to as the Edmonton protocol, 
in which initial exogenous insulin independence was achieved in seven patients with T1D 
(Shapiro et al., 2000). Currently, about 50-70% of diabetic patients who undergo either islet 
transplantation or whole-pancreas transplantation achieve insulin independence at 5 years 
(Shapiro et al., 2016). Given that beta cell replacement in the form of both solid pancreas and 
islet transplantation has yielded favorable insulin independence outcomes for patients with 
diabetes, these procedures serve as proof-of-concept models in which replacement of beta cells 
with glucose-sensing, insulin-secreting capabilities is a clinically feasible strategy towards a 
therapeutic cure for patients with diabetes. However, the limited supply of whole pancreata and 
cadaveric islets for transplantation creates a large demand for a renewable source of 
transplantation material if beta cell replacement were to be achieved for all patients with 
diabetes. 
 Embryonic stem cells have the ability to differentiate into any cell type in our bodies and 
thus represent an attractive source of material to generate an unlimited supply of beta cells for 
cell replacement therapies for diabetic patients. Specifically, given that the beta cell is the cell 
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type that is missing or dysfunctional in diabetes, in vitro directed differentiation of pluripotent 
human embryonic stem cells into functional beta cells can address one major bottleneck in beta 
cell replacement strategies: the limited supply of beta cells for transplantation. One main 
challenge to this feat, however, is developing a robust directed differentiation program that 
generates glucose-sensing, insulin-secreting beta cells from human pluripotent stem cells 
whose function mimics that of beta cells in vivo. Current directed differentiation protocols for 
generating beta-like cells from pluripotent human embryonic stem cells (hESCs) have been 
developed by recapitulating many of the same developmental stages observed in pancreatic 
development that are required to generate beta cells in vivo (Pagliuca et al., 2014; Rezania et 
al., 2014; Russ et al., 2015). Thus, the development of these directed differentiation strategies 
for producing beta-like cells from hESCs has relied heavily on foundational knowledge of in vivo 
beta cell development. 
 Although generation of insulin-producing, beta-like cells from hESCs has been achieved, 
these directed differentiation strategies are not able to generate beta cells at high efficiencies or 
beta cells that maintain glucose-stimulated insulin secretion (GSIS) for more than 6 weeks 
(Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015; Veres et al., 2019). Overcoming 
these current challenges are paramount for generating pure batches of hESC-derived beta cells 
for transplantation into patients with diabetes for sustained exogenous insulin independence. 
Given that developmental biology serves as the best guide for the stereotyped development of 
specialized cell types in vivo, a more complete understanding of the proper developmental 
stages required to make a beta cell during pancreatic development may be needed to generate 
functional hESC-derived beta cells in vitro. Additionally, beta cell development occurs in 
constant interaction with other cellular compartments. Clearly annotating these cellular 
compartments and how they support proper beta cell development will be critical for 
constructing more robust directed differentiation platforms for generating hESC-derived beta 
cells. Therefore, additional studies on in vivo models of pancreatic development are needed to 
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continue refining our understanding of the intrinsic genetic programs and extrinsic cellular 
signals that are required for constructing a bona fide beta cell with proper function.  
 
Pancreatic organogenesis: Development of the epithelial compartment  
 
 The pancreatic epithelium forms a compound gland with two functionally distinct 
compartments housed within the same organ. The exocrine compartment is made up of two 
main cell lineages: acinar and ductal. Acinar cells produce digestive enzymes required for food 
breakdown, and duct cells shuttle these enzymes from the pancreas into the duodenum. The 
endocrine compartment, on the other hand, is organized into the islets of Langerhans in which 
cells synthesize and secrete hormones required for energy homeostasis and nutrient 
metabolism. In addition to the insulin-producing beta cell, which makes up approximately 60% of 
the adult islet, there are four other hormone-secreting endocrine cell types that comprise the 
islets of Langerhans in the human adult pancreas: the glucagon-producing alpha cell (30%), 
somatostatin-producing delta cell (~10%), ghrelin-producing epsilon cell (~1%), and pancreatic 
polypeptide-producing gamma cell (less than 5%) (Da Silva Xavier, 2018). More recently, a sixth 
endocrine lineage, referred to as the gastrin lineage, has been described in the murine 
embryonic pancreas (Suissa et al., 2013). The exocrine compartment comprises the majority of 
the pancreatic mass (~98%), whereas islets make up ~2%. The construction of this mature 
pancreatic organ with distinct epithelial compartments requires the intricate coordination of cell 
specification, proliferation, and differentiation during development. Extensive research has 
focused on more clearly defining these cell lineages and the transcriptional programs that 
govern pancreatic organogenesis, with the hope that this knowledge can be harnessed in a 
therapeutic capacity for pancreatic diseases such as diabetes (Pan and Wright, 2011). 
 Studies of vertebrate pancreatic organogenesis have laid much of the foundation of what 
we understand about how pancreatic development is accomplished. Specifically in mouse, 
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murine pancreatic organogenesis begins at embryonic day 9 (E9) and can be segmented into 
two distinct periods: a primary transition that occurs E9.0-E12.5 and a secondary transition that 
occurs from E12.5 to birth. At the start of the primary transition, Pancreatic And Duodenal 
Homeobox 1+ (Pdx1) pancreatic progenitor cells, from which all epithelial lineages of the 
pancreas are derived, become specified in the dorsal and ventral foregut endoderm (Gu et al., 
2003). Following specification, these Pdx1+ cells proliferate and evaginate from the foregut 
endoderm into the surrounding mesenchyme to form the dorsal and ventral pancreatic buds at 
E9.5 and E9.75, respectively, which will later fuse at approximately E11.5 due to duodenum 
rotation during embryogenesis (Pictet et al., 1972). These early pancreatic buds are comprised 
mainly of multipotent pancreatic progenitor cells (MPCs) along with early differentiated 
endocrine cells that express glucagon (Herrera, 2000). As these early pancreatic buds grow and 
evaginate during this primary transition, stratification of the epithelium leads to the formation of 
microlumens that will coalesce to form the tubular network reminiscent of the classic pancreatic 
branched morphology (Kesavan et al., 2009; Villasenor et al., 2010). Tubulogenesis and 
branching morphogenesis results in the spatial compartmentalization of Pdx1+ progenitors in a 
multipotent “tip” domain and bipotent “trunk” domain (Zhou et al., 2007). Tip cells are marked by 
expression of Carboxypeptidase A1 (Cpa1) and Pancreas Associated Transcription Factor 1a 
(Ptf1a) and serve as multipotent progenitors for the ductal, acinar, and endocrine cell lineages 
until E13.5, after which they lose their multipotency and become restricted to the acinar fate 
(Zhou et al., 2007). Trunk cells, on the other hand, are limited to ductal and endocrine lineages 
and are marked by expression of SRY-Box 9 (Sox9), NK6 Homeobox 1 (Nkx6.1), and HNF1 
Homeobox B (HNF1β) (Schaffer et al., 2010; Seymour et al., 2007; Solar et al., 2009). Thus, 
this period of development during the primary transition is responsible for expanding the 
pancreatic progenitor pool and structuring progenitor domains from which specialized pancreatic 
epithelial lineages arise.  
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 The secondary transition of murine pancreatic development is defined by extensive 
differentiation and lineage allocation into the three main epithelial lineages: acinar, ductal, and 
endocrine. Mutual inhibitory interactions between Ptf1a and Nkx6.1/Nkx6.2 transcription factors 
regulate lineage allocation of MPCs toward acinar versus ductal and endocrine lineages 
(Schaffer et al., 2010). Specifically, Ptf1a represses Nkx6.1/Nkx6.2 expression to promote 
acinar differentiation, whereas Nkx6.1/Nkx6.2 expression represses Ptf1a expression to 
promote ductal and endocrine fate restriction (Schaffer et al., 2010). Additionally, Notch-
regulated lateral inhibition is responsible for controlling the commitment towards an endocrine or 
ductal cell lineage in the developing pancreatic epithelium (Apelqvist et al., 1999; Shih et al., 
2012). Notch signaling promotes Sox9 expression, which is required for both duct and 
endocrine differentiation (Shih et al., 2012). Cell-autonomous decreases in Notch signaling 
permit expression of Neurogenin3 (Ngn3), a key transcription factor that demarcates endocrine 
progenitors that will give rise to the endocrine lineages of the pancreas, including alpha, beta, 
delta, epsilon, and gamma cells (Gu et al., 2002; Heller et al., 2005; Shih et al., 2012). Ngn3+ 
endocrine progenitors produce Notch ligands, signaling to neighboring cells to activate Hes1, 
which in return suppresses Ngn3 expression and endocrine fate commitment. Cells with low to 
moderate levels of Ngn3 fail to enter into the endocrine lineage and are directed to other 
pancreatic fates, including the ductal lineage in which transcription factors Hnf1β and 
Hepatocyte nuclear factor 6 (Hnf6) are required (Beucher et al., 2012b; Haumaitre et al., 2005; 
Wang et al., 2010a; Zhang et al., 2009). Thus, high Ngn3 expression is required for commitment 
to an endocrine cell fate (Beucher et al., 2012b; Wang et al., 2010a).   
 
Pancreatic organogenesis: Transcriptional control of endocrine cell development 
 
Given the importance of Ngn3 expression in endocrine differentiation, extensive work 
has focused on the dynamics of Ngn3 expression and the timing of differentiation of Ngn3+ 
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progenitors throughout pancreatic development. Expression of Ngn3 within a single cell is 
transient, and emergence of the Ngn3+ progenitor throughout the course of pancreatic 
development is biphasic, occurring in two main waves in mouse pancreatic development that 
encompass distinct stages of endocrine cell differentiation. The first wave of Ngn3 expression 
occurs between E9.5 and E11.0 and coincides with the primary transition of pancreatic 
development during which the first hormone-expressing endocrine cells are observed 
(Villasenor et al., 2008), although these early hormone-expressing cells do not persist in the 
adult islet (Herrera, 2000; Herrera et al., 1998). The second wave of Ngn3 expression begins at 
approximately E12.0, peaks between E13.5 and E14.5, and progressively tapers as gestation 
ends (Villasenor et al., 2008). This second wave of Ngn3 expression encompasses the 
secondary transition of pancreatic development and produces a large fraction of hormone-
expressing endocrine cells that will comprise the adult pancreas (Gu et al., 2002). Although the 
Ngn3+ progenitor population gives rise to the endocrine compartment of the pancreas, each 
individual Ngn3+ endocrine precursor has the potential to only give rise to one endocrine cell 
type (Desgraz and Herrera, 2009), given that Ngn3+ progenitors are post-mitotic (Miyatsuka et 
al., 2011). When Ngn3 expression is induced during defined timepoints in Pdx1+ progenitors 
within the pancreatic epithelium using an inducible Ngn3 expression model in a Ngn3 null 
mouse, distinct endocrine lineages arise as dictated by the timing of Ngn3 expression and are 
restricted to specific developmental time ranges, termed “competence windows” (Johansson et 
al., 2007). Ngn3+ cells that emerge at the start of pancreatic development at E9.5 differentiate 
almost exclusively into alpha cells, whereas Ngn3+ cells that arise starting at E10.5 have the 
potential to differentiate into beta and gamma lineages in addition to alpha (Johansson et al., 
2007). After E14.5, the competence to form alpha cells dramatically decreases, while delta cells 
begin to emerge (Johansson et al., 2007). Therefore, these waves of Ngn3 expression coupled 
with distinct endocrine lineage competence windows ensure proper endocrine cell differentiation 
throughout pancreatic development.  
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Coordinated with lineage allocation of Ngn3+ progenitors are the movement, 
rearrangement, and coalescence of differentiating endocrine progenitors to form clustered 
structures that will become the islets of Langerhans. Ngn3 regulates the epithelial to 
mesenchymal transition (EMT) gene, Snail2, which represses E-cadherin expression in 
endocrine progenitors (Gouzi et al., 2011). This Ngn3-enforced transcriptional program is 
thought to facilitate endocrine progenitor exit from the pancreatic ductal epithelium during 
endocrine differentiation in a process known as delamination (Gouzi et al., 2011). Following 
delamination and subsequent endocrine differentiation, newly formed endocrine cells have been 
visualized to migrate and cluster with one another within the developing pancreatic structure 
(Puri and Hebrok, 2007), suggesting that each individual islet is not clonally derived. However, 
instead of outright exit of single endocrine progenitors from the pancreatic epithelium, a more 
recent study has proposed a model in which endocrine progenitors aggregate into peninsular 
structures within the epithelium and bud off in a cohesive fashion to form the endocrine clusters 
that give rise to adult islets (Sharon et al., 2019a). This peninsular model also involves E-
cadherin downregulation, similar to E-cadherin suppression in a delamination model of 
endocrine development (Gouzi et al., 2011). It remains to be determined what function Ngn3 
serves in this new model of endocrine cluster formation during pancreatic development. 
Nevertheless, as endocrine progenitors differentiate into hormone-expressing lineages, they 
must also couple their differentiation to the collective clustering efforts with other proto-islet cells 
in order to ensure proper assembly of future mature islets. 
The duration of Ngn3 expression in a single endocrine progenitor is about 24 hours, and 
the timing between Ngn3 downregulation and onset of hormone expression is estimated to be 
10 hours (Beucher et al., 2012b). Despite this short duration of the Ngn3+ endocrine progenitor 
stage and the stages leading to acquisition of endocrine cell identity, there are several key 
transcriptional factors that are expressed during this period between transient Ngn3 expression 
and hormone expression and that are required for proper endocrine differentiation. These 
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transcriptional regulatory networks can be categorized into those required for proper 
development of all endocrine lineages and those responsible for lineage allocation into specific 
endocrine cell types. Transcription factors that fall into this first category include Neuronal 
Differentiation 1 (NeuroD1), Insulinoma-associated 1A-1 (Insm1), Regulatory factor X6 (Rfx6), 
and Islet1 (Isl1), all of which are transcriptional targets of Ngn3 (Du et al., 2009; Gierl et al., 
2006; Huang et al., 2000; Mellitzer et al., 2006; Naya et al., 1997; Smith et al., 2010; Soyer et 
al., 2010). NeuroD1 mutant mice exhibit reduced numbers of all endocrine cell types (Huang et 
al., 2000; Naya et al., 1997). Like NeuroD1 mutants, Insm1 and Rfx6 mutants also display are 
arrested at the endocrine progenitor stage and display reductions in specific endocrine lineages 
(Gierl et al., 2006; Mellitzer et al., 2006; Smith et al., 2010; Soyer et al., 2010). Isl1, on the other 
hand, is not required for the proper differentiation of endocrine lineages but instead is required 
for the proliferation and survival of differentiated endocrine cells after Ngn3 downregulation (Du 
et al., 2009).  
The second category of key transcriptional regulators expressed between initial Ngn3 
expression and the acquisition of endocrine identity encompasses those that drive endocrine 
lineage-specific allocation. Following Notch-mediated lateral inhibition that specifies precursors 
toward the endocrine lineage through upregulation of Ngn3, a mutual antagonistic relationship 
between Paired box 4 (Pax4) and Aristaless related homeobox (Arx) transcription factors, both 
of which are targets of Ngn3, further specifies endocrine progenitors toward a beta/delta or 
alpha/gamma lineage (Collombat et al., 2003; Sosa-Pineda et al., 1997). Arx is required for 
alpha cell differentiation and represses acquisition of beta and delta cell identity (Collombat et 
al., 2003). Pax4 functions as an antagonist to Arx and guides lineage allocation towards beta 
and delta lineage (Collombat et al., 2003; Sosa-Pineda et al., 1997). When Arx or Pax4 is 
forcibly expressed in differentiated beta or alpha cells, respectively, Arx-expressing beta cells 
convert to an alpha identity and Pax4-expressing alpha cells convert to a beta lineage, 
demonstrating that Arx and Pax4 are sufficient to drive alpha and beta lineage identities 
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(Collombat et al., 2007; 2009). Similar to Arx, Pax6 is required for alpha cell differentiation from 
endocrine precursors (St-Onge et al., 1997). Additional genetic regulators of beta lineage 
specification include Nkx6.1 and Nkx2.2. The loss of Nkx6.1 or Nkx2.2 blocks beta cell 
differentiation from endocrine precursors (Sander et al., 2000). Similar to Pax4, Nkx6.1 also 
exhibits a mutually antagonist relationship with Arx to promote beta cell lineage allocation and 
repress acquisition of alpha cell identity (Schaffer et al., 2013). Interestingly, Nkx2.2 mutants 
exhibit increased ghrelin-expressing epsilon differentiation at the expense of beta cell 
production, demonstrating that Nkx2.2 promotes specific lineage allocation by suppressing 
genetic drivers of other endocrine lineages (Prado et al., 2004). The coordinated activities of 
these transcription factors during endocrine cell development ensures proper allocation of the 
multiple endocrine lineages from a single pool of endocrine progenitors during pancreatic 
organogenesis. However, a more complete understanding of how these lineage-specific 
transcription factors become expressed in a seemingly homogenous pool of Ngn3+ progenitors 
and how their expression influences when lineage specification occurs is needed.  
In addition to the transcription factors expressed between Ngn3 expression and 
acquisition of endocrine identity, critical transcriptional regulation after endocrine precursor 
differentiation ensures proper maturation of endocrine cell types and maintenance of endocrine 
cell identity. The majority of studies have focused on the beta cell and its maturation into a 
glucose-responsive, insulin-secreting cell, given the application of this knowledge to 
understanding and treating diabetes. MAF BZIP Transcription Factor A (MafA) and MAF BZIP 
Transcription Factor B (MafB) are transcription factors that activate genes required for mature 
beta cell function, including insulin, Pdx1, Glut2, and Nkx6.1 (Artner et al., 2007; Hang and 
Stein, 2011; Zhao et al., 2005). During murine beta cell development in utero, MafB is 
expressed by newly differentiated, immature beta cells that lack GSIS capabilities (Nishimura et 
al., 2006). After initiation of MafB expression in beta cells, MafA becomes expressed (Matsuoka 
et al., 2004). Following birth, MafB becomes downregulated, while MafA expression persists in 
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postnatal and adult beta cells (Artner et al., 2010). Given that MafB is required for maintenance 
of key beta cell genes, MafB null mutants display reduced beta cell formation during 
embryogenesis (Nishimura et al., 2008). MafA, on the other hand, has no impact on beta cell 
formation, despite its expression during beta cell development in utero (Artner et al., 2007). 
Instead, MafA serves to maintain beta cell identity and promote beta cell function after the 
decline in MafB expression during early postnatal development (Wang et al., 2007). Thus, MafA 
serves as a critical regulator of beta cell maturity by activating genes associated with proper 
GSIS. 
 
Human pancreatic organogenesis 
 
Although there is extensive work on murine pancreatic development, human pancreatic 
development is much less systematically characterized. Human fetal development is largely 
divided into individual stages based on morphology and is measured in time post-conception 
(days post-conception (dpc) or weeks post-conception (wpc)) (O'Rahilly and Müller, 2010). 
Similar to that of mouse, human pancreatic development begins with demarcation of pancreatic-
specified endoderm by PDX1 expression at approximately 4wpc (Jennings et al., 2015). 
Multipotent progenitors in this PDX1+ region undergo a large expansion, generating a 
SOX9+/NKX6.1+ duct-like region reminiscent of the trunk domain in mouse pancreatic 
development and SOX9+/NKX6.1+/GATA4+ peripheral cells similar to mouse developmental tip 
cells (Jennings et al., 2015; 2013; Zhou et al., 2007). Unlike Ngn3 expression in mouse 
pancreatic development, only a single, continuous wave of transient NGN3 expression in human 
development starting at 8wpc has been observed, which initiates human endocrine cell 
development (Jennings et al., 2015; Sarkar et al., 2008). NGN3 expression peaks around 
12wpc and is not detected after 35wpc (Salisbury et al., 2014). A more complete understanding 
 13	
of the dynamics of critical transcription factors and their activities in human pancreatic 
development is direly needed.  
Human islet neogenesis and structure also differ from those in mouse. The appearance 
of human beta cell clusters is timed with the onset of NGN3 expression at 8wpc (Jennings et al., 
2013; Lyttle et al., 2008; Piper Hanley et al., 2010; Piper et al., 2004). Beta cell clusters are well 
vascularized by 10wpc, and aggregated islets are already composed of alpha, beta, delta, and 
gamma cells by 12-13wpc (Jennings et al., 2013; Piper et al., 2004). In mouse pancreatic 
development, preliminary islet formation occurs late in gestation and continues into postnatal 
development. As proper islet structure takes shape, human islets display a comingling of alpha 
and beta cells throughout their structure, whereas mouse islets adopt a core-mantle structure in 
which alpha cells are located at the periphery and beta cells largely comprise the islet core (Kim 
et al., 2009). Understanding these structural differences that arise during mouse and human 
islet neogenesis and their functional outcomes will be critical for optimizing current in vitro 
efforts that attempt to construct 3D islets from stem cell-derived sources.  
 
The role of the microenvironment in shaping pancreatic epithelial development  
 
 The epithelial compartment in the developing pancreas is in close association with the 
surrounding microenvironment, and these interactions have critical roles at defined times in 
pancreatic organogenesis for proper epithelial development. The earliest of such known 
interactions involves contact with various embryonic structures that orchestrate the process of 
development of both the dorsal and ventral pancreas, which later fuse to give rise to a singular 
solid organ (Pan and Wright, 2011). As early at E8, the notochord is in contact with the 
prospective dorsal pancreatic endoderm and is responsible for repressing Sonic Hedgehog 
(Shh) in the pancreatic endoderm through the secretion of activin-betaB and Fibroblast growth 
factor 2 (Fgf2) (Hebrok et al., 1998). This suppression of Shh ensures proper morphogenesis 
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and permits subsequent Pdx1 induction in the pancreatic endoderm (Hebrok et al., 1998). The 
induction of Pdx1 in the dorsal endoderm is accomplished by contact with the dorsal aorta, 
which displaces the notochord by E8.5 (Lammert et al., 2001; Slack, 1995; Yoshitomi and Zaret, 
2004). Similar to dorsal pancreatic development, in ventral pancreatic development, contact with 
vitelline veins of the developing vasculature induces a pancreatic transcriptional program that 
includes Pdx1 and Ptf1a expression in the prospective ventral pancreatic endoderm (Lammert 
et al., 2001; Yoshitomi and Zaret, 2004). Without these intricate, step-wise physical interactions 
with various embryonic structures, specification of the pancreatic epithelium from the foregut 
endoderm does not occur (Hebrok et al., 1998; Lammert et al., 2001; Yoshitomi and Zaret, 
2004). 
 Following pancreatic bud specification, many cell types in the microenvironment work 
together to support proper growth, differentiation, and maturation of the pancreatic epithelium 
into a highly branched, 3D network. These include the vasculature, nerves, and mesenchymal 
cells. After serving to first promote early pancreatic specification, the developing vasculature 
plays different roles in the development of the epithelial compartment. In hypervascularization 
models of pancreatic development, exocrine differentiation is significantly reduced (Magenheim 
et al., 2011; Pierreux et al., 2010; Sand et al., 2011). Conversely, inhibition of blood vessel 
vascularization through small molecule treatment in the developing pancreas results in 
increased exocrine cell differentiation and a reduction in endocrine cell differentiation (Pierreux 
et al., 2010). Together, these findings suggest that endothelial cells serve to restrict exocrine 
lineage differentiation and promote endocrine cell differentiation. These changing roles of the 
vasculature could be the result of dynamic interactions that blood vessels have with the 
epithelial compartment as they invade and intercalate between epithelial branches (Villasenor 
and Cleaver, 2012). Thus, the varying interface between the vasculature and the pancreatic 
epithelium at different times in development may influence its dynamic functions in pancreatic 
organogenesis.  
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  Additionally, pancreatic development is dependent on proper sympathetic innervation, 
which is required not only for proper formation of the islets of Langerhans but also for their 
maturation into functional, glucose-sensing units (Borden et al., 2013). Both genetic and 
pharmacologic inhibition of sympathetic innervation in murine pancreatic development inhibits 
islet cell migration that facilitates formation of coalesced islets, demonstrating that the endocrine 
compartment relies on guidance cues from sympathetic nerves to establish correct islet 
architecture (Borden et al., 2013). One such cue is norepinephrine, which activates beta-
adrenergic signaling in migrating islet cells to enforce proper islet architecture (Borden et al., 
2013). These resulting defects in islet architecture from inhibition of sympathetic innervation 
lead to reduced insulin secretion and impaired glucose tolerance (Borden et al., 2013), 
highlighting the functional consequences of the absence of sympathetic nerves in the 
microenvironment that surrounds the developing epithelium during pancreatic organogenesis.  
Finally, the pancreatic mesenchyme has also been demonstrated to support the 
development of the pancreatic epithelium. Early studies of pancreatic development showed that 
physical removal of the mesenchyme in ex vivo culture blocked proper growth and 
morphogenesis of the pancreatic epithelial buds cultured ex vivo (Golosow and Grobstein, 
1962). These findings were later corroborated using more specific genetic ablation methods, 
where genetic ablation of the pancreatic mesenchyme in vivo halted expansion of both the 
endocrine and exocrine compartments of the pancreatic epithelium (Landsman et al., 2011). 
Fgf10, Wnt5a, and BMPs are all secreted factors expressed by the pancreatic mesenchyme 
whose deletion from the mesenchyme leads to reduced epithelial growth, branching, and 
differentiation (Ahnfelt-Rønne et al., 2010; Bhushan et al., 2001; Larsen et al., 2015). Beyond its 
role as a source of signaling cues, the mesenchyme also produces many ECM components that 
may be structurally important for the developing epithelium. The proportion of epithelium to 
mesenchyme steadily increases as the epithelium grows into a highly-branched structure with 
mesenchyme nestled between epithelial branches by the end of gestation. These direct, 
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physical interactions that the mesenchyme has with the epithelium may be important for 
supporting physical growth of the branched organ.    
Although the importance of the pancreatic mesenchyme on proper epithelial 
development has been established, there is not a well-established definition of what the 
pancreatic mesenchyme is or which cell types constitute this compartment. Classically, 
mesenchyme is defined as embryonic connective tissue made of loosely associated, fibroblast-
shaped cells of mesodermal origin (Hay, 2005). Defining pancreatic mesenchymal cells has 
largely depended on morphological features, such as elongated shape. Few molecular markers 
have been identified to specifically mark this population in pancreatic development, although 
genes including those in the collagen family, Pdgfra, and vimentin have been used. Exclusion of 
known epithelial markers, such as Epcam and E-cadherin has also been utilized as a strategy to 
define cells of the pancreatic mesenchymal compartment. Given the poor annotation of the 
entire mesenchymal compartment within pancreatic organogenesis, a better cellular and 
molecular atlas of the pancreatic mesenchyme is direly needed. In particular, one key question 
is whether the pancreatic mesenchyme is composed on a singular cell type or if multiple cell 
populations with distinct functions exist within this compartment. Clarifying lineage relationships 
of cells within the pancreatic mesenchyme will also enable better characterization of this 
compartment as a whole. By defining molecular markers of the different cell populations within 
the mesenchyme, more precise targeting strategies to study the different functions of different 
mesenchymal populations can be developed. 
 
Directed differentiation of human embryonic stem cell-derived beta cells  
 
 The key development cues found in pancreatic development laid the roadmap through 
which hESCs are differentiated through a step-wise process, first to definitive endoderm, then to 
a pancreatic progenitor stage, followed by transit through an endocrine progenitor stage, and 
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finally terminating in insulin-expressing cells of the beta lineage (Pagliuca et al., 2014; Rezania 
et al., 2014; Russ et al., 2015). The first hurdle in the development of directed differentiation 
protocols to generate hESC-derived beta cells was to induce the definitive endoderm lineage 
from hESCs (D'Amour et al., 2005). It is known in vivo that Nodal/activin signaling induces 
endoderm during gastrulation in vertebrates (Stainier, 2002). The addition of Activin A to hESC 
culture successfully differentiated hESCs toward the FOXA2+/SOX17+ definitive endoderm 
lineage (D'Amour et al., 2005). Following the production of definitive endoderm, generation of 
PDX1+ pancreatic progenitors was accomplished through the addition of retinoic acid, FGFs, 
and hedgehog inhibitors (D'Amour et al., 2006), all of which facilitate entry into the pancreatic 
lineage (Lau et al., 2006) and derive from the adjacent mesoderm or notochord during 
pancreatic development (Hebrok et al., 1998). In pancreatic development, Pdx1+ progenitors 
are multipotent and differentiate into acinar, ductal, and endocrine lineage (Zhou et al., 2007). 
The endocrine lineage begins with the onset of Ngn3 expression, which is induced with Notch 
inhibition (Apelqvist et al., 1999). Therefore, successful endocrine cell specification followed by 
the production of hESC-derived, PDX1+ pancreatic progenitors was accomplished through use 
of Notch inhibitors to permit expression of the pro-endocrine transcription factor NGN3, leading 
to the production of endocrine progenitors (D'Amour et al., 2006). From these NGN3+ endocrine 
progenitors, several groups have gone on to generate glucose-sensitive, insulin-producing beta 
cells (Nair et al., 2019; Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015; Veres et 
al., 2019). The studies on pancreatic development that have identified genetic programs and 
signaling pathways required for transit of pluripotent cells and progenitors into the pancreatic 
and subsequent endocrine lineages in vivo thus have been instrumental in the derivation of 
step-wise differentiation protocols that generate beta cells from hESCs.  
 Although the successful production of glucose-sensitive, insulin-producing beta cells was 
a major leap forward, there are several key limitations that remain before hESC-derived beta 
cells can be used as a therapeutic intervention for diabetes. First, the number of beta cells 
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required for transplantation into one diabetic patient is on the order of one billion (Jacobson and 
Tzanakakis, 2017; Lock and Tzanakakis, 2007). Although current hESC-derived beta cell 
differentiation protocols are capable of differentiating millions of hESCs at a time, the efficiency 
of generating beta cells is batch-dependent and low, at approximately 30-40% (Pagliuca et al., 
2014; Rezania et al., 2014; Russ et al., 2015) and even reported purification methods are low-
throughput and labor-intensive (Nair et al., 2019; Veres et al., 2019). Given the number of 
hESC-derived beta cells required to treat diabetes in one patient, improvements in the efficiency 
of functional beta cell production are needed for these regenerative-based therapies to be 
scalable and of consistent quality. Second, one key hallmark of a functional beta cell is that it 
can properly sense dynamic glucose levels and secrete insulin in a glucose concentration-
dependent manner (Blum et al., 2012). Although the hESC-derived beta cells from recent 
directed differentiation protocols initially exhibit glucose-sensitive insulin secretion (GSIS) 
(Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015), they are not able to maintain 
GSIS long-term. This lack of functionality of hESC-derived beta cells long-term makes them 
unsuitable as transplantation material for diabetes treatment. Third, although beta cells in 
human pancreatic islets have been thought to be a homogenous cell population, the level of 
beta cell heterogeneity in human islets has recently begun to be appreciated. Based on two cell 
surface markers alone, ST8SIA1 and CD9, four antigenically distinct beta cell subpopulations 
have been identified in human islets, and the frequencies of these beta cell subtypes are altered 
in individuals with T2D (Dorrell et al., 2016). Specialized beta cells with pacemaker properties 
residing in islets, deemed “hub cells,” have also been identified and regulate the coordinated 
islet responses to glucose (Johnston et al., 2016), supporting this notion that not all beta cells 
are created equal in the islet. Thus, future differentiation strategies should focus not only on the 
generation of functional beta cells but also on the formation of beta cell subtypes that may 
significant for the overall function of an islet. Lastly, stem-cell derived beta cells generated in 
vitro must be protected against immune attack in transplant recipients. Several strategies have 
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been formulated to circumvent this issue of immune system attack, including encapsulating 
hESC-derived beta cells in an immunoprotective device (Basta et al., 2011; Sneddon et al., 
2018), genetic engineering of hESC-derived beta cells to resist immune detection (Sneddon et 
al., 2018), and generating beta cells from human induced pluripotent stem cells (hiPSCs) 
derived from the transplant recipient (Millman et al., 2016). Addressing these limitations will 
prove critical for the adoption of stem-cell derived beta cells for use in the clinic to address 
diabetes. 
 These challenges in beta cell functionality and differentiation efficiency in hESC-derived 
beta cell differentiation protocols can be addressed by better understanding the gene 
expression programs that drive beta cell differentiation and maintain beta cell identity in vivo. 
Given that beta cells are tasked with the critical responsibility of producing, storing, and 
releasing insulin at dynamic glucose levels, beta cells require a host of transcription factors that 
activate expression of proteins that mediate beta cell function. Although current beta cell 
differentiation methods achieve expression of key transcription factors such as PDX1, NKX6.1, 
NGN3, and NEUROD1 (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015), these 
methods may be failing to activate other transcriptional programs not yet uncovered to be 
required for proper beta cell differentiation and function. Additionally, although current 
differentiation protocols for generating hESC-derived beta cells recapitulate key developmental 
stages and genetic programs used to make beta cells in vivo, we may not be fully mimicking the 
exact developmental path taken in vivo in in vitro approaches. For instance, incorporation of 
endothelial cells into insulin-producing cell implantation promotes functional maturation of these 
insulin-producing cells (Meivar-Levy et al., 2019). It is possible that there are several different 
differentiation trajectories that exist to push cells into the beta lineage, but only a select few 
generate the functional, bona fide beta cells observed in vivo. Current differentiation protocols 
span several weeks, but beta cell development in human gestation occurs over months. Thus, 
the compressed window of beta cell development in vitro in differentiation protocols may prevent 
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the generation of fully functional hESC-derived beta cells. Onset, duration, and dosage of 
expression of key genes must be finely coordinated during beta cell development, and these 
may not be fully refined in directed differentiation protocols to yield fully functional beta cells. 
Additionally, current differentiation strategies that result in poor differentiation efficiency 
and reduced beta cell functionality may require the support of other cell types known to form the 
microenvironment during pancreatic development. Although extensive work has elucidated 
several key cell intrinsic programs activated and repressed as progenitors differentiate into beta 
cells, this process of endocrine differentiation does not occur in isolation in vivo. Instead, beta 
cell differentiation and proper function are carried out in the presence of a milieu of other cell 
types, including other hormone-expressing islet cells, endothelial cells, perivascular cells, 
nerves, and mesenchymal cells (Hayden et al., 2008; Lammert et al., 2003; Reinert et al., 
2014). These additional cell types may serve important niche functions for supporting beta cell 
differentiation and function, and the lack of these cellular interactions in current in vitro beta cell 
differentiation platforms directly contrasts that seen in the in vivo microenvironment. Proper 
recapitulation of the microenvironment during in vitro derivation of beta cells may enforce proper 
beta cell differentiation and function (Sneddon et al., 2018). When hESC-derived pancreatic 
progenitor cells are transplanted in mice, these progenitors differentiate and mature into 
glucose-responsive insulin-producing beta cells (Bruin et al., 2015; Sneddon et al., 2018), 
suggesting that additional components found in the cellular microenvironment can facilitate 
proper beta cell differentiation and enforce proper GSIS function. Additionally, co-culture of 
pancreatic mesenchyme enhances proliferation and self-renewal of hESC-derived pancreatic 
progenitors that go on to give rise insulin-secreting beta cells (Sneddon et al., 2012), 
highlighting the beneficial aspects of including cells from the endogenous microenvironment in 
the directed differentiation of hESC-derived beta cells. Incorporation of endothelial cells also 
improved function of transplanted islets (Penko et al., 2011), suggesting that endothelial cells, 
too, can improve the functionality of transplanted hESC-derived beta cells. A more defined map 
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of the intricate cellular interactions within the microenvironment during beta cell differentiation 
and function in vivo will enable the development of improved in vitro beta cell differentiation 
platforms with better outcomes in terms of differentiation efficiency and beta cell functionality.  
 
Contribution to the field 
 
 This work builds a transcriptomic map of cellular dynamics and lineage relationships in 
both murine and human pancreatic development. In the developing murine pancreas, we use 
single-cell RNA-sequencing to characterize the previously underappreciated diversity of cell 
types present in the mesenchyme and construct lineage relationships among the pancreatic 
mesothelium and newly annotated mesenchymal populations. We apply a similar approach to 
the epithelial compartment and provide increased resolution to the cellular stages involved in 
endocrine cell differentiation of the pancreas. We identify a novel endocrine progenitor stage 
defined by differential expression of a transcription factor named Fev and show that Fev+ 
endocrine progenitors are derived from Ngn3+ progenitors and give rise to hormone-expressing 
lineages of the murine pancreas. By combining genetic lineage tracing of Fev-expressing cells 
with single-cell RNA-sequencing, we construct a high-resolution transcriptomic map of 
endocrine cell differentiation into the alpha and beta lineages and identify novel candidate 
regulators of alpha and beta fate restriction. Thus, our transcriptional profiling will serve as a rich 
resource for further understanding the cellular diversity present in both the developing 
mesenchymal and epithelial compartments of the murine pancreas. 
We extend our work in murine pancreatic development to examine the cellular 
heterogeneity present in human fetal pancreas through single-cell transcriptomic profiling. 
Examination of the human endocrine compartment of the fetal pancreas reveals a clearer 
transcriptomic profile of NGN3+ endocrine progenitors and identifies pre-alpha and pre-beta 
progenitors that express FEV. In silico reconstruction of lineage relationships in the alpha and 
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beta lineages uncover novel candidate regulators of lineage allocation. Using our single-cell 
transcriptomic profiling of human pancreatic development as a guidepost, we build a map of the 
cellular dynamics present during the directed differentiation of hESC-derived beta cells. This 
map of in vitro beta cell differentiation uncovers a novel lineage that results from mis-
differentiation of FEV-expressing progenitors and opens avenues through which current in vitro 
beta cell differentiation methods can be improved for greater differentiation efficiency. Given our 
findings of Fev/FEV+ progenitors in murine development, human fetal development, and the in 
vitro derivation of beta cells, we engineer valuable hESC lines to study the function of the FEV 
gene and FEV+ endocrine progenitors during the directed differentiation of beta cells and 
possibly, in the future, other hormone-expressing endocrine lineages. This work constructs a 
new differentiation model for human endocrine cell development and paves the way for 
improved in vitro beta cell derivation methods that better reflect in vivo human beta cell 
development.  
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Chapter 2 
Lineage dynamics of murine pancreatic development at single-cell resolution 
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Introduction 
 
Pancreatic organogenesis is a complex and dynamic process that ultimately results in 
the generation of multiple cell lineages that perform the functions of the mature organ: the 
regulation of glucose homeostasis by the endocrine compartment and the production of 
digestive enzymes by the exocrine compartment. In the mouse, all known epithelial lineages of 
the pancreas derive from a small field of epithelial precursor cells within the foregut endoderm 
specified by the expression of Pancreatic duodenal transcription factor 1 (Pdx1) (Fig. 2.1a) 
(Shih et al., 2013). These Pdx1+ cells evaginate into a cap of surrounding mesenchymal cells 
around embryonic day 9 (E9), proliferate, and begin the process of branching morphogenesis. 
Further epithelial lineage diversification continues with the specification of Pdx1+ cells into tip 
and trunk domains by E12 and progresses to the restriction of tip cells to a digestive enzyme-
producing acinar fate and of trunk cells to either a ductal or endocrine cell fate (Shih et al., 
2013). Within the trunk domain, induction of Neurogenin 3 (Ngn3) expression defines the cells 
that will differentiate into one of five endocrine lineages: alpha, beta, delta, gamma, or epsilon 
cells, marked by expression of the hormones Glucagon (Gcg), Insulin (Ins), Somatostatin (Sst), 
Pancreatic polypeptide (PP), or Ghrelin (Ghrl), respectively (Pan and Wright, 2011). Gastrin+ 
cells have also been recently described (Suissa et al., 2013). Despite previous work focused on 
the formation of the endocrine compartment, the precise timing and coordination of lineage 
decisions are not completely understood.  
Although the pancreatic mesenchyme is required for the proper differentiation, 
proliferation, and morphogenesis of the epithelial network (Shih et al., 2013), little is known 
about the cell identities and lineages that compose the pancreatic mesenchyme during 
development. Even less is known about the mechanisms by which these distinct mesenchymal 
cell types interact with one another and with the cells of the epithelial compartment during 
development and in the adult organ. Therefore, a deeper understanding of the full diversity of 
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the mesenchymal cell types, as well as their global gene expression profiles, will serve as a 
basis for understanding these key cellular interactions. 
 Recent studies of late embryonic, postnatal, and adult alpha and beta cells have 
demonstrated the power of single-cell transcriptomic profiling for unraveling endocrine lineage 
heterogeneity and revealing distinct transcriptional states of beta cell maturation (Dorrell et al., 
2016; Qiu et al., 2017a; Zeng et al., 2017). Here, we perform droplet-based, single-cell RNA-
sequencing of entire murine embryonic pancreata at earlier developmental timepoints to 
describe the cellular diversity and dynamics of gene expression in both the epithelial and 
mesenchymal compartments. We further identify and validate these populations within mouse 
and human pancreatic tissue, as well as human embryonic stem cell (hESC)-derived endocrine 
progenitor cells. Finally, we predict lineage relationships, identify previously unappreciated 
intermediate progenitor cells, and validate our methodology using in vivo genetic lineage 
tracing.  
 
Results 
 
Cellular heterogeneity in the murine pancreas 
 
We first characterized the major sources of cellular heterogeneity in the developing 
pancreas. Two batches of mouse pancreata at E14.5, a particularly active time of expansion, 
morphogenesis, and diversification (Pan and Wright, 2011) (Fig. 2.1a), were dissected from 
individual litters, dissociated into single-cell suspensions, sorted for live cells, and sequenced 
using the 10X Chromium Single-Cell version 1 (v1) kits (Fig. 2.1b and Fig. 2.2a-e). We 
performed filtering, normalization, variable gene identification, linear regression for batch, and 
Principal Component Analysis (PCA) with the R package, Seurat (Fig. 2.2d,e and 3a,b). Graph-
based clustering (Satija et al., 2015) of batch-adjusted, merged data identified 19 distinct cell 
populations, classified as epithelial, mesenchymal, immune, or vascular populations based on 
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the expression of known markers (Fig. 2.1c,d and Supplementary Data 1). We identified 
expected populations, including endocrine, exocrine (acinar and ductal), and endothelial cells 
(Fig. 2.1e). The proportions of endocrine, mesenchymal, immune, and vascular populations 
were similar between E14.5 batches (Fig. 2.3b-d).  Downsampling analysis confirmed that 
sufficient sequencing depth had been reached for calling clusters (Fig. 2.3e-g). These results 
reveal the power of single-cell RNA-sequencing to identify a broad range of cell types during 
development. 
 
Characterization of mesenchymal heterogeneity 
   
While previous studies have identified numerous markers of pancreatic epithelial 
populations(Pan and Wright, 2011), comparatively little is known about heterogeneity among 
pancreatic mesenchymal cells. We characterized the mesenchymal compartment by sub-
clustering only mesenchymal cells (5,069 cells) and re-performing the clustering analysis (Fig. 
2.4a and Fig. 2.5a). Despite being less divergent from one another than were cells in the 
epithelial compartment (Fig. 2.4b and Fig. 2.5b), mesenchymal cells could still be sub-divided 
into 10 transcriptionally distinct mesenchymal clusters (Fig. 2.4a,c and Supplementary Data 2). 
We verified the differential gene expression analysis with three tests: bimodal likelihood ratio 
test (McDavid et al., 2012), Wilcoxon rank sum, and MAST (Finak et al., 2015) (Fig. 2.5c and 
Supplementary Data 2). We annotated two clusters based on the expression of known marker 
genes: cluster 1 is pancreatic mesothelial cells (Wt1, Krt19, and Upk3b) (Kanamori-Katayama et 
al., 2011; Winters and Bader, 2013) and cluster 3 represents vascular smooth muscle (VSM) 
cells (Acta2, Tagln, and Myl9) (Fig. 2.4c and Supplementary Data 2) (Majesky et al., 2011). 
Indeed, in E14.5 pancreas, Wt1 expression was restricted to the tissue edge, as expected for 
mesothelial cells, while Acta2 expression was localized to cells surrounding vessels, as 
expected for VSM cells (Fig. 2.5d,e). Cells in the mesothelial cluster also expressed the 
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secreted factors Fgf9, Pdgfc, Rspo1, and Igfbp5 (Fig. 2.5f) and genes regulating prostaglandin 
hormone signaling and tight junctions (Fig. 2.4d and Supplementary Data 3).  
The remaining mesenchymal clusters included proliferating cells (clusters 6, 7, and 8), a 
large cluster (10) expressing pan-mesenchymal markers, and four clusters (2, 4, 5, and 9) each 
expressing a signature distinct from that of cluster 10 (Fig. 2.4a,c and Supplementary Data 2). 
Cluster 2 was defined by differential expression of Stathmin 2 (Stmn2), a gene involved in 
neurite outgrowth and osteogenesis (Chiellini et al., 2008; Grenningloh et al., 2003). We also 
found two populations, clusters 4 and 5, that differentially expressed multiple secreted factors. 
Cluster 4 expressed Ace2, the chemokines Cxcl12 and Cxcl13, and Vegfd, while cluster 5 
expressed high levels of the Wnt antagonists Secreted frizzled-related protein 1 and 2 (Sfrp1 
and Sfrp2) (Fig. 2.4c-e and Supplementary Data 2). Cluster 5 also expressed the transcription 
factor BarH-like homeobox1 1 (Barx1) and members of the Id DNA-binding protein family (Fig. 
2.4c-e and Supplementary Data 2). Cluster 9 expressed Nk2 homeobox 5 (Nkx2-5) and Tlx1, 
transcription factors reported to contribute to splenic development during a window in which the 
embryonic pancreas and spleen share a mesenchymal compartment (Fig. 2.4c) (Hecksher-
Sørensen et al., 2004). Pathway analysis identifies multiple signaling pathways that may be 
functionally relevant in these populations (Fig. 2.4d and Supplementary Data 3). We validated a 
subset of these distinct clusters using dual in situ hybridization/immunofluorescence (ISH/IF) on 
E14.5 pancreas for differentially-expressed markers of clusters 1 (Cav1 and Barx1), 2 (Stmn2), 
and 5 (Barx1) (Fig. 2.4e-h). These gene expression profiles demonstrate a previously 
underappreciated level of heterogeneity in the mesenchymal compartment of the developing 
pancreas.  
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Mesothelial cells undergo changes across developmental time 
 
 During organogenesis, the dynamics of each lineage are defined by the expansion, 
differentiation, and maturation of its constituent cells. To address how these processes change 
across chronological time within the developing pancreas, we performed single-cell sequencing 
at two additional timepoints, E12.5 and E17.5 (Fig. 2.6a). We identified mesenchymal cells from 
E12.5, E14.5, and E17.5 timepoints, merged them into one dataset, and re-performed the 
clustering analysis. We identified the clusters detected in our E14.5 analysis (clusters 1-10) 
along with seven new clusters (11-17) (Fig. 2.6a and Supplementary Data 4). The addition of 
E12.5 and E17.5 cells revealed further sub-division of the mesothelium into timepoint-specific 
clusters (1, 11, and 17), each with unique transcriptomic signatures (Fig. 2.6a,b). Within the 
mesothelium, we verified Paired-like homeodomain transcription factor 2 (Pitx2) expression at 
E12.5 and its absence at E17.5 and Mesothelin (Msln) expression at E17.5 and its absence at 
E12.5 (Fig. 2.6c), consistent with the single-cell data. These data provide evidence of 
transcriptional maturation over developmental time within the mesothelial compartment. 
 While the mesothelium is a well-established mesenchymal progenitor cell population for 
VSM and fibroblasts in multiple other organs, both the role of the mesothelium and the origin of 
the mesenchymal cell types within the pancreas remain uncharacterized (Wilm et al., 2005). We 
utilized our single-cell mesenchymal dataset to determine whether the pancreatic mesothelium 
may function as a mesenchymal progenitor cell population during development.  We found six 
populations (clusters 2, 3, 4, 5, 12, and 13) that expressed VSM cell genes, such as Acta2 and 
Tagln, or genes known to regulate VSM development, such as Mgp (Speer et al., 2009), Fhl1 
(Kwapiszewska et al., 2008; Wang et al.), Barx1 (Jayewickreme and Shivdasani, 2015), and 
Pitx2 (Shang et al., 2008) (Fig. 2.6d). Based on these VSM-related gene expression profiles, we 
hypothesized that these populations could represent VSM progenitors derived from the 
pancreatic mesothelium. To test the lineage relationships among these populations, we ordered 
cells in pseudotime based on their transcriptional similarity (Qiu et al., 2017b). This analysis 
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placed mesothelial cells on one side of the pseudotime trajectory (Fig. 2.6e). Mesothelial 
branches corresponded to either a maturation process, based on placement of E17.5 cells at 
the branch terminus, or proliferating mesothelium, based on expression of proliferation genes 
(Fig. 2.6e). VSM-related populations were placed on the other side of the trajectory (Fig. 2.6e). 
We calculated the proportion of each population over pseudotime and found a transition from 
the E12.5 mesothelial population (cluster 11) to cluster 12, both of which share expression of 
the gene Pitx2 (Fig. 2.6e-g). Cluster 12 then transitioned into the Stmn2-expressing cluster 2, 
which split into a branch composed of VSM populations, clusters 3 and 13 (Branch 1), and a 
branch composed of clusters 4 and 5 (Branch 2) (Fig. 2.6e-g). Thus, this analysis proposes 
clusters 2 and 12 as potential mesothelial-derived mesenchymal progenitor populations that can 
contribute to the VSM lineages (Fig. 2.6g). Our analysis has identified and validated multiple 
mesenchymal subtypes and possible lineage relationships among them. 
 
A previously undescribed endocrine progenitor population 
 
After assessing the heterogeneity within the mesenchymal compartment, we next 
focused on the epithelial cells. We first sub-clustered the 2,049 cells from our E14.5 dataset that 
comprised just the epithelial populations (Fig. 2.7a and Fig. 2.8a). We identified 10 clusters, 
including acinar, ductal, beta, alpha, and Ngn3+ progenitor populations, as revealed by 
differential expression of known markers (Fig. 2.7a,b, Fig. 2.8b, and Supplementary Data 5). 
Our analysis highlighted previously uncharacterized markers of acinar, Ngn3+, beta, and alpha 
cell populations, such as Reep5, Btbd17, Gng12, and Peg10, respectively (Fig. 2.7b and 
Supplementary Data 5). We also found Sst- and Pancreatic polypeptide (Ppy)-expressing cells, 
but they did not cluster into their own populations (Fig. 2.8c).  
 After the ductal, acinar, Ngn3+, and hormone+ populations had been accounted for, 
there still remained one population that eluded classification based on known marker genes. 
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This population was distinguished from all other epithelial populations by high-level expression 
of the E26 transformation-specific (ETS) transcription factor Fev, previously shown to be 
expressed within the developing pancreas but not described as a marker of a distinct epithelial 
population (Ohta et al., 2011) (Fig. 2.7a,b and Supplementary Data 5). This Fev+ population 
expressed genes marking endocrine lineage cells, such as Paired box 4 (Pax4), chromogranins 
A/B (Chga/b) and Neurod1 (Shih et al., 2013) (Fig. 2.8d), but not mature endocrine markers, 
such as Insulin1 (Ins1) or Gcg, or the transitory early endocrine lineage marker, Ngn3 (Fig. 
2.7b,c and Supplementary Data 5). Pairwise comparison between the Fev+ and Ngn3+ clusters 
identified 99 genes more highly expressed in Fev+ and 87 more highly expressed in Ngn3+ 
cells, suggesting that they are distinct populations (Fig. 2.7d). This Fev+, Ngn3-, hormone- 
cluster will henceforth be referred to as the FevHi population. Pathway analysis of the Ngn3+ 
and FevHi populations revealed enrichment of cell cycle and Notch signaling pathways in Ngn3+ 
cells (Fig. 2.7e and Supplementary Data 6), likely reflecting the exit of Ngn3+ progenitors from 
the cell cycle (Miyatsuka et al., 2011) and the role of Ngn3 in Notch signaling (Shih et al., 2012). 
The FevHi cluster expressed genes in pathways related to serotonin and insulin signaling, 
Activating Transcriptional Factor 2 (ATF-2) signaling, and sphingosine-1-phosphate signaling, 
which have been reported to regulate endocrine differentiation (Han et al., 2011; Serafimidis et 
al., 2017). This relationship to serotonin is consistent with prior work establishing Fev as a 
critical transcription factor in serotonergic neurons (Ohta et al., 2011; Spencer and Deneris, 
2017). 
Further sub-clustering of all 661 cells within the endocrine lineage revealed additional 
sub-groups of Fev-expressing cells. The first was marked by high expression of Pax4 and 
Runx1 Translocation Partner 1 (Runx1t1) and lower levels of Ngn3. The second was marked by 
Chgb and Vimentin (Vim) (Fig. 2.7f, Fig. 2.8e,f, and Supplementary Data 7). Therefore, our 
analysis proposed the existence of multiple intermediate states, marked by Fev, within the 
endocrine lineage. The Fev gene was also expressed at lower levels in a subset of the 
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hormone-producing alpha, beta, and epsilon cell populations, which will collectively be referred 
to as hormone+/FevLo populations (Fig. 2.7b).  
 Given that the Fev+ populations expressed endocrine lineage genes, we utilized 
pseudotime ordering (Qiu et al., 2017b) to test the hypothesis that both Fev+ populations were 
lineage-related to the Ngn3+ progenitors that give rise to the endocrine compartment of the 
pancreas (Gu et al., 2002). This de novo reconstruction of the developmental trajectory placed 
both the Fev+/Pax4+ and FevHi/Chgb+ cells between Ngn3+ endocrine progenitors and alpha 
and beta cells (Fig. 2.7g), suggesting that FevHi cells comprise a progenitor stage following 
Ngn3 expression and before hormone acquisition. The Fev+/Pax4+ population was placed 
closer in pseudotime to the Ngn3+ population and was followed by the FevHi/Chgb+ population 
(Fig. 2.7g), indicating that the former represents an earlier cell state. Unlike alpha and beta 
cells, epsilon cells were found throughout the trajectory populated by the Fev+/Pax4+ and 
FevHi/Chgb+ populations (Fig. 2.7g), possibly reflecting their function as multipotent progenitor 
cells for alpha and gamma lineages during development (Arnes et al., 2012).  
To validate these lineage relationships, we performed an in vivo lineage trace of Ngn3+ 
cells. In E14.5 Ngn3-Cre; ROSA26mTmG mouse pancreata, where lineage-traced cells are 
membrane-GFP+ (Muzumdar et al., 2007), approximately 20% of all Ngn3-lineage traced cells 
were identified as the FevHi population by the presence of Fev and the absence of both Ngn3 
and the pan-differentiated endocrine cell marker Islet1 (Isl1) (Fig. 2.9a,e, yellow arrows and 
bar). We also detected the hormone+/FevLo population identified by our single-cell data (Fig. 
2.9a, purple arrows) and cells that co-expressed Fev and Ngn3 (blue arrows), consistent with a 
model in which FevHi cells represent an intermediate progenitor state following Ngn3+ cells but 
prior to differentiated endocrine cells (Fig. 2.9g). 
We next tested if the FevHi population was also present in developing human pancreatic 
tissue. In human fetal pancreas at 23 weeks post conception, we observed cells that expressed 
only NGN3 (Fig. 2.9b, grey arrows), only CHGA (magenta arrows), a marker of all hormone-
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expressing endocrine cells, and both FEV and CHGA (purple arrows). We also detected cells 
that expressed FEV but not NGN3 or CHGA (Fig. 2.9c, yellow arrows), analogous to the murine 
FevHi population. The existence of these cellular states in human development suggests that the 
lineage relationships we identified generalize beyond murine pancreatic organogenesis to that 
of human, as well. 
We then probed hESCs undergoing directed differentiation towards the pancreatic beta 
cell lineage in vitro (Pagliuca et al., 2014). FEV was detected in endocrine progenitor-stage cells 
and beta-like cells (BLCs) at levels comparable to adult human islets, but not in undifferentiated 
hESCs (Fig. 2.8i). Further, we observed FEV+ (NGN3-/ISL1-) (yellow arrows), FEV+/ISL1+ 
(NGN3-) (purple arrows), and NGN3+/FEV+ (ISL1-) (blue arrows) populations in differentiating 
hESC-derived cells mid-way through the endocrine progenitor stage (Fig. 2.9d,f). While 
endocrine differentiation progresses as a wave throughout development (Johansson et al., 
2007) in vivo, it is more synchronized in the hESC differentiation platform in vitro (Pagliuca et 
al., 2014; Rezania et al., 2014; Russ et al., 2015). At a timepoint directly preceding beta cell 
differentiation, we found that nearly 70% of hESC-derived cells were either NGN3+/FEV+ or 
FEV+ (Fig. 2.9f, blue and yellow bars). These data place the FEV+ population at a timepoint 
consistent with an endocrine progenitor population during human beta cell differentiation in vitro.  
 
Endocrine dynamics over developmental time 
 
 Although we had captured comparatively fewer epithelial cells at E12.5 and E17.5 than 
at E14.5, we could still identify the FevHi cells at both timepoints (Fig. 2.10a). To capture more 
epithelial cells and account for those that were missing from E12.5 and E17.5 version 1 (v1) 
runs, we re-performed an entirely new (version 2) set of single-cell RNA-sequencing 
experiments at E12.5, E14.5, and E17.5 after depletion of CD140a+ mesenchymal cells in order 
to enrich for epithelial cells (Fig. 2.10b,c). Given the high numbers of red blood cells at E17.5, 
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we ran two wells of E17.5 cells (replicates 1 and 2) to increase our capture of epithelial cells and 
then aggregated the datasets. We first analyzed the exocrine compartment and identified 
acinar, ductal, and proliferating populations of both at all timepoints (Fig. 2.10d and 
Supplementary Data 8-10). We then focused on the endocrine compartment, where we 
captured 584, 1,267, and 1,837 endocrine cells at E12.5, E14.5, and E17.5, respectively. We 
found similar gene expression topologies as in our v1 dataset but gained additional resolution 
with increased cell numbers and transcriptomic coverage (Fig. 2.10e and Supplementary Data 
11-13).  
To analyze how endocrine populations change over time, we merged all three v2 
timepoints into one dataset using canonical correlation analysis (Butler et al., 2018). We 
correlated the v2 dataset to the v1 dataset and could identify all populations present in the v1 
dataset (Fig. 2.10f and Supplementary Data 14). We also found additional populations, including 
a cluster characterized by decreased expression of Fev and increased expression of Pdx1 and 
Mafb, genes with known roles in endocrine lineage decisions (Fig. 2.9h and Fig. 2.10g). This 
Pdx1+/Mafb+ population correlates most strongly with the FevHi/Chgb+ population, as well as 
both the alpha and beta cell populations in the v1 dataset (Fig. 2.10f). We also found a second 
beta cell population characterized by increasing expression of Ins1 and Ins2 and lower 
expression of Pdx1, perhaps representing more mature beta cells (Fig. 2.10g). Indeed, this 
second beta cell group is almost entirely comprised of cells from the E17.5 timepoint (Fig. 2.9i). 
To examine how these populations shift over developmental time, we calculated the proportion 
of these populations at each timepoint (Fig. 2.9j). We found shifts in cell proportions that match 
those reported in literature, such as a high proportion of alpha cells early in development at 
E12.5 and increasing proportions of beta and delta cells at later timepoints (Johansson et al., 
2007). The Ngn3+ population decreased over time, while the Fev+/Pax4+, FevHi/Chgb+, and 
Pdx1+/Mafb+ populations peaked at E14.5, consistent with previous studies that reported peak 
Ngn3 expression at approximately E14.5 and its subsequent downregulation as differentiation 
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into endocrine lineage ensues (Villasenor et al., 2008). At E17.5, we also found an increasing 
proportion of proliferating endocrine cells, presumably those responsible for the expansion of 
endocrine cell mass in later embryonic development (Bonner-Weir et al., 2016). These results 
from the larger v2 dataset confirm our initial findings from the v1 dataset and add additional 
resolution to the endocrine populations during pancreatic development. 
 
Lineage decisions within the endocrine compartment 
 
As the in vivo lineage tracing data had revealed that the FevHi population is derived from 
the Ngn3+ population, we hypothesized that the FevHi population could then function as a 
progenitor for the endocrine populations of the developing pancreas. We utilized a Fev-Cre; 
ROSA26mTmG lineage tracing strategy to label Fev-expressing cells and their progeny. We found 
that 100% of alpha, beta, and delta cells, 90.1% of gamma cells, and 23.2% of epsilon cells 
were lineage-traced in E14.5 pancreas (Fig. 2.11a-e). These proportions of lineage labeling held 
true later in development (E17.5) and in adulthood (6 weeks) (Fig. 2.12 and 2.13). Epsilon cells 
are rare in the adult pancreas (Arnes et al., 2012) and still exhibited only partial lineage tracing 
in E17.5 pancreas (47.8% traced) (Fig. 2.12e). These results demonstrate that the majority of 
endocrine cells pass through a Fev-expressing stage during development. 
We next combined this lineage tracing approach with single-cell RNA-sequencing to 
identify transcriptional regulators of endocrine differentiation. FACS sorting was used to enrich 
for Fev-expressing cells and their progeny (membrane-GFP+) from Fev-Cre; ROSA26mTmG 
pancreata at E14.5 (Fig. 2.11f,g). All expected endocrine populations were identified in the 
resulting single-cell dataset (Fig. 2.11h,i). In addition, we found that eGFP reads mapped to all 
endocrine populations except the Ngn3+ population (Fig. 2.11i), further confirming that Fev 
expression turns on after Ngn3.  
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We next set out to model the lineage relationships among the endocrine cells and 
identify transcriptional regulators of differentiation. Pseudotime ordering identified a trajectory 
that began with Ngn3+ cells, transitioned into Fev+ cells, and then split into two main branches 
(Fig. 2.14a; see similar branching pattern in analysis of our first v1 dataset, Fig. 2.15a). The 
termini of the branches were populated by differentiated beta and alpha cells, suggesting that 
the branches represent a transition from a progenitor to fully differentiated hormone+ cell (Fig. 
2.14a). 
We next used Monocle’s branched expression analysis modeling (BEAM) to identify the 
genes that distinguish the paths along the two branches to either alpha or beta cells. We found 
gene clusters that were upregulated along different segments of the pseudotime trajectory (Fig. 
2.14b and Supplementary Data 15) and performed pathway analysis to identify pathways 
enriched at each stage of pseudotime (Fig. 2.15c and Supplementary Data 16). Genes 
upregulated at the beginning of pseudotime in gene cluster 2 included early markers of 
endocrine differentiation, such as Sox4 and Ngn3 (Fig. 2.14b). Fev was in gene cluster 6 and 
increased in both branches before ultimately decreasing in expression at the branch termini 
(Fig. 2.14b,c). Gene cluster 6 also included other genes expressed within the FevHi population, 
including Cldn4, Vim, and Chgb (Fig. 2.14b,c and Fig. 2.15b). We found branch-specific clusters 
that included known markers of beta (Ins1) and alpha (Gcg) cells and known differentiation 
regulators of alpha (Arx, Pou3f4, Irx1, Slc38a5, and Tmem27) and beta (Pdx1, Pak3, and Nkx6-
1) cells (Fig. 2.14c and Fig. 2.15b) (Pan and Wright, 2011; Petri et al., 2006; Stanescu et al., 
2017). These clusters also contained genes that were enriched in either the alpha or beta 
branch but were expressed before acquisition of hormone expression (Fig. 2.15b). Within the 
alpha cell branch, Peg10, Smarca1, Auts2, and Wnk3 increased in expression before 
upregulation of Gcg occurred (Fig. 2.15b). Peg10 and Auts2 have roles in differentiation (Dekel 
et al., 2006; Hishida et al., 2007) and migration (Hori et al., 2014), but a role in endocrine 
differentiation has not been described. As a regulator of chromatin states and an adult human 
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alpha cell marker (Muraro et al., 2016), Smarca1 may be involved in the epigenetic regulation of 
alpha cell differentiation. Within the beta cell branch, Gng12, Tssc4, Ece1, Tmem108, Wipi1 and 
Papss2 increased in expression before upregulation of Ins1 (Fig. 2.15b). To our knowledge, a 
role in endocrine lineage decisions have not been described for these beta branch-specific 
genes. We found a similar endocrine differentiation trajectory by an orthogonal method that 
uses force-directed layouts to visualize gene topologies and infer lineage relationships within 
single-cell data (Tusi et al., 2018; Weinreb et al., 2018) (Fig. 2.15d). We hypothesize that the 
genes identified by the analysis above may represent regulators of the differentiation of an 
endocrine progenitor to a fully differentiated hormone-expressing cell.  
To validate our pseudotime results, we performed ISH for markers that defined each 
branch of the trajectory. First, we confirmed the expression of Peg10 and Gng12 within the 
FevHi population (Fig. 2.14d,e, indigo and teal gradient arrows), validating the expression of 
these genes in a stage before hormone acquisition. We also validated the enrichment of Peg10 
and Gng12 in alpha and beta cells, respectively (Fig. 2.14f,g, solid indigo and teal arrows). First, 
95.8% of beta cells expressed Gng12 (n=46 cells, 6 pancreata), while 30.5% expressed Peg10 
(n=71 cells, 7 pancreata) (Fig. 2.14f and Fig. 2.16a). Additionally, 100% of alpha cells 
expressed Peg10 (n=31 cells, 6 pancreata), while only 5.4% expressed Gng12 (n=32 cells, 4 
pancreata) (Fig. 2.14g and Fig. 2.16b). The lineage relationships generated by pseudotime 
ordering, combined with the validation in vivo, lead us to hypothesize that the Fev+/Peg10+ 
cells are fated towards an alpha cell identity and Fev+/Gng12+ cells towards a beta cell identity 
(Fig. 2.14h). These results suggest that lineage allocation of endocrine progenitors towards 
alpha or beta cell fates may occur after the onset of Fev expression. 
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Discussion  
 
The mesenchyme is critical for epithelial specification and proliferation throughout 
pancreatic development (Ahlgren et al., 1997; Golosow and Grobstein, 1962; Landsman et al., 
2011), yet the individual cell types responsible for these processes remain unidentified. Our 
single-cell dataset has enabled the identification of multiple mesenchymal subpopulations and 
gene candidates for regulating epithelial-mesenchymal interactions. Secreted factors, such as 
mesothelial-derived Fgf9, may play a similar role in the pancreas as in the lung, where it 
regulates mesenchymal cell proliferation and vascular formation (Yin et al., 2011).  Additionally, 
secretion of Wnt antagonists by cluster 5 may regulate Wnt signaling in the developing 
pancreas, influencing processes such as epithelial specification, expansion, and exocrine 
development (Murtaugh, 2008). Future work can focus on uncovering the functions of these 
individual mesenchymal populations in development, physiology, and pathology of the 
pancreas. 
With the cell types of the mesenchyme now enumerated and their markers identified, we 
can begin to elucidate the maturation and lineage relationships of the pancreatic mesenchymal 
compartment. Our time course data have provided evidence of maturation within the mesothelial 
population. Genes such as Pitx2, kallikren 13 (Klk13) and 8 (Klk8), were differentially expressed 
in younger, E12.5 mesothelial cells. Pitx2 regulates differentiation in multiple systems (Cao et 
al., 2013; Hernandez-Torres et al., 2017; Shang et al., 2008), and the kallikren family are serine 
proteases involved in extracellular matrix and adhesive molecule degradation (Kapadia et al., 
2004). Expression of these genes suggests that the E12.5 mesothelial population may be 
primed for migration and differentiation. In contrast, the E17.5 mesothelial population expressed 
genes related to barrier or immune function, such as dermokine (Dmkn) (Hasegawa et al., 2013; 
Huang et al., 2017), bone marrow stromal antigen 2 (Bst2), and retinoic acid receptor responder 
2 (Rarres2) (Ernst and Sinal, 2010). These results suggest stage-dependent roles for the 
mesothelium throughout development.  
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The different roles for the mesothelium across time are also evident from our pseudotime 
analysis, which proposes that the mesothelium serves as a progenitor for other mesenchymal 
cell types during development. The mesothelium is a critical mesenchymal progenitor population 
in other organs, such as the heart, intestine, lung, and liver (Wilm et al., 2005). Our data 
suggest that mesothelial progenitor activity occurs at E12.5 or earlier during pancreatic 
development, consistent with other organ systems (Bin Zhou et al., 2011; Que et al., 2008; 
Winters and Bader, 2013). Indeed, a recent study identified that parietal mesothelial cells can 
function as progenitor cells prior to pancreatic specification (Angelo and Tremblay, 2018). The 
transcriptomic information obtained by this study will allow the development of tools to target 
individual populations within the mesenchyme and perform lineage tracing, ablation, and 
expression studies in vivo. Furthermore, this developmental dataset can be compared to 
mesenchymal population dynamics during adult disease progression, where aberrant 
recapitulation of developmental pathways can lead to disease states in the pancreas (Jensen et 
al., 2005; Rhim and Stanger, 2010). Thus, this dataset is a broad resource for the 
implementation of future studies in pancreatic mesenchymal biology. 
Within the epithelial compartment, our identification of a FevHi endocrine progenitor 
population provides increased resolution of endocrine differentiation. The relative timing of 
expression of canonical endocrine lineage genes can now be mapped onto these additional 
differentiation stages. Several lines of evidence suggest that the gene Fev may be a direct 
target of Ngn3: Fev is the transcription factor most strongly expressed in Ngn3+ endocrine 
progenitors (Miyatsuka et al., 2009), and Ngn3 knockout embryos do not express Fev in the 
developing pancreas (Ohta et al., 2011). Known target genes of Ngn3, such as Pax4 (Collombat 
et al., 2003) and Runx1t1i (Benitez et al., 2014), are expressed by the early-stage Fev+/Pax4+ 
population. Additionally, Pax6 is upregulated within the FevHi population. Although Chga and 
Chgb are often utilized as markers of differentiated endocrine lineages, we found that both are 
expressed in the FevHi population prior to hormone acquisition. This result is consistent with 
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previous work that identified Chga+, hormone- cells in rodent pancreatic development (Butler et 
al., 2016). The FevHi cell stage likely represents the cell stage during endocrine differentiation 
preceding specialized hormone production and may now serve as a cellular landmark for 
understanding endocrine lineage gene expression dynamics. 
The gene Fev has been previously studied mainly in serotonergic neurons, where it is a 
master transcriptional regulator required for cellular differentiation, maturation, and serotonin 
synthesis (Spencer and Deneris, 2017). Fev switches transcriptional targets from differentiation 
genes during development to maturation genes postnatally in serotonergic neurons (Wyler et 
al., 2016). In an insulinoma cell line, Fev directly binds to the regulatory regions of serotonergic 
genes, such as Tph1, Tph2, Ddc, Slc18a2, and Slc6a4, as well as the Ins1 promoter itself (Ohta 
et al., 2011). Future ChIP-seq studies of embryonic pancreas will globally identify direct targets 
of Fev and Fev-regulated transcriptional networks in developing endocrine cells.  
Using genetic lineage tracing in vivo, we have demonstrated that the majority of 
endocrine cells in the developing pancreas transit through a Fev-expressing stage, and that 
Fev-lineage cells contribute not only to embryonic, but also to adult pancreatic endocrine cells. 
The fraction of epsilon cells not derived from a Fev-lineage may represent the subset of Ghrl+ 
cells previously reported to give rise to the ductal and exocrine lineages (Arnes et al., 2012). As 
all adult gamma cells are Fev-lineage labeled, the small subset of gamma cells not lineage 
traced during pancreatic development may represent those that do not persist in the adult 
pancreas.  
 Further highlighting the relevance of FevHi progenitors during pancreatic development, 
our pseudotime analysis revealed that Fev-expressing cells may be pre-specified towards an 
alpha or beta cell fate. As expected, we found expression of Ins1 and Gcg at the termini of the 
beta and alpha branches, and upregulation of Pdx1 and Arx, which are known regulators of 
endocrine cell fate decisions, earlier in pseudotime. In addition, our pseudotime analysis 
identified genes enriched along the alpha or beta branch and expressed prior to upregulation of 
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hormones. These genes warrant further study as potential regulators of the acquisition of alpha 
or beta cell identity. 
 For the eventual application of this knowledge to human therapeutics, the findings in the 
murine model must be validated in human pancreatic development.  Our staining of human fetal 
pancreas identified the analogous FEVHi population, consistent with our findings in murine 
pancreata. Directed differentiation of hESCs towards endocrine cell fates will provide a platform 
for modeling and manipulating the putative lineage regulators found in this study. Indeed, we 
have identified a FEV+ population within hESC-derived endocrine progenitor cells. Deeper 
knowledge of these lineage decisions may substantially improve directed differentiation efforts 
to efficiently generate functional beta cells for cellular replacement therapy for people with 
diabetes. This study highlights the power of combining single-cell transcriptomic information with 
in vivo lineage tracing to reconstruct developmental trajectories within cellular compartments. 
Discovery of populations and their lineage relationships will promote identification of the 
mechanisms that drive lineage decisions and commitment. 
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Materials and Methods 
 
Mice 
All mouse procedures were approved by the University of California, San Francisco 
(UCSF) Institutional Animal Care and Use Committee (IACUC). Mice were housed in a 12-hour 
light-dark cycle in a controlled temperature climate. Noon of the day of vaginal plug was 
considered embryonic day 0.5. 
Timed-pregnant Swiss Webster mice were obtained from Charles River Laboratories. 
Ngn3-Cre (Schonhoff et al., 2004) (a gift from Dr. Matthias Hebrok), Fev-Cre (Scott et al., 2005) 
(The Jackson Laboratory 012712), and ROSA26mTmG (Muzumdar et al., 2007) (the Jackson 
Laboratory 007676) mice were maintained in a C57BL/6J background. The Cre transgene was 
genotyped using the following primers: GGGCGGCATGGTGCAAGTT and 
CGGTGCTAACCAGCGTTTTC.  
 
Human tissue procurement and isolation 
Human fetal pancreata were harvested from post-mortem fetuses at 23 weeks of 
gestation with permission from the ethical committee of the University of California, San 
Francisco (UCSF). Tissue was fixed in 4% paraformaldehyde overnight at 4°C. After three 
washes in 1X PBS, tissue was either cryopreserved in 30% sucrose solution at 4°C overnight 
and embedded in OCT, or placed in 40% ethanol then 70% ethanol before paraffin embedding. 
8 um sections were cut on the cryostat or microtome. In situ hybridization and 
immunofluorescence were then performed as described below.  
Adult human islets were isolated from cadaveric donor tissue by the UCSF Islet 
Production Core with permission from the UCSF ethical committee. Consented cadaver donor 
pancreata were provided by the nationally-recognized organization UNOS via local organ 
procurement agencies.  The identifiers were maintained at the source only, and the 
investigators received de-identified specimens.   
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Informed consent was obtained for all human (fetal and adult) tissue collection, and 
protocols were approved by the Human Research Protection Program Committee on Human 
Research of the University of California, San Francisco (UCSF). 
 
Embryonic stem cell culture and differentiation  
The human embryonic stem cell (hESC) line HUES8 was obtained from Harvard 
University and used for the generation of hESC-derived beta-like cells (BLCs). Pluripotent 
HUES8 cells were maintained as spherical clusters in suspension in mTeSR-1 (StemCell 
Technologies) in 500mL spinner flasks (Corning, VWR) on a magnetic stir plate (Dura-Mag) 
within a 37°C incubator at 5% CO2, 100% humidity, and a rotation rate of 70 rpm. Cells were 
screened for mycoplasma contamination using the MycoProbe Mycoplasma Detection Kit (R&D 
Systems), according to the manufacturer’s instructions. 
hESC-derived endocrine progenitor cells were generated as previously described 
(Pagliuca et al., 2014). In brief, HUES8 cells were seeded into a spinner flask at a concentration 
of 8 x 105 cells/mL in mTeSR-1 media with 10μM Rock inhibitor Y27632 (StemCell 
Technologies) to allow formation of spherical clusters. Differentiation was initiated 72 hours 
later. Differentiation was achieved in a step-wise fashion using the following growth factors 
and/or small molecules: definitive endoderm (Stage 1) (1 day of 100 ng/mL Activin A (R&D 
Systems) and 14 μg/mL of CHIR99021 (Stemgent); 2 days of 100 ng/mL Activin A); gut tube 
endoderm (Stage 2) (3 days of 50 ng/mL KGF (Peprotech)); early pancreatic progenitors (Stage 
3) (1 day of 200 nM LDN193189 (Fisher Scientific), 50 ng/mL KGF,  0.25 μM Sant-1 (Sigma), 2 
μM Retinoic Acid (Sigma), 500 nM PdbU (EMD Biosciences); 1 day of 50 ng/mL KGF,  0.25 μM 
Sant-1, 2 μM Retinoic Acid, 500 nM PdbU); later pancreatic progenitors (Stage 4) (5 days of 50 
ng/mL KGF, 0.25 μM Sant-1, 0.1 μM Retinoic Acid); endocrine progenitors (Stage 5) (4 days of 
0.25 μM Sant-1, 0.1 μM Retinoic Acid, 1 μM XXI (EMD Millipore), 10 μM Alk5i (Axxora), 1 μM 
T3 (EMD Biosciences), 20 ng/mL Betacellulin (Fisher Scientific); 3 days of 25 nM Retinoic Acid, 
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1 μM XXI, 10 μM Alk5i, 1 μM T3, 20 ng/mL Betacellulin); BLCs (Stage 6) (6 days of 10 μM Alk5i; 
1 μM T3). Successful differentiation was assessed at Stages 1, 3, 4, 5, and 6 via 
immunofluorescence or FACS for stage-specific marker genes. 
To measure the expression of FEV at various stages of human endocrine differentiation, 
aliquots of clusters were removed from the flask and analyzed at several timepoints: after 5 
days in Stage 5 (“mid-stage endocrine progenitors”), after 7 days in Stage 5 (“late-stage 
endocrine progenitors”), and after 5 days at the BLC stage.  As a comparator, pluripotent, 
undifferentiated hESCs in mTeSR-1, as well as human adult islets, were also analyzed for FEV 
expression. 
 
Immunofluorescence 
Embryonic mouse pancreata were dissected in cold 1X PBS and fixed in zinc-buffered 
formalin (Anatech LTD) at room temperature (RT) for 30-90 minutes or overnight at 4°C. After 
three washes in 1X PBS, tissue was processed for either cryopreservation or paraffin 
embedding. Cryopreserved pancreata were placed in 30% sucrose solution at 4°C overnight 
before embedding in OCT. Paraffin-embedded pancreata were placed in 40% ethanol and 70% 
ethanol before paraffin tissue processing. 8 um sections were cut on the cryostat or microtome. 
For immunofluorescence on paraffin sections, slides were baked at 55°C for 30 minutes, 
deparaffinized in xylene, and rehydrated in decreasing concentrations of ethanol. Heat-
mediated antigen retrieval was performed using Antigen Retrieval Citra Solution (Biogenex 
Laboratories). Tissue sections were blocked in 5% normal donkey serum (NDS; Rockland 
Immunochemicals) and Mouse-on-Mouse IgG blocking reagent (Vector Laboratories) when 
appropriate in 0.2% Triton X-100 in PBS (PBT) for 1 hour and then stained overnight at 4°C 
using the following primary antibodies: Acta2 (1:200, Abcam ab21027), Cav1 (1:200, Abcam 
ab2910), Chromogranin A (1:100, Abcam ab15160), E-cadherin (1:200, BD Transduction Lab 
610182), Glucagon (1:100, Abcam ab82270), Insulin (1:50, DAKO A0564), Vimentin (1:200, 
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Abcam ab92547), and Wt1 (1:100, Abcam ab89901). All antibodies have been validated by the 
manufacturer. The next day, sections were washed three times in 0.1% Tween 20 in 1X PBS 
and then incubated with species-specific Alexa Fluor 488-, 594-, or 647-conjugated secondary 
antibodies (1:500, Jackson ImmunoResearch) and DAPI in 5% NDS in 0.2% PBT for 1 hour at 
RT. Sections were washed three times in 0.1% Tween 20 in 1X PBS, rinsed in 1X PBS, and 
then mounted in Fluoromount-G mounting medium (SouthernBiotech). Slides were stored at 
4°C.  
For immunofluorescence on cryosections, slides were removed from -80°C storage and 
allowed to reach RT. Sections were rinsed in 1X PBS three times and permeabilized in 0.5% 
PBT for 10 minutes at RT. Tissue sections were blocked in 5% NDS and, if needed, Mouse-on-
Mouse IgG blocking reagent in 0.1% PBT for 1 hour and then stained overnight at 4°C using the 
following primary antibodies: Epcam (1:200, BD Transduction Lab 552370), Glucagon (1:2000, 
Millipore 4031-01F), Insulin (1:250, DAKO A0564), Somatostatin (1:500, Santa Cruz 
Biotechnology sc-7819, Ghrelin (1:1500, Santa Cruz Biotechnology sc-10368), Pancreatic 
Polypeptide (PP; 1:250, Abcam ab77192), and Vimentin (1:200, Abcam ab92547). All 
antibodies have been validated by manufacturer. Sections were washed the next day three 
times in 1X PBS and then incubated with species-specific Alexa Fluor 488-, 555-, 594-, or 647-
conjugated secondary antibodies and DAPI in 5% NDS in 0.1% PBT for 1 hour at RT. Sections 
were washed three times in 1X PBS and mounted in Fluoromount-G mounting medium. Slides 
were stored at 4°C. 
Images were captured on a Zeiss Apotome Widefield microscope with optical sectioning 
capabilities or Leica confocal laser scanning SP8 microscope. Maximum intensity z-projections 
were then prepared using ImageJ, where brightness, contrast, and pseudo-coloring adjustments 
were applied equally across all images in a given series. 
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In situ hybridization 
 In situ hybridization was performed on 8 um sections using RNAscope technology 
(Advanced Cell Diagnostics) (Wang et al., 2012) according to the manufacturer’s instructions. In 
situ probes against mouse Ngn3 (422409-C2), Fev (413241-C3), Isl1 (451931), Ins1 (414661-
C4), Gcg (400601), Sst (404631-C3), Ghrl (415301-C2), Ppy (482701), Peg10 (512921-C4), 
Gng12 (462521-C2), Nnat (432631-C2), Barx1 (414681), Pitx2 (412841-C2), Stmn2 (498391-
C3), Msln (443241) and human NGN3 (505791-C4), FEV (471421-C3), and ISL1 (478591-C2) 
were used in combination with the RNAscope Multiplex Fluorescent Reagent Kit v2 for target 
detection. Following signal amplification of the target probes, sections were washed in 1X PBS 
three times and blocked in 5% NDS in 0.1% PBT for 1 hour at RT. Tissue sections were then 
stained with primary and secondary antibodies as described above in the “immunofluorescence” 
section.  
For in situ hybridization of hESC-derived clusters, cells were fixed with 4% PFA for 15 
minutes at RT, washed with PBS, and cryoprotected in 30% sucrose overnight. The next day, 
clusters were embedded in a small sphere of 1.5% low-melting temperature agarose; these 
were again cryoprotected in 30% sucrose overnight. The following day, the agarose spheres 
were soaked in OCT and frozen in a dry ice bath. In situ hybridization was then performed on 8 
um sections using human NGN3, FEV, and ISL1 RNAscope probes.  
 
Quantification of cell proportions 
Quantification of pancreata was performed by manual counting using ImageJ software. 
Cell populations present at less than 1% in Ngn3-lineage traced E14.5 replicates were deemed 
artifact and excluded from further analysis.  
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Quantitative RT-PCR 
 hESCs from various stages of directed differentiation were collected and RNA extracted 
with the RNeasy Mini Kit (Qiagen). Reverse transcription was performed with the Clontech RT-
PCR kit. RT-PCR was run on a 7900HT Fast Real-Time PCR instrument (Applied Biosystems) 
with Taqman probes for FEV (assay ID: Hs00232733_m1) and GAPDH (assay ID: 
Hs02758991_g1) in triplicate. Data were normalized to GAPDH. Error bars represent standard 
deviation.  
  
Dissociation and FACS of embryonic pancreas  
Embryonic mouse pancreata were dissected and placed in 1X PBS on ice, then 
dissociated into single cells using TrypLE Express dissociation reagent (Thermo Fisher) at 37°C 
with pipet trituration at 5-minute intervals during incubation. For v1 datasets, E12.5 pancreata 
were dissociated for 10 minutes, E14.5 pancreata for 15 minutes, and E17.5 pancreata for 30 
minutes. For batch 1, we pooled 14 E14.5 pancreata from one litter. For batch 2, which was 
collected on a different day, we pooled tissue from each timepoint separately: 18 E12.5 
pancreata from two litters, 11 E14.5 pancreata from one litter, and 8 E17.5 pancreata from one 
litter. Dissociations were neutralized with FACS buffer (10% FBS + 2mM EDTA in phenol-red 
free HBSS). Dissociated cells were passed through a 30 um cell strainer and stained with Sytox 
live/dead stain (Thermo Fisher). Stained cells were washed twice in FACS buffer and then 
sorted using a BD FACS Aria II. After size selection to remove doublets, all live cells were 
collected. 
For version 2 10X datasets, we pooled tissue from each time point separately, each 
performed on a different day: 14 E12.5 pancreata from one litter, 13 E14.5 pancreata from one 
litter, and 13 E17.5 pancreata from one litter. For the E14.5 Fev-Cre; ROSA26mTmG 10X sample, 
we pooled 3 pancreata from one litter. Dissociations were performed as described above. Cells 
undergoing a CD140a negative selection were stained with CD140a-APC (1:50; eBiosciences, 
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cat. 17-1401-81; validated by manufacturer). Stained cells were washed twice in FACS buffer 
and then sorted using a BD FACS Aria II. After size selection to remove doublets, all live 
CD140a- cells were collected. For the E14.5 Fev-Cre; mTmG pancreata, live GFP+ cells and 
GFP-/TdTomato+ cells were collected. All 4,000 GFP+ (Fev-lineage traced) cells were loaded 
onto the 10X Genomics platform, supplemented with an additional 21,000 TdTomato+/GFP- 
(non-lineage traced). 
 
Single-cell capture and sequencing 
To capture individual cells, we utilized the Chromium Single Cell 3’ Reagent Version 1 
Kit (10X Genomics) (Zheng et al., 2017). For batch 1, 12,800 cells from E14.5 pancreata were 
loaded into one well of the 10X chip, while for batch 2, 18,000 cells per time point were each 
loaded into their own respective wells to produce Gel Bead-in-Emulsions (GEMs). GEMs 
underwent reverse transcription to barcode RNA before cleanup and cDNA amplification. 
Libraries were prepared with the Chromium Single Cell 3’ Reagent Version 1 Kit. Each sample 
was sequenced on 2 (Batch 1) or 1 (Batch 2) lanes of the HiSeq2500 (Illumina) in Rapid Run 
Mode with paired-end sequencing parameters: Read1, 98 cycles; Index1, 14 cycles; Index2, 8 
cycles; and Read2, 10 cycles.  
The CD140a-depleted E12.5, E14.5, and E17.5 datasets and Fev-Cre; ROSA26mTmG 
dataset in Figures 5 and 7 were generated with Chromium Single Cell 3’ Reagent Version 2 kits 
(10X Genomics). 27,000 cells were loaded onto their respective wells and underwent the same 
processing as the Version 1 kits, according to manufacturer instructions for Version 2 kits. 
Libraries were sequenced on the NovaSeq (Illumina) with the same sequencing parameters as 
above. 
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Single-cell analysis 
For the v1 datasets, we utilized CellRanger v1.1.0 software for v1 datasets and v2.1.0 
for v2 datasets with default settings for de-multiplexing, aligning reads to the mouse genome 
(10X Genomics pre-built mm10 reference genome) with STAR (Dobin et al., 2012) and counting 
unique molecular identifiers (UMIs) to build transcriptomic profiles of individual cells. For the v1 
datasets, gene-barcode matrices were analyzed with the R package Seurat v1.4, using the 
online tutorial as a guide (Satija et al., 2015). We first performed a filtering step, retaining only 
the cells that expressed a minimum of 200 genes and only the genes that were expressed in at 
least 3 cells. A large number of cells did not meet this threshold in the E17.5 time point and 
were determined to be red blood cells by the high expression of hemoglobin genes. Variable 
genes were determined by mean-variance relationship to identify highly-expressed and variable 
genes with the Seurat function MeanVarPlot with default settings.  UMI counts were log-
normalized, and linear regression was performed with RegressOut to account for differences in 
the number of UMIs between cells. Principal component analysis (PCA) was then utilized to 
determine sources of variability in the dataset with PCAfast. Significant PCs were determined 
based on the Scree plot and utilized for Seurat’s graph-based clustering algorithm (function 
FindClusters) with default parameters, except for the resolution parameter. To vary cluster 
numbers, the resolution parameter in FindClusters was adjusted from 0.6 – 3.0, and resulting 
clusters analyzed as follows. Clusters were visualized with t-distributed stochastic neighbor 
embedding (t-SNE) with Seurat’s RunTSNE function with default settings (Maaten and Hinton, 
2008). Differentially-expressed genes were determined with the FindAllMarkers function, which 
uses a bimodal likelihood ratio test (McDavid et al., 2012). We confirmed differential gene 
expression analysis with the Wilcoxon rank sum test and MAST (Finak et al., 2015) utilizing 
Seurat v2’s FindMarkers function with default settings. These tests calculate adjusted p-values 
for multiple comparisons. To determine the final number of clusters, clusters were required to 
have at least 9 significantly (p <0.05) differentially expressed genes with a 2-fold difference in 
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expression in comparison to all other clusters. Clusters were manually curated for differential 
gene expression, and those that did not meet this threshold were manually merged with the 
nearest cluster based on the phylogenetic tree from Seurat’s BuildClusterTree. In some cases, 
clusters met the 9-gene threshold but appeared to have very similar differentially-expressed 
genes to another cluster. This is likely a result of the comparison of individual clusters against all 
other clusters in determining differentially-expressed genes. In these cases, a pairwise 
comparison between the two clusters was performed and the same 9-gene threshold applied. 
An exception to the 9-gene threshold was made to annotate the proliferating population in early 
stages of the cell cycle within the E14.5 mesenchymal analysis (Fig. 2.4, cluster 8). Additionally, 
cluster 10 in the E14.5 mesenchymal dataset did not meet the 9-gene threshold. Rather, 
clusters 1-9 had distinct transcriptomic signatures (with at least 9 differentially expressed genes) 
that distinguished them from cluster 10.  Lists of at least 2-fold differentially-expressed genes for 
individual analyses are provided in Supplementary Data 2.  
For v2 datasets, Seurat v2.2 and v2.3 was utilizing to perform the analysis. Cells with 
less than 200 genes and genes expressed in fewer than 3 cells were removed, as above. UMI 
counts were normalized with NormalizeData using default settings. Variable genes were 
determined with FindVariableGenes, using the following cut-offs suggested by the online tutorial 
(x.low.cutoff = 0.0125, x.high.cutoff = 3, y.cutoff = 0.5). Data was scaled and UMI counts 
regressed out with the ScaleData function. Principal component analysis was performed with 
RunPCA, and significant PCs determined based on the Scree plot. t-SNE analysis and 
clustering was performed as described above for the v1 datasets. For the E12.5 exocrine 
dataset, the ductal population did not meet the 9-gene threshold. All other populations within 
this dataset could be distinguished from the ductal population by at least 9-differentially 
expressed genes, therefore we still annotated this cluster. Some of the clusters depicted for the 
Fev-Cre; ROSA26mTmG dataset do not meet the 9-gene threshold. We chose to visualize these 
clusters in order to better illustrate their placement along the pseudotime trajectory.  
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Custom genome build 
 The custom genome for alignment of reads to eGFP and TdTomato sequences from the 
mTmG mouse line was created according to instructions provided by 10X Genomics reference 
support (https://support.10xgenomics.com/single-cell-gene-
expression/software/pipelines/latest/advanced/references). eGFP and TdTomato sequences 
were concatenated to the mm10-2.1.0 reference genome (FASTA file) provided by 10X 
Genomics.  eGFP and TdTomato annotations were then concatenated to the mm10 annotations  
(GTF file) provided by 10X Genomics. The cellranger mkref command was then utilized with the 
genome and annotations with eGFP and TdTomato, as described in the above link. 
 
Pathway analysis 
Pathway analysis and calculation of associated p-values were performed using the 
ConsensusPathDB over-representation analysis for pathway-based sets category 
(http://cpdb.molgen.mpg.de) (Kamburov et al., 2008).  
 
Aggregating E17.5 v2 datasets 
E17.5 technical replicates from the v2 dataset were aggregated with Cellranger v2.1, 
utilizing the aggr function with default settings. The aggregated dataset was used for analysis 
and merging with the E12.5 and E14.5 v2 datasets. 
 
Sub-clustering and merging datasets 
Sub-clustering was performed by isolating clusters of interest with the Seurat function 
SubsetData and reanalyzing as described above (identification of variable gene, regression, and 
determination of significant PCs). Cells were classified as epithelial based on the expression of 
E-cadherin (Cdh1) and other known epithelial population markers. Cells that were Cdh1-, Vim+, 
and collagen3a1 (Col3a1)+ were classified as mesenchymal. Multiple batches were merged 
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with the MergeSeurat function. The merged dataset was reanalyzed as above, with batch 
included as a latent variable in the RegressOut function. The v1 E14.5 batch 1 and batch 2 
clusters were robust to the sampling differences between batches as evidenced by the 
contribution of cells from both batches to each cluster (Fig. 2.3b). We find high correlation of cell 
type proportion between batches in all populations except the exocrine compartment (acinar 
and ductal) (Fig. 2.3c), possibly due to technical challenges of pancreatic dissociation. Within 
each cluster, batch 1 cells correlated most highly with those of batch 2 contained in the same 
cluster, indicating proper cluster calling with the merged datasets (Fig. 2.3d).  
For v2 datasets (E12.5, E14.5 and E17.5), multiple canonical correlation analysis 
(multiCCA) from Seurat v2.3 was utilized to merge the epithelial datasets (Butler et al., 2018). 
The top 1,000 most highly variable genes that were variable in at least 2 datasets were used for 
the alignment, as recommended in the Seurat tutorial. The shared correlation strength of each 
CC was measured with Seurat’s MetageneBicorPlot, and those before the drop-off were used 
for alignment, analogous to the Scree plot in choosing significant PCs. We then aligned the 
datasets with AlignSubspace and ran an integrated t-SNE and clustering analysis, as outlined in 
the Seurat tutorial. Clusters were required to have 9 significantly differentially expressed genes 
as described above. Clusters with similar differentially expressed genes were verified with 
pairwise comparisons to the most related clusters (based on BuildClusterTree) and merged if 
they did not meet the pairwise 9-gene threshold. The Beta 2 cluster in the v2 endocrine merged 
timecourse data met the 9-gene threshold for 2 out of the 3 differential expression tests 
(Bimodal likelihood ratio and Wilcoxon rank sum tests), but had only 8 differentially expressed 
genes for the MAST test.  
Doublets were identified based on co-expression of two mutually exclusive genes, such 
as both mesenchymal and epithelial genes, and removed from further analysis. In the v2 
datasets, rare cells (4 cells in E12.5 and 13 cells in E14.5 endocrine datasets) with high levels 
of hemoglobin gene expression were removed from the analysis. 
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Downsampling analysis 
 To determine if the sequencing depth was sufficient for calling clusters, downsampling 
analysis was performed for the v1 E14.5 batch 1 dataset. Reads were randomly downsampled 
from the 10x Cellranger bam file output to a specified percentage, then grouped based on UMI 
to generate a count profile for each cell. The number of genes with greater than 0 counts was 
then calculated. UMI downsampling was performed with the SampleUMI function. A new Seurat 
object was created with the downsampled matrix and reanalyzed as above.  
The number of UMIs/cell was downsampled from an average of 4,600 UMIs/cell in the 
full dataset to 200 UMIs/cell, and the median number of genes/cell and clustering robustness 
was then calculated. Clustering robustness was determined as the percentage of cells within the 
same cluster, with clusters required to maintain at least 9 genes with a 2-fold change in 
expression in comparison to all other clusters. Within this dataset, robust clustering was 
maintained all the way down to 500 UMIs/cell, when the percentage of cells in the same cluster 
began to climb, indicating collapsing of individual clusters.  Both of these downsampling 
analyses indicate that sufficient sequencing depth was reached. 
 
Pseudotemporal ordering 
We utilized Monocle 2.6.4 (Qiu et al., 2017b) to order cells in pseudotime based on their 
transcriptomic similarity. For v1 timecourse datasets, batch-corrected values and variable genes 
from Seurat analysis were used as input, utilizing the gaussianff expressionFamily, and clusters 
were projected onto the minimum spanning tree after ordering.  
For the Fev-lineage traced dataset, UMI counts and variable genes from the Seurat 
analysis were used as input, utilizing the negBinom expressionFamily. To find genes 
differentially-expressed across the branch point in the trajectory, we used monocle’s internal 
BEAM analysis and selected genes with an FDR cutoff of 0.001. Gene expression patterns were 
plotted with plot_genes_branched_heatmap and plot_multiple_branches_pseudotime. 
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Code availability 
Seurat and monocle R objects used for analysis are available, along with scripts, at Figshare, 
DOI: 10.6084/m9.figshare.c.4158458.  https://figshare.com/collections/_/4158458 
Scripts are available at https://github.com/sneddonucsf/2018-Developmental-single-cell-RNA-
sequencing. 
 
Data availability  
RNA sequences for the single-cell RNA-sequencing analyses reported in this paper have been 
deposited in the GEO database under accession code GSE101099. 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101099 
 
  
 54	
 
 
Figure 2.1. Single-cell sequencing identifies broad patterns of cellular heterogeneity in 
E14.5 murine pancreas. (a) Overview of murine pancreatic development. (b) Schematic of 
experimental approach. (c) t-Distributed Stochastic Neighbor Embedding (t-SNE) visualization 
of populations from pooled E14.5 mouse pancreata (n=14). Each dot represents the 
transcriptome of a single cell, color-coded according to its cellular identity (epithelial, 
mesenchymal, or immune/vascular). Each cell compartment contains multiple sub-populations, 
represented by varying degrees of color shading. (d) Established marker genes identify 
epithelial cells (Cdh1+), endocrine cells (Chga+), mesenchymal cells (Vim+ and Col3a1+), 
endothelial cells (Pecam1+), and immune cells (Rac2+). (e) Heatmap depicting greater than 2-
fold differentially-expressed genes in each cluster compared to all other clusters. Cells are 
represented in columns, and genes in rows. Specific genes used to annotate clusters are 
indicated to the right of the heatmap.  
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Figure 2.2. Quality Control for Single-cell RNA-sequencing Runs. (a) Representative FACS 
plot of single, live cells sorted from dissociated Swiss Webster embryonic pancreata and used 
for single-cell sequencing. (b) Quality control statistics for all single-cell sequencing runs 
prepared with the Chromium Single Cell 3’ Reagent Version 1 Kit. The “valid barcodes” metric 
indicates the percentage of cells with barcodes that match a known barcode contained on a 
bead. “Mapped reads to transcriptome” refers to the percentage of reads that confidently map to 
a unique gene in the reference transcriptome. “Fraction Reads in Cells” is the percentage of 
reads that contain a cell-associated barcode. (c) Cellranger cell calls based on the number of 
UMIs. The dropoff indicates the threshold for the number of UMIs required for a barcode to be 
considered a cell. (d) Histogram of the number of genes per cell in all single-cell runs pre-
filtering steps. (e) Histogram of the number of genes per cell in all single-cell runs post-filtering 
steps. E17.5 Batch 2 contained a large number of red blood cells, which expressed fewer than 
200 genes, resulting in their removal during minimum gene threshold filtering (see Methods). 
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Figure 2.3. Single-cell RNA-sequencing Batch Information from E14.5 Pancreata. (a) 
Selection of variable genes in the E14.5 dataset (all cells) by Seurat’s MeanVarPlot function. (b) 
t-SNE visualization of merged E14.5 batches, color-coded by batch. Batch 1 and 2 contribute to 
all clusters, reflecting a successful batch correction. (c) Pearson’s correlation of E14.5 batch 1 
cells with E14.5 batch 2 cells within each cluster based on average expression of variable 
genes. Batch 1 cells correlate most highly with batch 2 cells within the same cluster, indicating 
proper merging of the two batches. (d) Cell type proportions in E14.5 batch 1 and 2 with 
exocrine (acinar and ductal) clusters included (top panel) and excluded (bottom panel). All cell 
types except the exocrine compartment show high correlation between the two batches. (e) 
Pearson’s correlation between clusters from the E14.5 batch 1 full dataset and those from the 
E14.5 batch 1 dataset downsampled to 50% of the reads, based on average expression of 
shared variable genes. (f) Maintenance of the number of median genes/cell after random 
downsampling of reads, indicating sufficient sequencing depth. (g) Maintenance of cluster 
structure after random downsampling of UMIs is reflected by the similar percentage of cells 
found within the same cluster with fewer UMIs. 
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Figure 2.4. Identification of multiple uncharacterized mesenchymal populations. (a) t-SNE 
visualization of subclustered E14.5 mesenchymal clusters (from n=14 pancreata). (b) Density 
plot depicting Pearson’s correlation values (depicted in heatmap in Fig. 2.5b) within the 
epithelial and mesenchymal populations based on average gene expression in each cluster. (c) 
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Dot plot of top differentially-expressed markers of each mesenchymal population. Bars are 
color-coded by cluster identity in (a). The grey bar represents pan-mesenchymal markers. The 
size of each dot represents the proportion of cells within a given population that expresses the 
gene; the intensity of color indicates the average level of expression. (d) Pathway analysis of 
genes greater than 2-fold differentially-expressed by cells in clusters 1, 2, 4, and 5. (e) 
Expression of genes marking clusters 1 (Cav1), 2 (Stmn2), 4 (Cxcl12), and 5 (Barx1) in all 
E14.5 mesenchymal cells. Color intensity indicates level of expression. (f-h) Multiplexed 
fluorescent ISH combined with Epcam IF validates clusters 2 and 5 (e) and cluster 1 (f-g). 
Epcam marks pancreatic epithelium. In (f), Barx1+ cells (red arrows, cluster 5) are distinct from 
Stmn2+ cells (green arrows, cluster 2), validating the single-cell data. In (g), Cav1+ cells (red 
arrows, cluster 1) are distinct from Stmn2+ cells (green arrows, cluster 2). In (h), Barx1+ cells 
that do not express Cav1 (red arrows) represent cluster 5, whereas Barx1+/Cav1+ cells (yellow 
arrows) represent cluster 1. Cav1+ cells that do not express Barx1 are also identified (green 
arrows), likely representing endothelial cells (Frank, 2003). Scale bar represents 50 um in f-h.  
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Figure 2.5. Transcriptomic Signatures and Lineage Dynamics among Mesenchymal 
Populations. (a) t-SNE visualization of E14.5 biological replicates, colored by batch, 
demonstrating effectiveness of batch correction. (b) Pearson’s correlation of E14.5 epithelial 
and mesenchymal clusters based on average expression of variable genes. (c) Comparison of 
bimodal likelihood ratio test adjusted p-values to adjusted p-values calculated by either MAST 
(left panel) or Wilcox rank sum (right panel) tests for all greater than 2-fold differentially-
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expressed genes. Pearson’s correlation value is shown in top left corner. (d,e) IF validation of 
(d) mesothelium (Wt1+) and (e) vascular smooth muscle (Acta2+) cells in E14.5 pancreata. 
Ecadherin marks epithelium, and Vim marks mesenchyme. Scale bar: 50 um. (f) Expression of 
secreted factors within the mesothelium. Color indicates level of expression. (g) t-SNE 
visualization of merged mesenchymal timecourse dataset. E14.5 biological replicates are 
colored, serving as a measure of batch correction effectiveness within the merged 
mesenchymal timecourse dataset. Grey dots represent both E12.5 and E17.5 cells. (h) 
Correlation of E14.5 mesenchymal populations with merged (E12.5, E14.5 and E17.5) 
mesenchymal clusters based on average expression of the variable genes from all datasets. 
Merged populations were matched with E14.5 (Fig. 2.4) by highest correlation and assigned the 
same cluster identity (cluster 1-10). Remaining merged clusters were assigned cluster identities 
11-17. (i) Dot plot of differentially-expressed genes from each merged mesenchymal cluster. 
Colored bars correspond to t-SNE in Fig. 2.14a (j) Contribution of cells from each timepoint is 
mapped onto pseudotime plots. Expression of proliferation markers, Birc5 and Top2a, in the 
pseudotime trajectory. Color indicates level of expression. Contribution of cells from each 
timepoint is broken down by individual cluster and mapped onto pseudotime plots. Colors 
correspond to cell clusters in Fig. 2.4a,e.  
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Figure 2.6. Mesothelial cells are dynamic over developmental time and are predicted to 
give rise to vascular smooth muscle populations. (a) t-SNE visualization of merged 
mesenchymal clusters from E12.5 (n=18 pancreata), E14.5 (n=14 pancreata for batch 1; n=11 
for batch 2), and E17.5 (n=8 pancreata) tissue. Mesenchymal clusters were identified at each 
timepoint, subclustered, merged together, and reanalyzed. Cells are colored by cluster or 
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timepoint. Dotted circle highlights timepoint-segregated mesothelial clusters. (b) Dot plot of top 
differentially-expressed genes in timepoint-specific mesothelial clusters (clusters 1, 11, and 17). 
Size of the dot represents proportion of the population that expresses each specified marker. 
Color indicates level of expression. (c) ISH for Pitx2 and Msln in E12.5 and E17.5 pancreata. 
Pitx2 expression was detected in E12.5 but not E17.5 mesothelium, whereas Msln was detected 
in E17.5 but not E12.5 mesothelium. Vimentin (Vim) IF staining depicts pancreatic 
mesenchyme. Dotted line indicates tissue boundary. Yellow arrows identify Pitx2+ mesothelial 
cells. Red arrows identify Msln+ mesothelial cells. Scale bar represents 50 um. (d) Expression 
levels of VSM-related genes in merged mesenchymal clusters. Color intensity indicates level of 
expression. (e) Pseudotime ordering of mesothelial and VSM-related merged mesenchymal 
clusters. Colors correspond to t-SNE in (a). All clusters are individually plotted in Fig. 2.5j. (f) 
Cluster proportions over pseudotime. Pseudotime was binned into 10 groups and the proportion 
of each cluster within that bin of pseudotime was calculated. (g) Model of lineage relationships 
among mesothelial, vascular smooth muscle, and VSM-related mesenchymal populations 
based on pseudotime ordering in (e). 
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Figure 2.7: Identification of epithelial cell populations in E14.5 mouse pancreas. (a) t-SNE 
visualization of epithelial groups only, as defined in Figure 1. (b) Dot plot depicting known and 
uncharacterized markers of epithelial populations, as well as markers specific to the FevHi 
population. Size of the dot represents proportion of the population that expresses each specified 
marker. Color indicates level of expression. (c) Expression of Fev and Ngn3 within epithelial 
cells. Color indicates level of expression. (d) Gene expression comparison between the Ngn3+ 
and FevHi population. Genes greater than 2-fold differentially-expressed are highlighted in dark 
blue (higher in FevHi cells) or light blue (higher in Ngn3+ cells). (e) Pathway analysis of genes 
greater than 2-fold differentially-expressed in Ngn3+ and FevHi populations (f) t-SNE 
visualization of the 661 cells of the endocrine lineage (Ngn3+, FevHi, alpha, beta, and epsilon 
populations). (g) Pseudotime ordering of Ngn3+, Fev+/Pax4+, FevHi, alpha, and beta cell 
populations place Fev+ cells between Ngn3+ and hormone+ populations. 
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Figure 2.8. Identification of Known and Novel Epithelial Cell Populations in E14.5 
Pancreas.  (a) t-SNE visualization of E14.5 epithelial batches, colored by batch. Significant 
overlap and most importantly, clusters that include cells from both batches, reflects successful 
batch correction. (b) Comparison of bimodal likelihood ratio test adjusted p-values to adjusted p-
values calculated by either MAST (left panel) or Wilcox rank sum (right panel) tests for all 
greater than 2-fold differentially-expressed genes. Pearson’s correlation value is shown in top 
left corner. (c) Expression maps of Ppy and Sst hormones within E14.5 epithelial dataset. (d) 
Dot plot of endocrine lineage genes across the epithelial populations. (e) Heatmap depicting 
genes over 2-fold differentially-expressed in Ngn3+ and Fev+ populations. Differentially 
expressed genes were determined from the endocrine dataset depicted in Fig. 2.7f and only 
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Ngn3+ and Fev+ populations were shown in the heatmap. (f) Expression of selected markers of 
early- and late-Fev+ populations in all endocrine cell lineages. (g) Pseudotime ordering of 
Ngn3+, Fev+/Pax4+, FevHi, alpha, and beta cell populations, colored by batch. (h) Expression of 
Islet1 (Isl1) in E14.5 epithelial cells is largely confined to hormone+ populations. (i) 
Quantification of FEV expression by quantitative RT-PCR in pluripotent hESCs, mid- and late-
stage endocrine progenitor cells, beta-like cells (BLCs), and adult human islets. FEV expression 
is normalized to GAPDH. Error bars represent standard deviation. N.D = not detected.  
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Figure 2.9. FevHi cells are endocrine progenitors. (a) In situ hybridization (ISH) for Ngn3, 
Fev, and Isl1 in lineage-traced Ngn3-Cre; Rosa26mTmG E14.5 pancreata where Ngn3-lineage 
traced cells are mGFP+. Grey arrowheads identify Ngn3+ cells, presumably not yet Ngn3-
lineage labeled due to the transient nature of Ngn3 expression and the delay of Cre-mediated 
recombination that permits expression of mGFP. Blue arrowheads identify Ngn3+/Fev+ cells 
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that are Ngn3-lineage traced. Yellow arrowheads identify Ngn3-lineage traced cells that are 
Fev+ but do not express Ngn3 or Isl1. Purple arrowheads identify Fev+/Isl1+ cells that are 
Ngn3-lineage traced. Magenta arrowheads identify Isl1+ cells that are Ngn3-lineage-traced. (b-
c) Dual ISH/immunofluorescence (IF) for NGN3 and FEV mRNA and CHGA protein in human 
fetal pancreas at 23 weeks of gestation (n=1 pancreas). Grey arrowheads identify NGN3+ cells. 
Yellow arrowheads identify FEV+ cells. Purple arrowheads identify FEV+/CHGA+ cells. 
Magenta arrowheads identify CHGA+ cells. (d) Multiplexed fluorescent ISH for NGN3, FEV, and 
ISL1 mRNA in hESC-derived endocrine progenitor cells. Blue arrowheads identify NGN3+/FEV+ 
cells. Yellow arrowheads identify FEV+ cells. Purple arrowheads identify FEV+/ISL1+ cells. (e) 
Quantification of each population detected in Ngn3-lineage traced pancreata as a percentage of 
Ngn3-lineage traced cells (n=464 cells, 6 pancreata). Data are represented as mean + standard 
deviation (SD). (f) Quantification of each population detected in hESC-derived progenitor cells 
as a percentage of total stained cells (n=418 cells, 3 clusters representing technical replicates 
from one hESC differentiation). Data are represented as mean + SD (g) Proposed model for the 
derivation of FevHi endocrine cells from Ngn3+ cells, and their differentiation into 
hormone+/FevLo endocrine cells. Colors of arrowheads and bars in a-f correspond to cell identity 
in g. (a and d) Scale bar: 10 um. (b and c) Scale bar: 20 um. (h) t-SNE visualization of v2 
merged endocrine timecourse (E12.5, E14.5, aggregated E17.5). Clusters are annotated based 
on correlation with v1 dataset or top differentially-expressed genes. (i) Timepoint labels for v2 
merged endocrine timecourse data. t-SNE is the same as Fig. 2.9h. (j) Cell type proportions at 
each timepoint, calculated from the clusters depicted in Fig. 2.9h.   
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Figure 2.10. Epithelial Populations over Developmental Time. (a) t-SNE visualization of 
merged version 1 epithelial clusters from E12.5 (n=18 pancreata), E14.5 (n=14 pancreata for 
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batch 1; n=11 for batch 2), and E17.5 (n=8 pancreata). All panels depict the same t-SNE plot. In 
the far-left panel, cluster identity is denoted by different colors. Throughout figure, cells are 
color-coded by cluster identity. In the three remaining panels, cells from the indicated timepoint 
are represented by black dots; all cells from the other timepoints are gray. (b) FACS plots 
depicting CD140a negative selection from E12.5 (n=14), E14.5 (n=13), and E17.5 (n=13) 
pancreata. CD140a-negative cells were used for single-cell sequencing. (c) Quality control 
statistics for 10X Chromium version 2 single-cell RNA-sequencing runs. These datasets are 
referred to as v2 datasets. Two technical replicates of E17.5 cells were run from the same 
pancreata on two separate wells on the 10X Chromium machine. The two E17.5 runs were 
aggregated and analyzed as one dataset. (d) Individual t-SNE plots of v2 E12.5, E14.5, and 
E17.5 (aggregated) exocrine dataset. Clusters are annotated based on gene expression. (e) 
Individual t-SNE plots of v2 E12.5, E14.5, and E17.5 (aggregated) endocrine dataset. Clusters 
are annotated based on correlation with v1 datasets and differentially expressed genes. (f) 
Pearson’s correlation among clusters from v1 merged endocrine timecourse and v2 merged 
endocrine timecourse. (g) Dot plot of top differentially expressed genes for clusters in the v2 
merged endocrine dataset. Clusters correspond to those depicted in t-SNE in Fig. 2.9h. 
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Figure 2.11. Differentiated hormone+ endocrine cells transit through a Fev-expressing 
stage during pancreatic development. (a-e) Dual IF (for membrane GFP) and fluorescent ISH 
for hormones in Fev-Cre; ROSA26mTmG lineage traced animals at E14.5. n=46 cells of 4 
pancreata for Ins1 (100% labeled-lineage); n=103 of 4 pancreata cells for Gcg (100% lineage-
labeled); n=6 cells of 2 pancreata for Sst (100% lineage-labeled); n=26 cells of 2 pancreata for 
Ghrl/Gcg (23.2% lineage-labeled); n=71 cells of 8 pancreata for Ppy (90.1% lineage-labeled). 
Scale bar represents 10um. (f) Schematic of E14.5 Fev-Cre; ROSA26mTmG FACS sorting and 
single-cell RNA-sequencing. (g) Representative FACS plots of sorted single, live GFP+ and 
TdTomato+/GFP- cells from dissociated pancreata used for single-cell sequencing. (h) t-SNE 
visualization of endocrine cells in Fev-lineage traced E14.5 mouse pancreata (n=3). (i) 
Expression of major markers of endocrine cell types. Color indicates level of expression, except 
for the eGFP plot, which indicates presence or absence of eGFP counts. 
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Figure 2.12. In vivo Fev lineage tracing of E17.5 mouse pancreata. (a-d) 
Immunofluorescence (IF) for hormones Ins1 (100% lineage-labeled), Gcg (100% lineage-
labeled), Sst (96.7% lineage-labeled), and Ppy (100% lineage-labeled) in embryonic pancreatic 
hormones in Fev-Cre; ROSA26mTmG lineage traced animals at E17.5 (n=86 cells of 5 pancreata 
for Ins1; n=57 cells of 5 pancreata for Gcg; n=30 cells of 5 pancreata for Sst; n=47 cells of 5 
pancreata for Ppy). (e) Dual IF (for membrane-GFP) and multiplexed fluorescent ISH for Ghrl 
and Gcg in Fev-Cre; ROSA26mTmG lineage traced animals at E17.5 (n=23 cells of 2 pancreata 
for Ghrl/Gcg). Ghrl+/Gcg- cells (47.8% lineage-labeled) represent the epsilon population. Non-
lineage labeled epsilon cells are denoted by the arrowheads, and lineage-labeled epsilon cells 
are denoted by the arrows. Scale bar represents 10um in a-e. 
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Figure 2.13. In vivo Fev lineage tracing of adult mouse pancreata. (a-d) IF for adult 
hormones in 6-week Fev-Cre; ROSA26mTmG lineage-traced pancreas. From one animal: n=172 
cells for Ins1 (100% lineage-labeled); n=65 cells for Gcg (100% lineage-labeled); n=86 cells for 
Sst (97.7% lineage-labeled); n=30 cells for Ppy (100% lineage-labeled). Scale bar represents 
10um in a-d. 
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Figure 2.14. Identification of candidate regulators of beta and alpha cell fate decisions. 
(a) Pseudotime ordering of the endocrine cells at E14.5 depicted in Fig. 2.8h yields a bifurcated 
tree in which the two main branches terminate in cells that highly express Ins1 (beta cell branch) 
or Gcg (alpha cell branch). (b) Heatmap depicting the expression of genes along each branch, 
in pseudotime. An independent expression pattern is calculated across the entire pseudotime 
trajectory for each branch. Therefore, the portion of the trajectory before the branch point is 
displayed for each branch separately. Genes are clustered based on expression pattern across 
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pseudotime; selected genes with differential expression along the branches are highlighted to 
the right. (c) Gene expression plots depicting the kinetic trends along each branch. (d-e) 
Multiplexed fluorescent ISH for Fev, Gng12, and Islet1 (d) or Fev, Peg10, and Islet1 (e) in 
lineage-traced E14.5 Ngn3-Cre; ROSA26mTmG pancreas. Arrowheads identify lineage-traced 
Fev+/Islet1- cells with Gng12 (d, teal gradient arrowheads) or Peg10 (e, indigo gradient 
arrowheads) expression. (f) Multiplexed fluorescent ISH for Fev, Gng12, and Ins1. Teal 
arrowheads identify lineage-traced Ins1+ beta cells that express Gng12.  (g) Multiplexed 
fluorescent ISH for Fev, Peg10, and Gcg. Indigo arrowheads identify lineage-traced Gcg+ alpha 
cells that express Peg10. (h) Model for FevHi (yellow) cell differentiation into distinct alpha or 
beta cells. Peg10 and Gng12 expression in FevHi cells may represent progenitors pre-fated 
towards the alpha and beta lineages, respectively, during endocrine lineage allocation. (d-g) 
Scale bars represent 10 um. Blue staining represents DAPI-labeled nuclei. Colors of 
arrowheads match colors of cells represented in (h). 
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Figure 2.15. Identification of Candidate Genes and Pathways Enriched Along Beta and 
Alpha Cell Lineages. (a) Pseudotime ordering trajectory of v1 timecourse dataset, including 
E12.5, E14.5 (batch 1 and batch 2), and E17.5 datasets. (b) Gene expression plots depicting 
the kinetic curves of individual genes (from Fig. 2.14b) across pseudotime in the alpha or beta 
branches. (c) Pathway analysis for clusters of genes from the BEAM analysis. Gene clusters 
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correspond to Figure 14b. (d) SPRING plots for Fev-lineage traced dataset, including all 
endocrine cells. Colors match those in Fig. 2.11h. Expression of selected genes predicted from 
monocle BEAM analysis.  
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Figure 2.16. Expression of Candidate Regulators within the Endocrine Lineage Prior to 
Alpha or Beta Cell Identity. (a) Multiplex fluorescent ISH for Fev (yellow), Peg10 (cyan), and 
Ins1 (magenta) in lineage-traced E14.5 Ngn3-Cre; ROSA26mTmG pancreas. Indigo-graded 
arrows highlight lineage-traced Fev+/Peg10+ cells that do not express Ins1. Teal arrows 
highlight Ins1+ beta cells that do not express Peg10. (b) Multiplex fluorescent ISH for Fev 
(yellow), Gng12 (cyan), and Gcg (magenta) in lineage-traced E14.5 Ngn3-Cre; ROSA26mTmG 
pancreas. Teal-graded arrows highlight lineage-traced Fev+/Gng12+ cells that do not express 
Gcg. Indigo arrows highlight Gcg+ alpha cells that are not enriched for Gng12.  
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Chapter 3 
Lineage allocation in human endocrine cell development 
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Introduction 
 
 Defining endocrine lineage allocation in mouse pancreatic development has been largely 
motivated by the desire to understand how endocrine cells arise in human development. 
Gaining a better understanding of the cell stages required for human endocrine cell 
development as well as the transcriptional circuitry driving lineage allocation into distinct 
endocrine linages will refine our ability to generate these hormone-expressing cell types from 
human embryonic stem cells. Several key transcription factors important for endocrine cell 
development in mouse have already been found to be conserved and required in that of human. 
Like in Pdx1-null mice, inactivating mutations in PDX1 results in neonatal diabetes that requires 
insulin treatment as well as exocrine pancreas deficiency (Stoffers et al., 1997). PDX1 is 
expressed in the pancreatic endoderm and is retained in multipotent pancreatic progenitors that 
are postulated to give rise to acinar, duct, and endocrine lineages of the human pancreas 
(Jennings et al., 2013; Lyttle et al., 2008; Piper et al., 2004). Homozygous mutations in NGN3 
also cause neonatal diabetes due to the lack of differentiated beta cells in the pancreas. This 
pancreatic phenotype of NGN3-deficient neonates is also accompanied with the lack of 
intestinal enteroendocrine differentiation that results in congenital diarrhea (Pinney et al., 2011; 
Wang et al., 2006), which is concordant with Ngn3’s role in enteroendocrine differentiation in 
murine intestine (Gehart et al., 2019). Downstream of NGN3, the transcription factors 
NEURDO1, NKX2.2, PAX6, and MNX1 have all been identified to cause neonatal diabetes 
when mutated (Bonnefond et al., 2013; Flanagan et al., 2014; Rubio-Cabezas et al., 2010; 
Solomon et al., 2009). NEUROD1 and NKX2.2 are considered direct targets of NGN3 
(Gradwohl et al., 2000; Sussel et al., 1998) and, like PAX6, are expressed in differentiated beta 
cells in early development (Jennings et al., 2013; Lyttle et al., 2008). Thus, there is functional 
conservation of critical transcription factors required for pancreatic development in both mouse 
and human.  
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 In particular, although the function of NGN3 as a key regulator in endocrine cell 
development appears to be conserved in human, the duration of NGN3 expression and the 
events following NGN3 upregulation in human pancreatic development remain unclear. In 
mouse, Ngn3 expression in the pancreas is biphasic (Villasenor et al., 2008) and within each 
endocrine progenitor, Ngn3 expression persists for about 24 hours (Beucher et al., 2012b). In 
human, it has been reported that NGN3 expression occurs as a single wave (Jennings et al., 
2015). However, the duration of this single wave of NGN3 expression in human development 
has not been fully mapped, and the lack of genetic and time-resolution studies of human 
endocrine development makes it difficult to assess the true dynamics of NGN3 expression. 
Additionally, in human, hormone-expressing lineages are presumed to be derived from NGN3+ 
endocrine progenitors, but the events following transient NGN3 expression and the 
differentiation into a hormone-expressing endocrine lineage remain unclear. Without 
understanding the cell stages during this critical window of endocrine cell differentiation, we also 
lack understanding of the transcriptional mechanisms that may be regulating endocrine lineage 
allocation in one of five distinct hormone-expressing lineages in human pancreatic development.  
The discovery of a novel endocrine progenitor defined by high Fev expression in mouse 
prompted the question of whether additional endocrine progenitor stages exist in human 
endocrine cell development beyond the NGN3+ endocrine progenitor stage. Defining these 
stages in human can be leveraged to more properly mimic human endocrine cell development 
in vitro during directed differentiation protocols that harness the power of hESCs. Here, we use 
single-cell RNA-sequencing to interrogate the diversity of cell types that arise during human 
pancreatic development. We construct transcriptional profiles of previously known human 
pancreatic cell compartments, including epithelial, mesenchymal, endothelial, neural, and 
immune populations. Within the endocrine compartment, we identify previously known NGN3+ 
endocrine progenitors and uncover new transcriptional markers of these cells. We also annotate 
alpha, beta, delta, and epsilon lineages based on expression of GCG, INS, SST, and GHRL, 
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respectively. In silico lineage reconstruction of endocrine lineages identifies two novel endocrine 
populations in human pancreatic development that represent pre-beta and pre-alpha endocrine 
progenitors derived from NGN3+ progenitors and that distinctly precede differentiation into the 
alpha and beta lineages. Both these pre-beta and pre-alpha progenitor populations express 
FEV. This in silico reconstruction of endocrine lineage relationships also enabled the 
identification of candidate regulators of alpha and beta cell lineage fates in human development. 
Using in vivo human beta cell development as a guidepost for proper beta cell generation from 
in vitro differentiation of hESCs, we construct a lineage map of hESC-derived beta cell 
differentiation and identify FEV-expressing endocrine cells that have mis-differentiated into a 
hormone-negative lineage. Dissection of the transcriptomic profiles of this mis-differentiated 
lineage reveals candidate regulators of improper beta cell differentiation that become expressed 
during the directed differentiation process. Thus, we now have mapped proper and improper 
differentiation trajectories of human endocrine lineages during both fetal development and the 
directed differentiation of hESCs towards a beta lineage. Our work forms a roadmap from which 
our understanding of human endocrine cell development can be further refined.  
 
Results 
 
Diversity of cell types in the developing human pancreas 
 
 We first characterized the different cellular compartments and their transcriptional 
profiles from human fetal pancreas. We focused on a 12wpc timepoint, which represents a 
period of peak NGN3 expression and active cell differentiation in the developing human 
pancreas (Nair and Hebrok, 2015). Tissue from this 12wpc timepoint was dissociated into a 
single-cell suspension, and RBCs were removed via immunomagnetic separation. The resulting 
single-cell suspension was loaded onto two wells of the 10X Chromium Single-Cell Platform and 
prepared for sequencing using version 3 (V3) chemistry. Following sequencing and de-
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multiplexing of single-cell data, UMAP-based clustering of merged well replicates revealed 22 
cell clusters organized into acinar, ductal, endocrine, mesenchymal, endothelial, immune, and 
nerve populations based on the expression of known marker genes, such as CPA1 (acinar), 
SOX9 (ductal), CHGA (endocrine), COL1A1 (mesenchymal), PECAM1 (endothelial), PTPRC 
(immune), and SOX10 (nerves) (Fig. 3.1a-c). The contribution of each cell cluster from each 
replicate well showed no batch effect based on use of different lanes on the Chromium 10X 
platform (Fig. 3.1a). Similar to our work using single-cell RNA-sequencing to interrogate the 
diversity of cell populations in mouse pancreatic development, transcriptomic profiling at single-
cell resolution facilitated our preliminary construction of a cellular roadmap of the cell 
populations present in the developing human pancreas.  
 
Identification of novel cell stages during human endocrine cell development 
 
 Given our previous identification of novel progenitor stages in mouse pancreatic 
development, we next focused on the endocrine compartment of the developing human 
pancreas in order to determine if additional endocrine stages exist beyond those characterized 
by NGN3+ progenitors and differentiated hormone+ endocrine cells. Sub-clustering of the 
CHGA+ cell clusters resulted in increased resolution of the endocrine lineage populations 
present in 12wpc human fetal pancreas, revealing 11 distinct endocrine lineage populations 
(Fig. 3.2a). We identified clusters defined by GCG, INS, SST, and GHRL, corresponding to 
alpha, beta, delta, and epsilon cells, respectively (Fig. 3.2b). By sequencing, INS transcript 
appeared to be also present in the alpha cell cluster (Fig. 3.2b). However, it is likely that 
differentiated alpha cells do not translate the INS transcript into protein. While we only identified 
one cell cluster each for alpha, delta, and epsilon populations, we observed 3 distinct fetal INS+ 
beta cell populations (clusters 0, 2, and 4) defined by distinct differentially-expressed genes 
(Fig. 3.2a-c). Many of these differentially-expressed genes, such as DLK1, MEG3, and RBP4, 
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have been previously identified to drive beta cell heterogeneity in the adult human pancreas, 
suggesting that sources of beta cell heterogeneity arise as early as in fetal pancreatic 
development (Lawlor et al., 2017; Segerstolpe et al., 2016). This heterogeneity in beta cells 
observed in development could serve as a major underpinning of the heterogeneity in the 
regulation of functional maturation and levels of ER stress seen in both mouse and human beta 
cells (Baron et al., 2016; Muraro et al., 2016; Qiu et al., 2017a; Zeng et al., 2017).  
We also found three additional cell clusters (clusters 6, 8, and 9) that were devoid of any 
hormone expression (Fig. 3.2a,b and 3a). Cluster 6 displayed expression of NGN3 (Fig. 3.2b, 
3a), and clusters 8 and 9 exhibited FEV expression (Fig. 3.2b, 3a). Given our previous work 
identifying that Fev marks a endocrine progenitor population that is derived from Ngn3+ 
progenitors in mouse pancreatic development (Byrnes et al., 2018), we wanted to determine 
whether these clusters gave rise to hormone-expressing endocrine lineages. We performed in 
silico reconstruction of lineage relationships using pseudotemporal ordering with only cluster 6, 
cluster 8, cluster 9, beta 1, beta 2, and the alpha cell cluster as input (Fig. 3.3b, left panel). This 
analysis revealed that clusters 6, 8, and 9 were precursors to the alpha and beta lineages (Fig. 
3.3b, c). Cluster 6 represented a common endocrine progenitor population that gave rise to both 
alpha and beta lineages (Fig. 3.3a, b). Clusters 8 and 9, on the other hand, were precursor 
populations that gave rise to differentiated beta and alpha cells, respectively (Fig. 3.3a-c). Thus, 
cluster 8 was postulated to represent a pre-beta progenitor population, and cluster 9 was 
postulated to represent a pre-alpha progenitor population. FEV was a top 1.5-fold differentially 
expressed gene in both clusters 8 and 9 (Fig. 3.3a and Supplementary Data 17), suggesting 
that FEV-expressing progenitors give rise to both alpha and beta lineages in human endocrine 
cell development. FEV expression persisted into the alpha lineage but was not expressed by 
differentiated beta cells (Fig. 3.3a, c), suggesting that FEV must turn off in pre-beta progenitors 
prior to the acquisition of beta cell identity while this requirement is not true for pre-alpha 
progenitors that differentiate into the alpha lineage. This was in contrast to mouse pancreatic 
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development in which Fev is expressed in a subset of differentiated alpha and beta cells 
(Byrnes et al., 2018). In examining other critical transcription factors for endocrine development, 
we observed upregulation of PDX1, NKX6.1, and PAX4 expression in the pre-beta progenitor 
stage (Fig. 3.3c). PAX6 and NEUROD1, on the other hand, were expressed in both the alpha 
and beta lineages, starting at the common progenitor stage (cluster 6) (Fig. 3.3c). Our 
pseudotemporal ordering analysis thus provides additional insight into the cell stages required 
to generate alpha and beta cells in human pancreatic development.  
The inclusion of other hormone-expressing endocrine lineages in pseudotemporal 
ordering did not result in a continuous differentiation trajectory (Fig. 3.3b, middle and right 
panels). Inclusion of the third beta cell population (beta 3) resulted in a trajectory that excluded 
this population from the main trajectory (Fig. 3.3b, middle panel), meaning that our 
pseudotemporal ordering analysis considered this beta 3 cluster as not lineage related to any 
other population. Similarly, inclusion of the GHRL+ epsilon and SST+ delta clusters resulted in a 
disjointed trajectory that did not place these other hormone-expressing lineages in lineage 
relationships with the progenitor populations we have annotated (Fig. 3.3b, right panel). 
Sequencing of additional timepoints will increase the number of endocrine lineage cells 
captured and thus may provide increased resolution to differentiation process of these other 
hormone-expressing lineages.  
Pairwise comparisons and examination of the top differentially expressed genes of 
clusters 6, 8, and 9 revealed that these populations represent novel cell stages of human 
endocrine cell differentiation at a resolution that we have not been able to appreciate with 
previous techniques. NGN3 expression was concentrated within the common endocrine 
progenitor population (cluster 6), although NGN3 was not among the top 5 differentially-
expressed genes (Fig. 3.2b and Supplementary Data 17). Instead, this common endocrine 
progenitor cluster was defined by expression of genes such as EMC10, SOX4, and HES6 (Fig. 
3.2c, 4a-c). EMC10 is a ER membrane protein with reported roles as an angiogenic factor that 
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promotes tissue repair after myocardial infarction (Reboll et al., 2017). SOX4 is a member of the 
SOX family of transcription factors and is a reported target of Ngn3 in mouse pancreatic 
development (Xu et al., 2015). HES6 suppresses HES1, which suppresses the onset of NGN3 
expression that initiates endocrine cell development in the pancreas (Masjkur et al., 2016). 
Other notable genes whose canonical functions involve transcription and DNA binding and that 
were more than 1.5-fold differentially expressed in common endocrine progenitors (cluster 6) 
include NEUROD1, NKX2-2, PAX4, RFX3, SMARCC1, CITED2, HMGB3, KDM5B, ZBTB18, 
TGIF2, ARID4A, CBFA2T2, and PROX1 (Fig. 3.4 and Supplementary Data 17). According to 
our pseudotime reconstruction of endocrine lineage relationships, these common endocrine 
progenitors in cluster 6 gave rise to both pre-beta and pre-alpha progenitors (clusters 8 and 9) 
(Fig. 3.3b). Although both the pre-beta and pre-alpha progenitor populations expressed 
hormones (Fig. 3.3a), their expression of either INS or GCG was markedly lower compared to 
the expression levels of both hormones found in differentiated beta or alpha cells (Fig. 3.3a), 
suggesting that these clusters were not fully differentiated into their respective endocrine 
lineages. The top differentially-expressed genes in pre-beta progenitors in cluster 8 were MEG3, 
NR4A2, and IGFBP5 (Fig. 3.2c). Notable factors involved in transcription that were more than 
1.5-fold differentially-expressed in pre-beta progenitors include SOX4, NKX6-1, PDX1, PAX6, 
PAX4, EGR3, ARID5B, RYBP, SIM1, MNX1, TSHZ1, ATF3, FOXA2, NR4A3, NR4A1, NR4A2, 
MAFB, EGR4, NPAS4, ID4, and ETS2 (Fig. 3.4a, b, and d and Supplementary Data 17). In 
contrast, the top differentially expressed genes in pre-alpha progenitors in cluster 9 were IRX2 
and ARX, which both regulate alpha cell lineage allocation (Petri et al., 2006; Wilcox et al., 
2013), as well as CDKN1C, which is a cyclin-dependent kinase inhibitor (Fig. 3.2c). Notable 
factors involved in transcription that were more than 1.5-fold differentially-expressed in pre-
alpha progenitors include NEUROD1, PAX6, ISL1, PSIP1, ST18, SIM1, MLXIPL, TOX3, PBX1, 
ESRRG, and ID4 (Fig. 3.4a, c and d and Supplementary Data 17). Pairwise comparisons 
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among these three endocrine progenitor clusters reveal that each population is transcriptionally 
distinct and arises at defined stages along endocrine cell differentiation. 
 
Candidate lineage regulators of the beta cell lineage 
 
 The onset of NGN3 expression marks the beginning of endocrine cell development as 
cells differentiate towards a hormone+ endocrine lineage. However, the transcriptional 
programs that guide these endocrine progenitors toward a distinct hormone-expressing 
endocrine lineage are not well defined in human endocrine cell differentiation. With the lack of 
lineage tracing tools available for in vivo human studies, we used our single-cell RNA-
sequencing data to make inferences about the transcriptional machinery that regulates 
endocrine lineage allocation. Given that we observed distinct stages of cellular differentiation 
leading to both alpha and beta lineages (Fig. 3.3b), we next investigated potential transcriptional 
regulators involved in mediating the acquisition of either alpha or beta cell identity.  
We used pseudotemporal ordering to identify genes that were differentially expressed 
across a single-cell trajectory. We first applied this analysis to the beta lineage branch, which 
exhibited differentiation starting with cluster 6 cells (common endocrine progenitors) to cluster 8 
cells (pre-beta progenitors) and finally to beta cells (Fig. 3.5a). Our lineage branch analysis 
resulted in 7 major gene clusters that displayed 3 main patterns of gene expression: genes that 
were highly expressed in the common progenitor stage but tapered in expression as 
differentiation proceeds (gene clusters 2-4), genes that turned on specifically in the pre-beta 
progenitor stage and were either subsequently downregulated or remained expressed (gene 
clusters 1, 6, and 7), and genes that turned on specifically in differentiated beta cells (gene 
cluster 5) (Fig. 3.5a). NGN3 was found in gene cluster 3, along with other genes known as 
endocrine progenitor markers, such as NKX2-2, RFX6, NEUROD1, PROX1, HES6, and GATA6 
(Fig. 3.5a and Supplementary Data 18). These known endocrine progenitor markers were highly 
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expressed in the common progenitor cluster (cluster 6) but were downregulated during the pre-
beta progenitor stage (Fig. 3.5b). On the other hand, genes within gene cluster 7, which were 
expressed specifically in differentiated beta cells, included WNT4, which regulates beta cell 
proliferation, and RGS2, which regulates beta cell mass (Supplementary Data 18) (Dong et al., 
2017; Heller et al., 2011). INS, which is a definitive marker of beta cells, began to become 
upregulated in the pre-beta progenitor stage and reached peak expression in the differentiated 
beta cell stage (Fig. 3.5c). 
We reasoned that genes within gene clusters 1, 6, and 7 that were upregulated during 
the pre-beta progenitor stage may serve as potential regulators of beta cell lineage allocation. 
FEV was found in gene cluster 7 (Supplementary Data 18). Genes that displayed high 
upregulation during the pre-beta progenitor stage also included genes known to be involved in 
beta cell differentiation and function, such as CHGB, SCG5, ERO1B, MAFB, and PAX6 (Fig. 
3.5c). The upregulation of known genes involved in insulin production, insulin processing, and 
the beta cell differentiation program confirmed that our pseudotemporal ordering analysis was 
robust. Genes involved in cytoskeletal remodeling and cell migration, including ROBO2, VIL1, 
CALY, TAGLN2, KIF5C, KIF12, and PHACTR2, were also upregulated beginning in the pre-
beta progenitor stage (Supplementary Data 18). These cytoskeletal remodeling and cell 
migration genes could be reflective of islet cell migration and formation that occurs concurrently 
with beta cell differentiation (Sharon et al., 2019a).  
We also identified candidate regulators not previously known to be involved in beta cell 
lineage allocation. These genes were organized into 3 broad categories: those that were 
imprinted, those involved in neural development, and others involved in transcription and 
canonical signaling pathways. Imprinted genes that were upregulated during beta cell 
differentiation included DLK1, MEG3, GNAS, PLAGL1, PEG3, and PEG10 (Fig. 3.5d). The role 
of imprinting in endocrine cell development has not been previously explored, although loss or 
dysregulation of imprinted genes has been implicated in impaired pancreatic endocrine cell 
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function. Epigenetic dysregulation of DLK1-MEG3 microRNAs has been observed in human 
T2D islets (Kameswaran et al., 2014). In the GNAS locus, improper mono-allelic expression of 
GNAS from the maternal allele results in a host of growth and metabolic disorders, including 
obesity (Weinstein et al., 2010). Bi-allelic expression of PLAGL1 causes 60% of all cases of 
transient neonatal diabetes mellitus (TNDM) (Hoffmann and Spengler, 2012; Kamiya et al., 
2000). PEG3 encodes a zinc finger transcription factor that inhibits beta cell proliferation in mice 
(Sojoodi et al., 2016), and PEG10 was recently identified by our group to be a lineage marker of 
the murine alpha lineage (Byrnes et al., 2018).  
Upregulated genes known to be involved in neural development included ASCL2, AHI1, 
and SEZ6L2 (Fig. 3.5e). ASCL2 (also called MASH2) is also an imprinted gene and comes from 
a family of bHLH transcription factors that regulates neuronal progenitor differentiation and 
peripheral nerve regeneration (Ge et al., 2006; Guillemot et al., 1993; Küry et al., 2002). AHI1 
regulates cortical development in humans (Doering et al., 2008). Mutations in SEZ6L2 have 
been implicated in seizure-related phenotypes, and more recently, the gene has been identified 
as marker for developing islet cells during embryogenesis (Bedoyan et al., 2010; Hald et al., 
2011). Finally, ARID5B and ACVR1C were genes significantly expressed as differentiation into 
the beta lineage occurred (Fig. 3.5e). ARID5B participates as a transcriptional coactivator that is 
required for adipogenesis (Okuno et al., 2013). Signaling through ACVR1C, an Activin A 
receptor, has been reported to inhibit insulin secretion from beta cells (Bertolino et al., 2008), 
suggesting that signaling downstream of ACVR1C possibly blocks premature insulin secretion in 
pre-beta progenitors or early-forming beta cells during human endocrine cell development. The 
identification of these genes upregulated during the pre-beta progenitor stage begins to 
elucidate transcriptional circuitry involved in human beta cell differentiation that can be 
subsequently validated in in vitro differentiation models (Fig. 3.5f).  
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Candidate lineage regulators of the alpha cell lineage 
 
 We applied a similar analysis to identify genes that were differentially expressed during 
differentiation into alpha cells. Based on pseudotemporal ordering, differentiation of the alpha 
lineage from endocrine progenitors began with cluster 6 (common progenitors) that differentiate 
into cluster 9 cells (pre-alpha progenitors), which then become differentiated alpha cells found in 
cluster 9 (Fig. 3.3b). Alpha lineage branch analysis resulted in 6 major gene clusters that, 
similar to the beta lineage branch analysis (Fig. 3.5a), displayed 3 main patterns of gene 
expression: genes that were highly expressed in the common progenitor stage but tapered in 
expression as differentiation proceeds (gene clusters 2 and 3), genes that turned on specifically 
in the pre-alpha progenitor stage and were either subsequently downregulated or remained 
expressed (gene clusters 1, 4, and 5), and genes that turned on specifically in differentiated 
alpha cells (gene cluster 6) (Fig. 3.6a). Genes known to be expressed by differentiated alpha 
cells, including GCG, TTR, ALDH1A1, FAM46A, and CRYBA2 (Dorajoo et al., 2017; Muraro et 
al., 2016; Su et al., 2012), displayed upregulated expression along pseudotime (Fig. 3.6b). 
Genes known to regulate alpha lineage allocation, such as IRX2, ARX, and ISL1, also were 
upregulated but specifically beginning in the pre-alpha progenitor cluster (Fig. 3.6c).  
Given that gene clusters 4 and 5 contained genes that were upregulated specifically 
after NGN3 downregulation and the acquisition of alpha cell identity, these genes may 
potentially serve as candidate regulators of alpha lineage allocation. Similar to our analysis of 
the beta cell lineage, MAFB, PAX6, ERO1B, AHI1, PEG10, SCG5, and ACVR1C were found to 
be upregulated along alpha cell differentiation (Supplementary Data 19), suggesting that these 
markers are common genes upregulated during endocrine cell differentiation as a whole. We 
observed upregulation of various neural transcription factors and genes during alpha cell 
differentiation. BEX2, BEX4, and BEX5 were all upregulated during alpha cell fate allocation and 
are members of the brain-expressed X-linked transcription factor family that are highly 
expressed in the brain (Alvarez et al., 2005) (Fig. 3.6d). ST18 was another neuronal lineage 
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transcription factor that promotes cholinergic motor neuron differentiation and that was 
upregulated during alpha cell development (Teratani-Ota et al., 2016) (Fig. 3.6d). Other genes 
upregulated during this process and implicated in neural function included ANK3, which is 
required in neurons for proper synapse structure and function (Smith et al., 2014), and STMN2, 
which is required for normal axonal outgrowth and regeneration in the nervous system (Klim et 
al., 2019) (Fig. 3.6d). Furthermore, we identified a number of cell surface markers that were first 
expressed during the pre-alpha progenitor stage and can be used to guide cell purification. 
These included SLC3A2, SLC7A2, SLC7A8, SLC30A8, ALCAM, and CD99 (Fig. 3.6e). 
SLC30A8 has already been shown to be required in adult alpha cells for hypoglycemia-induced 
glucagon secretion (Solomou et al., 2015). Our analysis of the alpha differentiation trajectory 
(Fig. 3.6f), paired with that of the human beta lineage, highlights the power of pseudotemporal 
ordering that defines the dynamic transcriptional programs in place as endocrine progenitors 
become specified towards distinct hormone-expressing lineages. 
 
Cellular and transcriptional dynamics of the developing endocrine compartment  
 To understand endocrine cell development across actual developmental time, we 
performed single-cell RNA-sequencing on tissue at 3 additional timepoints to add to our analysis 
on 12wpc human fetal pancreas (referred to as 12wpc_1): a second biological replicate of 
12wpc (referred to as 12wpc_2), 15.5wpc, and 16wpc. All datasets were depleted of red blood 
cells through immunomagnetic separation and generated using the 10X Genomics version 3 
(V3) sequencing chemistry, except for the 15.5wpc sample, which was enriched for EPCAM+ 
cells through FACS and processed using version 2 (V2) sequencing chemistry. All datasets 
were merged with Seurat 3’s new integration method for merging and batch correction, resulting 
in 31 distinct clusters (Fig. 3.7a) that were classified as CPA1+ acinar cells, SOX9+ ductal cells, 
CHGA+ endocrine cells, COL1A1+ mesenchymal cells, PECAM1+ endothelial cells, PTPCR+ 
immune cells, and SOX10+ nerve cells (Fig. 3.7c). The two 12wpc samples and single 16wpc 
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sample were represented in all clusters, highlighting the robustness of Seurat 3’s new 
Integration method for batch correction by biological sample (Fig. 3.7b). As expected, given that 
the 15.5wpc sample was enriched for EPCAM+ cells, this timepoint only contributed to the 
EPCAM+ populations in the merged dataset (Fig. 3.7b, c). To focus on the endocrine 
compartment, CHGA+ endocrine clusters from the merged dataset were sub-clustered (Fig. 
3.7c).  
Sub-clustering of the endocrine lineage resulted in 15 distinct populations (Fig. 3.8a), 
including NGN3+ endocrine progenitors, INS+ beta cells, GCG+ alpha cells, SST+ delta cells, 
and GHRL+ epsilon cells (Fig. 3.8c). We also observed a FEV+ cluster that was not defined by 
any hormone expression (Fig. 3.8c), which is in line with the FEV+ endocrine progenitor cells 
we identified in 12wpc pancreas (Fig. 3.2b, 3a). This FEV+ cluster had representation from all 4 
fetal timepoints (Fig. 3.8b, c), suggesting that FEV+ progenitors appear as early as 12wpc and 
persist at least as late as 16wpc in human pancreatic development. Plotting the top 3 
differentially-expressed genes from each cluster highlighted the gene expression profile 
differences of each endocrine cluster (Fig. 3.8d).   
 We next sought to reconstruct lineage relationships across multiple timepoints through 
pseudotemporal ordering. Batch effect, unfortunately, is a major issue that still confounds 
single-cell RNA-sequencing analysis, despite multiple groups developing algorithms to address 
this problem (Butler et al., 2018; Haghverdi et al., 2018; Stuart et al., 2019). In our merged 
dataset, batch effect became problematic as our 15.5wpc sample was processed with V2 10X 
Genomics version chemistry as opposed to V3 chemistry, which was utilized for processing our 
12wpc and 16wpc samples. V3 chemistry increases the sensitivity of gene capture, and this was 
particularly evident by the percentage of mitochondrial genes captured in V3 datasets, in which 
more mitochondrial genes were represented in V3 datasets (Fig. 3.8e). This discrepancy in 
mitochondrial gene capture led to a batch effect in pseudotemporal ordering that was not 
resolved through regressing on mitochondrial content (Fig. 3.8e). Endocrine cells from the 
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15.5wpc sample clustered more closely to one another than integrating with cells from other 
timepoints, and this was driven by differences in mitochondrial content of the datasets (Fig. 
3.8e). In order to reconstruct lineage relationships across multiple timepoints, additional human 
fetal datasets using V3 chemistry will be used in the future.  
 
Understanding the emergence of distinct cellular compartments during in vitro beta cell 
differentiation at single-cell resolution  
 Directed differentiation of hESCs to a beta cell lineage represents a powerful approach 
for not only generating beta cells for diabetes but also understanding human beta cell 
differentiation. Given the significant heterogeneity in cells generated by directed differentiation 
of hESCs towards the beta lineage, we leveraged single-cell RNA-sequencing to classify distinct 
cellular populations that arose across five main stages of in vitro beta cell differentiation: stages 
containing early-, middle-, and late-stage endocrine progenitors (ES4, S5D4, and S5D7) and 
two stages within the beta lineage stage (S6D4 and S6D10). UMAP-based clustering of all five 
timepoints revealed the presence of PDX1+ clusters, reflecting induction towards the pancreatic 
lineage during the directed differentiation towards the beta lineage (Figs. 9, 10). In ES4, we 
identified proliferating PDX1+ pancreatic progenitors, PDX1+/NKX6.1+ pancreatic progenitors, 
early-induced endocrine cells marked by CHGA and NEUROD1, and CDX2+ clusters that likely 
represent intestinal lineages that arose from improper differentiation (Fig. 3.9c). Of mid- to late-
stage endocrine progenitors in Stage 5, only a small percentage expressed the endocrine 
progenitor marker NGN3 (Fig. 3.9d, e), which was expected given the transient nature of NGN3 
expression. Instead, we observed PDX1+/NKX6.1+ progenitors, replicating PDX1+/NKX6.1+ 
progenitors, the persistence of CDX2+ cluster, and CHGA+/NEUROD1+ endocrine clusters that 
began to express hormones, such as INS and GCG (Fig. 3.9d, e). During Stage 6, which is 
defined as the beta cell stage, we again observed CDX2+ clusters and CHGA+/NEUROD1+ 
endocrine clusters that contain INS- and GCG-producing cells (Fig. 3.10a-d).  
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hESC-derived FEV+ cells are transcriptionally similar to in vivo FEV+ progenitors 
 
 Given that we had identified an endocrine progenitor stage defined by FEV expression in 
both mouse (Byrnes et al., 2018) and human fetal beta cell development (Fig. 3.2b), we 
examined whether the derivation of hESC-derived beta cells also involved transit through a 
FEV-expressing cell stage. From qPCR, we determined that FEV began to be expressed 
starting in Stage 4 pancreatic progenitors and was robustly expressed in Stage 5 endocrine 
progenitors (Fig. 3.11a). FEV expression persisted in cells at the Stage 6 beta cell stage (Fig. 
3.11a), which was in contrast to differentiated beta cells in human pancreatic development that 
did not express FEV (Fig. 3.2b, 3a). This was consistent with in situ hybridization for FEV, in 
which FEV transcript was observed in S5D3 and S6D11 clusters (Fig. 3.11b). Similarly, in our 
transcriptomic profiling of cells from the end of Stage 4 to Stage 6, we observed FEV+ cells 
present at each sampled timepoint (Fig. 3.11c). To determine how transcriptionally similar the 
FEV+ cells found in beta cell differentiation in vitro were to FEV+ progenitors found in human 
endocrine cell development in vivo, we performed a Pearson’s correlation analysis. Correlation 
analysis of FEV+ progenitors from the 12wpc_1 and 12wpc_2 datasets compared to the hESC-
derived FEV+ cells revealed higher transcriptional correlation of all FEV+ clusters than 
compared to all FEV- clusters (Fig. 3.11d), suggesting that cells undergoing in vitro 
differentiation to a beta cell fate transit through a FEV-expressing stage similar to that found in 
vivo.  
 
Mapping in vitro beta cell differentiation at single-cell resolution 
 
 We next wanted to reconstruct the lineage relationships among hESC-derived endocrine 
cells during in vitro beta cell differentiation. We first merged all CHGA+ endocrine clusters from 
each sampled timepoint using Seurat 3 (Fig. 3.12a, b). Given that batch correction via Seurat 
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3’s integration method is currently not compatible with pseudotemporal ordering by Monocle 3, 
we utilized Monocle 3’s internal batch correction method to merge hESC-derived endocrine 
clusters from different timepoints and subsequently performed pseudotemporal ordering. The 
result was one main trajectory, which we used in subsequent analyses, that began with ES4 
cells, our first sampled timepoint and the designated start of our pseudotemporal ordering (Fig. 
3.12c, d). As pseudotime progressed, three main endpoints of the differentiation trajectory were 
observed (Fig. 3.12c, d). As expected, a beta cell lineage that expressed INS constituted one 
endpoint and was primarily composed of S6D4 and S6D10 cells (Fig. 3.12e). A second endpoint 
was composed of poly-hormonal cells that expressed INS, GCG, and SST (Fig. 3.12e). These 
polyhormonal cells also were derived from the S6D4 and S6D10 timepoints (Fig. 3.12c). A third 
endpoint in the differentiation trajectory surprisingly resulted from a bifurcation event early in 
pseudotime before the acquisition of hormone identity (Fig. 3.12f). The cells at this third 
endpoint did not express INS, GCG, or SST (Fig. 3.12e). Instead, this population appeared to 
be mis-differentiated and expressed transcription factors such as PHOX2A, TLX2, and TBX2 
(Fig. 3.12f), all of which regulate differentiation and function of cells in the nervous system. 
These transcription factors were not expressed in a large fraction of the endocrine compartment 
of human fetal pancreata (Fig. 3.12g). PHOX2A is required for proper differentiation of neurons 
in the autonomic nervous system, as it is crucial for the development of neural crest-derived 
cells (Borghini et al., 2006; Hirsch et al., 1998; Lo et al., 1999; Pattyn et al., 1997; Tiveron et al., 
1996). TLX2 is a transcriptional target of the PHOX2 family of transcription factors and is also 
required for proper development of the neural crest lineage and thus, also the enteric nervous 
system (Borghini et al., 2006). TBX2 promotes anterior neural specification by suppressing FGF 
signaling (Cho et al., 2017). FEV was still expressed in this mis-differentiated lineage (Fig. 
3.12e), suggesting that there may be a subset of FEV+ endocrine progenitors during in vitro 
beta cell differentiation that improperly differentiated into a neural lineage (Fig. 3.12h). The 
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expression of these transcription factors in this blocked cell type within our in vitro beta cell 
differentiation suggests that these cells have mis-differentiated into a neural identity.  
 
FEV appears to be required for proper human beta cell differentiation and function 
 
 In addition to serving as a marker for endocrine progenitor stages in human endocrine 
cell development, we wanted to determine if FEV had any functional role in beta cell 
differentiation. In Fev knockout (KO) mice, glucose clearance from the blood following a glucose 
challenge was significantly slowed, and insulin content of beta cells was decreased (Ohta et al., 
2011). Given that this study utilized a whole-body Fev KO, the defects in glucose homeostasis 
and reduction in insulin content could have been a result of a requirement of Fev in non-
pancreas cells or Fev function in multiple stages in the lifetime of a beta cell. To test the 
requirement of FEV in human beta cell differentiation and function, we used our in vitro beta cell 
differentiation platform and first generated a FEV-KO hESC line through CRISPR (clustered 
regularly interspaced short palindromic repeats)/Cas9-mediated genomic editing (Fig. 3.13a). 
The human FEV locus contains three exons, and the guide RNA (gRNA) we designed targeted 
the end of exon 1 (Fig. 3.13a). Wildtype hESCs were nucleofected with Cas9 and a FEV-KO 
gRNA, cultured for 2 passages following nucleofection to allow for recovery, and then clonally 
plated (Fig. 3.13b). We identified one clone that exhibited a 1-bp insertion in one FEV allele and 
a 1-bp insertion 1 in the second allele, both located at the end of exon 1 (Fig. 3.13a). Both 
genomic edits result in frameshift mutations that changed the entire amino acid sequence 
following exon 1. The DNA-binding domain normally found in exon 3 was predicted to no longer 
be properly translated in the new amino acid sequence following these frameshift mutations.   
This FEV-KO clonal hESC line, along with a WT control clonal line, was expanded and 
subsequently adapted to suspension-based culture for the in vitro beta cell differentiation 
platform. Directed differentiation of both FEV-KO and WT control hESCs was then performed 
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(Fig. 3.13c). Ablation of FEV did not affect pluripotency of hESCs, as measured by OCT4 and 
TRA-1-60 staining (Fig. 3.13d). Ablation of FEV also did not inhibit differentiation into Stage 2 
definitive endoderm as marked by SOX17 and FOXA2 (Fig. 3.13d), which is concordant with the 
lack of FEV expression before Stage 2. By the Stage 6 beta-like cell stage, however, FEV 
deficiency did result in a reduction of CHGA+/CPEP+ cells (21.2% in WT differentiation vs. 
11.6% in FEV-KO differentiation) (Fig. 3.13d), suggesting that FEV is needed for proper 
differentiation into the hormone-expressing beta lineage.  
 
Generation of new tools and platforms for understanding human beta cell development: 
Identification of FEV transcriptional targets 
 Our discovery that the transcription factor FEV is expressed in hESC-derived endocrine 
progenitors and beta-like cells prompted us to generate tools through which we could 
interrogate the function of the FEV gene. Through CRISPR/Cas9-mediated genomic editing, we 
first constructed a FEV-MYC hESC line in which a MYC epitope tag was fused to the 
endogenous FEV transcription factor at the C-terminus (Fig. 3.14a). This tagging would allow us 
to perform ChIP-seq to identify transcriptional targets of FEV (Fig. 3.14b). To engineer this line, 
we designed a FEV-KI (knock-in) gRNA that targeted the end of exon 3 of the FEV locus (Fig. 
3.14a). We obtained a commercially-synthesized DNA targeting template containing 3 
sequential MYC epitopes separated by small genomic spacers (termed 3xMYC) (Fig. 3.14a). 
This 3xMYC sequence was flanked by homology arms found around the cut site in the 
endogenous FEV locus (Fig. 3.14a). The 3xMYC sequence with the flanking homology arms 
was cloned into a pUC19 vector and transformed into competent cells in order to obtain 
sufficient DNA quantity for PCR amplification of the targeting template. This targeting template 
along with the FEV-KI gRNA and Cas9 protein were then nucleofected into wildtype hESCs, 
cultured for 2 passages following nucleofection to allow for recovery, and then clonally plated. 
The FEV locus of isolated clones was screened for successful knock-in of the 3xMYC by PCR 
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amplification of the knock-in region and Sanger sequencing the resulting PCR amplicon. This 
screening strategy identified a FEV-MYC hESC clonal line with one FEV allele that showed 
successful knock-in of the 3xMYC tag in frame with the FEV locus (Supplementary Data 20).  
 Given that FEV is a transcription factor that appears to be required for proper endocrine 
differentiation in in vitro beta cell differentiation, the generation of this FEV-MYC hESC line will 
be valuable in interrogating the mechanism through which FEV regulates proper human beta 
cell differentiation. ChIP-seq on FEV+ endocrine progenitors at Stage 5 of our in vitro 
differentiation can identify transcriptional targets of FEV (Fig. 3.14b), which will serve as 
candidate effectors of proper endocrine cell differentiation. Additionally, FEV is expressed in 
Stage 6 cells when cells of the beta lineage begin to form. In Stage 6, we found non-beta, FEV-
expressing cells that appeared to be blocked in their differentiation potential (Fig. 3.14b). ChIP-
seq on these blocked cells may identify transcriptional targets of FEV that may mediate 
improper beta cell differentiation. Fev-KO mouse studies demonstrated that Fev binds to the 
insulin promoter to promote Ins transcription (Ohta et al., 2011). ChIP-seq on sorted INS+ beta 
cells from Stage 6 will also identify FEV targets that regulate beta cell function and can confirm 
if INS is also a target of FEV in human beta cells.  
 
Generation of new tools and platforms for understanding human beta cell development: 
Isolation of FEV-expressing cells during in vitro beta cell differentiation 
 We have generated tools with which we could isolate and characterize the FEV-
expressing population during human beta cell differentiation. We constructed two FEV reporter 
hESC lines: a FEV-GFP line and a FEV-tNGFR (truncated Nerve Growth Factor Receptor) line 
(Fig. 3.15a). The FEV-GFP line will allow for fluorescent-based isolation of FEV-expressing cells 
during in vitro beta cell differentiation. For applications that require quicker isolations of much 
larger quantities of FEV-expressing cells than what fluorescent-based sorting can provide, the 
FEV-tNGFR line can be utilized. The tNGFR is a surface marker in which the cytoplasmic 
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intracellular signaling domain of the NGFR is removed and thus can be leveraged for magnetic 
bead-based isolation methods (Dever et al., 2016). This tNGFR enrichment strategy has already 
been implemented in human clinical studies for the isolation of large quantities of tNGFR-tagged 
cells (Bonini et al., 2003; Oliveira et al., 2015). Both the GFP and the tNGFR sequences used 
for these KI lines were preceded by a T2A element that would enable bicistronic translation of 
FEV and the reporter protein. Similar to our strategy with the FEV-MYC hESC line generation, 
we obtained commercially-synthesized DNA targeting templates containing either the 2A-GFP 
or 2A-tNGFR sequences flanked by homology arms around the cut site. Following cloning and 
subsequent PCR amplification of the FEV-GFP or FEV-tNGFR targeting templates, they were 
nucleofected into wildtype hESCs along with the same FEV-KI gRNA used for FEV-MYC line 
generation and Cas9 protein. The nucleofected hESCs were cultured for 2 passages to allow for 
recovery and then clonally plated. The FEV loci of isolated clones were screened for successful 
knock-in of the 2A-GFP or 2A-tNGFR sequences by PCR amplification of the knock-in region 
and Sanger sequencing the resulting PCR amplicon. This screening strategy identified both a 
FEV-GFP and FEV-tNGFR hESC clonal line with one FEV allele that showed successful knock-
in of the reporter in frame with the FEV locus (Supplementary Data 21 and 22).  
 Purification of FEV-expressing cells at defined stages of the in vitro beta cell 
differentiation process will enable us to understand the differences among FEV-expressing 
populations at each differentiation stage. Specifically, purifying FEV+ endocrine progenitors at 
stage 5 of our differentiation program will permit small molecule screens to identify compounds 
that can either induce progenitor expansion prior to beta cell lineage commitment or enhance 
differentiation toward the beta lineage (Fig. 3.15b). Similarly, given that we found FEV-
expressing cells that appeared to be mis-differentiated in Stage 6, we can also harness the 
utility of these reporter lines to isolate these mis-differentiated cells and screen for compounds 
that can correct their differentiation into the beta lineage or block their emergence altogether 
(Fig. 3.15c). Finally, given that beta cells in human pancreatic development transit through a 
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FEV-expressing precursor stage, we can test whether enriching for FEV+ endocrine progenitor-
stage cells during Stage 5 will yield higher efficiencies of beta cell differentiation at Stage 6. 
Given that large quantities of cells would be needed, utilizing our FEV-tNGFR line would allow 
us to isolate enough FEV+ endocrine progenitors in Stage 5 that we can re-aggregate into 
clusters for differentiation into Stage 6. Thus, the ability to isolate FEV-expressing cells 
throughout in vitro beta cell differentiation will refine our understanding of the cellular 
heterogeneity that emerges during this directed differentiation process.  
 
Generation of new tools and platforms for understanding human beta cell development: 
Validation of novel candidate regulators of beta cell lineage allocation and function 
 Our in vivo and in vitro single-cell RNA-sequencing analyses have resulted in the 
identification of candidate beta cell lineage regulators that require validation. In order to 
functionally validate these candidate regulators, we developed a flexible platform on which we 
can test whether these genes regulate beta cell lineage allocation (Fig. 3.16a). In this platform, 
we design different gRNAs that will introduce a frameshift mutation within the genomic locus of 
each candidate regulator we wish to functionally test. Given that these genes are candidate 
regulators of endocrine lineage allocation, we utilize the endocrine progenitor-stage (Stage 5) 
clusters from our in vitro beta cell differentiation and dissociate them into a single-cell 
suspension. We then nucleofect endocrine progenitor-stage cells with Cas9 and a specific 
gRNA against the candidate regulator of interest. Since editing is not 100% efficient, 
nucleofection of these gRNAs will lead to a knockdown, not a full knock-out, of the candidate 
regulator of interest. Following nucleofection, we reaggregate the endocrine progenitor-stage 
cells into clusters and proceed with the directed differentiation towards the beta lineage. This 
platform leveraging both in vitro beta cell differentiation and temporally controlled 
CRISPR/Cas9-mediated genomic editing provides a versatile solution to functionally validate the 
candidate regulators identified through in silico methods.  
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Discussion 
Redefining the NGN3+ endocrine progenitor population in human pancreatic 
development 
 In human endocrine cell development, NGN3 has long been thought to mark the 
endocrine progenitor population, given the function of Ngn3 in mouse pancreatic development. 
Indeed, NGN3 is required for endocrine cell differentiation in human endocrine cell 
development, as inactivating mutations of NGN3 lead to neonatal diabetes (Pinney et al., 2011; 
Wang et al., 2006). Beta cell mass is suspected to be reduced, not absent, in human cases of 
inactivating NGN3 mutations given that C-peptide is detected in the blood, albeit at low levels 
(Pinney et al., 2011). This is in contrast to mouse development, in which NGN3 ablation halts 
beta cell generation altogether (Gradwohl et al., 2000). Through our study of human endocrine 
cell development, NGN3 did not appear to be the most robust marker of the endocrine 
progenitor population common to hormone-expressing lineages, such as the alpha and beta 
lineages, in our 12wpc_1 human fetal pancreas dataset. Other markers that appeared to more 
faithfully label this common endocrine progenitor population included EMC10, SOX4, HES6, 
and KRT19. CTD-2545M3.8 also emerged from our differential gene expression analysis as a 
marker specific to this common endocrine progenitor population but awaits functional 
characterization. It is possible that NGN3 was already been downregulated in this common 
endocrine progenitor population and that we did not capture enough NGN3-expressing 
progenitors for UMAP-based clustering to categorize them in their own distinct cluster. If this is 
true, this may imply that the period between NGN3 downregulation and differentiation into a 
hormone-expressing lineage is proportionally much longer in human development than in 
mouse. Time-lapsed imaging of live, human fetal pancreatic explants will provide a more refined 
profile of NGN3 expression dynamics in human pancreatic development. 
 In murine endocrine development, Ngn3+ endocrine progenitors give rise to all five 
hormone-expressing lineages of the pancreas (Gradwohl et al., 2000; Heller et al., 2005). 
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However, in the human fetal pancreas, the NGN3-expressing common endocrine progenitor 
population appeared to only give rise to alpha and beta lineages. In our pseudotemporal 
ordering analysis, there was no trajectory that connected NGN3-expressing progenitors to the 
SST-expressing delta lineage or the GHRL-expressing epsilon lineages. We did not observe a 
distinct PPY-expressing gamma population, as all PPY-expressing cells also expressed GCG 
and thus were annotated as alpha cells. This differentiation potential of the NGN3-expressing 
common progenitors that we identified in human pancreatic development could be the result of 
not obtaining enough cells for pseudotemporal ordering analysis, which relies on similarities in 
gene expression profiles to order cells along a differentiation trajectory. This result also was 
derived from one timepoint in fetal development, and the development of improved batch 
correction methods for pseudotemporal ordering may allow us to combine multiple timepoints 
together for more powerful analysis. However, if this discrepancy in the differentiation potential 
reflects true lineage relationships of NGN3-expressing endocrine progenitors in the developing 
human pancreas, this would depart from the dogma established by findings of the lineage 
potential of Ngn3+ progenitors in murine pancreatic development. Future work clarifying the 
hormone-expressing lineages derived from NGN3+ endocrine progenitors in human fetal 
development is needed.  
 
Identification of novel pre-alpha and pre-beta cell stages in human pancreatic 
development 
 Mapping endocrine cell development at a higher resolution using single-cell RNA-
sequencing can be leveraged for developing new methods to generate endocrine cell types 
more efficiently from stem cell sources. In this work, we have identified novel pre-alpha and pre-
beta progenitor stages that provide increased resolution regarding the steps required to 
differentiate into alpha or beta lineages in human pancreatic development. While a handful of 
other single-cell RNA-sequencing studies have identified additional endocrine progenitor stages 
 103	
in mouse pancreatic development, to our knowledge, no published work has identified novel 
endocrine progenitor stages in human pancreatic development using single-cell RNA-
sequencing. Our work in human fetal pancreatic development thus offers novel endocrine 
progenitor stages onto which we can compare and contrast the biological relevance of these 
murine progenitor stages to those of human.   
The advent of single-cell RNA-sequencing has led to the discovery of several novel 
endocrine progenitor stages in mouse pancreatic development. One example is our own work, 
in which we discovered a novel intermediate endocrine progenitor population defined by high 
Fev expression (Byrnes et al., 2018). Fev expression has also been identified in endocrine 
progenitor populations reported by several other single-cell RNA-sequencing studies of murine 
pancreatic development (Krentz et al., 2018; Scavuzzo et al., 2018), confirming the 
reproducibility of our finding. This Fev+ endocrine progenitor is derived from an Ngn3+ 
population, and differentiated endocrine lineages in the murine pancreas transit through a Fev-
expressing cell stage (Byrnes et al., 2018).  
Within the Fev+ progenitor population, we also identified cells that appeared to be pre-
specified towards an alpha or beta cell fate (Byrnes et al., 2018). This is analogous to human 
pancreatic development in which we not only identified endocrine progenitors that expressed 
FEV but also observed that these FEV-expressing progenitors appeared to be already lineage-
specified towards an alpha or beta cell fate. Our in silico reconstruction of endocrine lineage 
relationships suggested that endocrine cell fate decisions in progenitors occurs at the Fev/FEV-
expressing cell stage in both mouse and human.    
 Beyond this Fev-expressing endocrine progenitor stage, there are additional endocrine 
progenitor stages that have been identified in murine development. In particular, four distinct 
endocrine progenitor stages (termed EP1-4) have been proposed in mouse endocrine cell 
development (Yu et al., 2019). Expression of Ngn3, the canonical pro-endocrine lineage marker 
in pancreatic development, increased in EP1, peaked in EP2, decreased in EP3, and was not 
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observed in EP4. Expression of Fev was found in EP3 and EP4 stages only (Yu et al., 2019), 
which is concordant with Fev being downstream of Ngn3 (Byrnes et al., 2018; Miyatsuka et al., 
2014). Interestingly, many of the differentially expressed genes in each EP stage were also 
identified as top differentially expressed genes in either our human endocrine progenitor 
clusters or during pseudotemporal ordering. Specifically, Krt19 and Gadd45a, two genes that 
defined a human common endocrine progenitor stage in our dataset of 12wpc_1 human fetal 
pancreas, were found to be differentially expressed in EP2. Several candidate beta lineage 
regulators in human fetal development were also found in EP1 (Arid5b), EP3 (Ahi1), and EP4 
(Rbp4, Peg10, Acvr1c, Sez6l2) (Yu et al., 2019). Similarly, several candidate alpha lineage 
regulators in human fetal development were found in EP3 and EP4 (Arx, Irx2, Fam46a, 
Slc30a8, Slc7a2, Slc7a8, Cryba2, St18, and Alcam) (Yu et al., 2019). Thus, these EP stages 
found in murine endocrine development appear to also have relevance to endocrine progenitor 
stages found in human fetal pancreatic development, and we believe it is important to confirm 
these murine progenitor stages in human pancreatic development. 
 
Transcriptional mechanisms underlying fate decisions are shared across tissues 
 Our single-cell RNA-sequencing analysis of human endocrine lineage allocation 
identified many candidate regulators previously identified and studied in the nervous system. 
Despite their derivation from different germ layers, both the pancreatic endocrine and neural 
lineages employ many of the same transcription factors that regulate their own development, 
including Ngn3, NeuroD1, Nkx2.2, Nkx6.1, Pax family of transcriptional regulators, and Fev 
(Blake and Ziman, 2014; Churchill et al., 2017; Gradwohl et al., 2000; Hendricks et al., 1999; 
Mastracci et al., 2013; Napolitano et al., 2015; Ohta et al., 2011; Pataskar et al., 2016; Prakash 
et al., 2009; Qi et al., 2001; Schaffer et al., 2010; Simon-Areces et al., 2010; St-Onge et al., 
1997) . These transcriptional similarities have an evolutionary basis, as the main source of 
insulin in invertebrates is in neurons (Wong et al., 2014). Thus, from an evolutionary 
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perspective, it is not surprising that additional genes previously identified to be required for 
proper nervous system development and function are also implicated in pancreatic endocrine 
development and, more specifically, lineage allocation. As functional validation is performed of 
these candidate regulators of pancreatic endocrine lineage allocation, key insights and 
similarities may be drawn from understanding the transcriptional hierarchies that govern both 
pancreatic endocrine and neural developmental programs.  
 The development of enteroendocrine cells (EEs) in the intestine also shares striking 
similarity to pancreatic endocrine cell development. Proper differentiation of EEs in the intestine 
during development requires transcription factors also critical for pancreatic endocrine cell 
differentiation, including Ngn3 (Jenny et al., 2002; López-Díaz et al., 2007; Schonhoff et al., 
2004), Nkx2.2 (Gross et al., 2016), Isl1 (Terry et al., 2014), NeuroD1 (Naya et al., 1997), Pax4 
(Beucher et al., 2012a). As in pancreatic endocrine cell development, the EE lineage comprises 
multiple hormone-expressing cell types that are derived from a common progenitor cell defined 
by Ngn3 (Jenny et al., 2002). Recent work applying single-cell RNA-sequencing to murine EE 
development uncovered novel markers and lineage-specific regulators of the multiple EE 
lineages (Gehart et al., 2019), and many of these genes overlapped with the markers and 
candidate transcriptional regulators that we identified in mouse and human endocrine cell 
development and lineage allocation. Ngn3+ EE progenitors differentially express Sox4, Tox3, 
and Gadd45a (Gehart et al., 2019), all of which were also defining markers of our common 
endocrine progenitor in human endocrine cell development. Known hormone-specific lineage 
regulators in pancreatic endocrine cell development, such as Arx, Pax6, and Isl1, were also 
identified as EE-specific lineage regulators (Gehart et al., 2019). Interestingly, a number of 
novel candidate lineage regulators that we identified in mouse and human endocrine lineage 
allocation were also found to be lineage-specific regulators of the different EE lineages (Gehart 
et al., 2019). These include Nr4a2, Smarca1, Peg3, Id1, S100a1, and Klf4 (Gehart et al., 2019). 
Thus, given these transcriptional similarities between the hormone-expressing lineages of the 
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pancreas and intestine, future work focused on deciphering additional lineage-specific 
regulators of the multiple hormone-expressing EE lineages may provide additional insight into 
transcriptional regulation of pancreatic endocrine cell fate selection. 
 
Timing of endocrine lineage fate decisions 
 The timing of endocrine lineage fate commitment in pancreatic development is not fully 
understood. The Ngn3+ endocrine progenitor stage has long been regarded as the master 
stage prior to endocrine cell differentiation, but single-cell RNA-sequencing studies of pancreatic 
development, including our own, have identified additional progenitor stages that arise between 
initial Ngn3 expression and acquisition of differentiated cell identity. This increased resolution of 
endocrine cell differentiation has provided us with new cell stages that we can interrogate for 
determining when endocrine lineage decisions are made. From both our mouse and human 
studies of endocrine cell development, Fev/FEV-expressing endocrine progenitors were already 
specified towards an alpha or beta cell fate (Byrnes et al., 2018). This heterogeneity in 
Fev/FEV-expressing progenitors suggests that endocrine lineage specification occurs at this 
Fev/FEV-expressing progenitor stage or prior. With the advent of single-cell ATAC-seq, future 
work can look beyond the transcriptome and into the epigenome to determine if certain subsets 
of endocrine progenitors are primed to express alpha or beta-specific lineage genes or are pre-
committed to a specific hormone lineage. This fate commitment could also possibly be made in 
Pdx1+ pancreatic progenitors prior to the expression of pro-endocrine genes, such as Ngn3, 
altogether, although our single-cell RNA-sequencing combined with pseudotemporal ordering 
identified endocrine progenitor populations that appeared to be fated towards one specific 
endocrine lineage. Future transcriptomic and epigenomic profiling of stages preceding 
endocrine differentiation will help determine the exact stage at which endocrine lineage 
determination occurs.   
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The timing of endocrine fate decisions can also be regulated by extrinsic signals derived 
from the surrounding microenvironment. In murine development, the developmental time at 
which Ngn3+ progenitors form corresponds to their ultimate hormone lineage selection 
(Johansson et al., 2007). The competence window for alpha differentiation arises the earliest in 
murine pancreatic development, resulting in alpha cells being the first emerging endocrine 
lineage, followed by beta and gamma cells, and then lastly followed by delta cells (Johansson et 
al., 2007). In contrast, in human pancreatic development, the beta lineage is the earliest 
endocrine cell type to be detected (at 6wpc), followed by alpha cells (at 8-9wpc), delta cells 
(10wpc), and gamma cells (at 17wpc) (Jeon et al., 2009; Piper et al., 2004). The differences in 
timing of emergence of endocrine lineages between mouse and human could be a direct result 
of the changing microenvironment during development that can be providing dynamic cues that 
promote one endocrine lineage over the other. From murine studies, we know that several 
compartments of the microenvironment influence pancreatic development, including 
vasculature, nerves, and mesenchyme (Borden et al., 2013; Golosow and Grobstein, 1962; 
Landsman et al., 2011; Magenheim et al., 2011; Reinert et al., 2013). However, the cellular 
composition of each microenvironment compartment can widely differ between that of mouse 
and human. From our single-cell profiling of human fetal pancreas, we identified several 
populations of endothelial cells whose transcriptional expression profiles changed throughout 
the course of development. These changes may influence the competency of endocrine 
progenitors to differentiate into distinct hormone lineages, either through secreted signaling 
molecules or direct interactions. Our single-cell profiling in both mouse and human pancreatic 
development also reflects different mesenchymal and nerve populations whose dynamics may 
regulate endocrine differentiation at distinct periods in development.  
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FEV in human endocrine cell differentiation and function 
Fev is a transcription factor best known for its role in serotonergic neuron differentiation 
and function (Haugas et al., 2016; Wyler et al., 2016), and more recently, Fev has also been 
implicated as a regulator of the differentiation of multiple hormone-expressing enteroendocrine 
lineages in the intestine (Gehart et al., 2019). Given that hormone-producing cells in the brain 
and hormone-producing cells in the pancreas are evolutionarily related, Fev function was 
previously investigated in the islet lineages of the pancreas, where it was found to regulate 
insulin production in adult mouse beta cells (Ohta et al., 2011). Fev-KO mice exhibited defects 
in glucose clearance from the blood following a glucose tolerance test, and this defect was 
attributed to decreased insulin content in beta cells (Ohta et al., 2011). Following ChIP-seq 
studies in a beta cell cell line, Fev was identified to bind directly to the Insulin promoter, thus 
regulating its transcription and resulting in less Insulin transcription with the loss of Fev in beta 
cell (Ohta et al., 2011). Beta cell mass in Fev-KO mice was not decreased, indicative of 
decreased insulin production across the entire pancreas in Fev-KO mice as opposed to fewer 
beta cells present in the adult pancreas (Ohta et al., 2011). Fev ablation also did not result in 
obvious defects in the differentiation of alpha, beta, delta, epsilon, and gamma cells during 
embryonic development (Ohta et al., 2011), although a robust quantification to assess possible 
skews towards specific endocrine lineages with the loss of Fev should be performed.  
Our work investigating the role of FEV in human endocrine cell differentiation and 
function highlights potential differences between Fev/FEV in mouse versus human. In both 
mouse and human endocrine cell development, Fev/FEV was expressed in an intermediate 
progenitor stage that followed initial NGN3 expression and preceded hormone acquisition 
(Byrnes et al., 2018). FEV was also expressed in endocrine progenitor stage cells during in vitro 
beta cell differentiation from hESCs, which was concordant with FEV expression in endocrine 
progenitors in human fetal pancreatic development. Notably, although Fev-KO mice do not 
exhibit obvious differentiation defects in the islet lineages during development, we did observe a 
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reduction in the differentiation into CHGA+/CPEP+ beta cells in our in vitro beta cell 
differentiation model. This suggests that FEV may be required for human beta cell differentiation 
and is dispensable for mouse beta cell differentiation. Quantification of the beta lineage during 
pancreatic development in Fev-KO mice will confirm whether this discrepancy between mouse 
and human is indeed true. 
Notable differences were also observed between Fev/FEV in mouse and human 
differentiated endocrine cells. While Fev expression persists in the alpha and beta lineages 
during mouse pancreatic development, FEV expression was downregulated in beta cells and 
only maintained in the alpha lineage in human pancreatic development. Single-cell RNA-
sequencing of adult human islets has indicated that FEV is expressed in alpha cells and not 
beta cells (Segerstolpe et al., 2016). This is in contrast to our in vitro beta cell differentiation 
system, in which beta cells appeared to maintain FEV expression following differentiation of the 
FEV+ endocrine progenitor stage. In mouse beta cells, FEV binds to the insulin promoter to 
regulate Insulin transcription and thus insulin production. Given that FEV turns off in 
differentiated human beta cells in vivo, it is possible that FEV is either not needed for beta cell 
function or FEV inhibits beta cell function. In our in vitro beta cell differentiation, we actually 
observed a subset of INS+ beta cells that did not express FEV, whereas another subset of INS+ 
beta cells did express FEV. The INS+/FEV- hESC-derived beta cells may correspond to bona 
fide beta cells found in vivo, and the INS+/FEV+ hESC-derived beta cells may either be mis-
differentiated or on their way towards a FEV- state. This discrepancy in Fev/FEV expression 
during endocrine cell differentiation is just one example that highlights the need for validating 
findings from mouse studies in human studies.  
Identification of FEV transcriptional targets will illuminate a clearer picture of its function. 
In the human beta cell lineage, loss of FEV coincided with a reduction in beta cell differentiation. 
Given that FEV was expressed in pre-beta progenitors in vivo and hESC-derived endocrine 
progenitor stage cells, it is possible that FEV serves as a key transcriptional regulator for 
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differentiation from a progenitor to a beta cell. Using our FEV-MYC hESC line during in vitro 
beta cell differentiation and performing ChIP-seq on FEV+ endocrine progenitor stage cells can 
identify transcriptional targets that may mediate the transition from a pre-beta progenitor to a 
differentiated beta cell. By acquiring a transcriptional map of FEV transcription factor activity, we 
may be able to modify our current in vitro beta cell differentiation protocol to one that promotes 
the expression of key FEV-regulated transcriptional circuits that promote beta cell differentiation 
from endocrine progenitors. 
Identification of transcriptional targets in hESC-derived FEV+ beta cells will also 
illuminate the function of FEV in differentiated beta cells. Given that FEV was expressed in pre-
alpha progenitors in vivo and was maintained in differentiated alpha cells, identifying 
transcriptional targets during alpha cell differentiation and function and how they differ from 
those identified in the beta lineage will augment our understanding of endocrine cell 
specification. Finally, ChIP-seq on endocrine lineages in the human fetal pancreas across 
multiple timepoints can also be performed once a suitable FEV antibody for ChIP-seq is 
generated.  
 
Suppressing the formation of hESC-derived blocked endocrine progenitors 
 Tremendous effort has been devoted to determining the molecular cues that will make 
derivation of the beta lineage from hESCs more efficient. Given that we uncovered a hESC-
derived FEV-expressing population that appeared to be mis-differentiated during in vitro beta 
cell differentiation, we can begin to uncover the molecular circuitry that pushes hESC-derived 
cells down this mis-directed lineage. The top differentially-expressed gene of this blocked, FEV-
expressing cell population was the transcription factor PHOX2A. Interestingly, PHOX2A was 
also previously reported to mark a non-endocrine population that emerged in in vitro beta cell 
differentiation but was not described as mis-directed in differentiation potential (Veres et al., 
2019). PHOX2A is a pro-neural homeodomain transcription factor and a key regulator of neural 
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progenitor differentiation into noradrenergic neurons of the central nervous system (CNS) and 
the peripheral nervous system (PNS) (Lo et al., 1998; Morin et al., 1997). Noradrenergic 
neurons are characterized by synthesis and storage of catecholamines, including 
norepinephrine, which serve as neurotransmitters (Hayashida and Eisenach, 2018). In this 
differentiation process, BMP2 and cyclic AMP (cAMP) signaling synergistically induce 
noradrenergic neuron differentiation through Phox2a transcription and Phox2a activation 
(Benjanirut et al., 2006; Chen et al., 2005; Paris et al., 2006). Given the expression of PHOX2A 
specifically in cells occupying the mis-differentiated trajectory in our pseudotemporal ordering 
analysis, it is possible that the PDX1+/NKX6.1+ pancreatic progenitors in our in vitro beta cell 
differentiation process have mis-differentiated towards this PHOX2A+ noradrenergic neural 
lineage.  
 Inhibition of BMP2 and cAMP signaling represents possible avenues through which we 
can prevent in vitro beta cell differentiation from entering down this mis-directed differentiation 
path that resembled the noradrenergic neural lineage. Interestingly, a recent iteration of our in 
vitro beta cell differentiation process was published adding LDN193189, a BMP inhibitor, to 
endocrine progenitor stage cells (Veres et al., 2019). LDN193189 is typically used at the 
beginning of the pancreatic progenitor stage to inhibit BMP signaling but is removed from the 
cocktail of exogenous growth factors following this stage (Pagliuca et al., 2014). This newer 
iteration of in vitro beta cell differentiation resulted in the generation of beta cells that were 
functional and maintained stimulation indices for up to four weeks in culture, but it also 
contained modifications to other stages, including removal of various growth factors from Stage 
3 pancreatic progenitors (SANT1, LDN193189, and PdBU), Stage 4 pancreatic progenitors 
(SANT1 and RA and Rock inhibitor), and Stage 6 beta-like cells (Alk5i and T3 were removed). It 
is possible that the addition of LDN193189 to Stage 5 endocrine progenitors inhibited the 
formation of cells blocked in differentiation potential and generated beta cells with a more stable 
functional phenotype, although future work will need to test this possibility in a more controlled 
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manner. Given that these mis-differentiated, noradrenergic-like cells emerge in Stage 5 and 
persist into Stage 6, addition of BMP inhibitors such as LDN193189 to Stage 5 and 6 cultures 
can potentially block this mis-differentiation into PHOX2A+ noradrenergic-like cells and increase 
the efficiency at which hESC-derived endocrine progenitors differentiate into the beta lineage. 
Addition of cAMP signaling inhibitors, such as H89 and okadaic acid, that have been used to 
block PHOX2A-mediated differentiation of neural progenitors into noradrenergic lineages can 
also be added in order to potentially suppress mis-differentiation of endocrine progenitors during 
in vitro beta cell differentiation (Chen et al., 2005; Shin et al., 2009).  
 
Reported enterochromaffin cells in in vitro beta cell differentiation 
 Currently, in vitro beta cell differentiation does not result in 100% purity of beta cells, and 
there are other cell types that arise during the directed differentiation of hESCs to the beta 
lineage. Recently, a population deemed enterochromaffin cells (ECs) has been described to 
arise in in vitro beta cell differentiation (Veres et al., 2019). ECs reside along the epithelial lining 
of the intestine and are the most abundant cell type among the enteroendocrine cells found in 
the intestine (Lund et al., 2018). The main functions of ECs are to regulate intestinal motility 
required for digestion and modulate the activity of the enteric nervous system through the 
production and secretion of the neurotransmitter serotonin. Although ECs make up less than 1% 
of the total intestinal epithelium, they produce more than 90% of the body’s serotonin (Gershon, 
2013; Mawe and Hoffman, 2013). Unlike neurons, ECs utilize tryptophan hydroxylase 1 (TPH1) 
and not TPH2 to synthesize serotonin, and instead of employing small neurosecretory vesicles, 
ECs store serotonin in large dense core vesicles (LDCVs) with the help of CHGA and CHGAB 
(Côté et al., 2003; Machado et al., 2010; Walther and Bader, 2003). Thus, ECs resemble 
lineages of both the nervous system and hormone-secreting pancreatic islets.  
 ECs are defined by the expression of markers that also are expressed by both 
serotonergic neurons and pancreatic endocrine cells. These markers include Fev, Lmx1a, 
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Lmx1b, and Tph1 (Ding et al., 2003; Kiyasova and Gaspar, 2011; Liu et al., 2010; Maurer et al., 
2004; Ohta et al., 2011; Wyler et al., 2016; Zhang et al., 2017). Proper differentiation of ECs in 
the intestine during development also requires transcription factors critical for pancreatic 
endocrine cell differentiation, including Ngn3 (Jenny et al., 2002; López-Díaz et al., 2007; 
Schonhoff et al., 2004), Nkx2.2 (Gross et al., 2016), Isl1 (Terry et al., 2014), NeuroD1 (Naya et 
al., 1997), Pax4 (Beucher et al., 2012a). Interestingly, Fev is also expressed by ECs but is not 
required for EC differentiation in mice (Wang et al., 2010b). Given the striking similarity in gene 
expression profiles of ECs and EC differentiation to those of pancreatic endocrine cells, it is not 
surprising to observe ECs generated in in vitro beta cell differentiation. The mis-differentiation of 
hESC-derived endocrine progenitors towards similar lineages, such as that of the EC, is not 
surprising, given that in vitro beta cell differentiation is not 100% efficient. It is likely that the ECs 
observed during in vitro beta cell differentiation represent another mis-differentiation process, 
similar to that observed with mis-differentiated PHOX2A+ cells. Given that these hESC-derived 
ECs also express FEV, these ECs could be mistaken for the FEV+ endocrine progenitors we 
identified in human pancreatic development. However, this is not the case, given that a separate 
population of FEV+ hESC-derived endocrine progenitors is found and that give rise to the beta 
lineage in not only our in vitro differentiation process but also in that reported by others (Veres 
et al., 2019). It is likely that these FEV+ ECs are derived from the same hESC-derived FEV+ 
endocrine progenitors that give rise to beta cells. The molecular cues that drive differentiation 
into the EC lineage over the beta lineage will be important to dissect in order to improve the 
outcomes of in vitro beta cell differentiation. The mis-differentiation into the EC lineage, coupled 
with the emergence of mis-differentiated PHOX2A+ cells, highlights the need for a more refined 
understanding of the transcriptional machinery that pushes pancreatic and endocrine 
progenitors toward the beta lineage. 
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Materials and Methods 
Human tissue procurement, isolation, and processing 
Human fetal pancreata were harvested from post-mortem fetuses with approval from the ethical 
committee of UCSF. Tissue was obtained through two sources: the University of Washington 
Birth Defects Research Laboratory (12wpc_1 and 15.5wpc samples) and Advanced Bioscience 
Resources, Inc (12wpc_2 and 16wpc samples). Tissue was harvested at respective clinics and 
shipped overnight on ice in either 1X PBS (samples from University of Washington Birth Defects 
Research Laboratory) or RPMI media (samples from Advanced Bioscience Resources, Inc). 
Following delivery to our laboratory, tissue was washed once with 1X PBS, minced with a sterile 
scalpel, and dissociated in Liberase TM and 0.1 mg/mL DNase in 1X HBSS for 30-55 minutes in 
a 37°C Thermomixer programmed to shake at 1000rpm. Dissociation was quenched with 5mM 
EDTA and 10% FBS in 1X HBSS. Cell suspension was filtered through a 30um cell strainer. 
Red blood cells (RBCs) were removed from the cell suspension using immunomagnetic 
negative selection with STEMCELL Technologies’ EasySep RBC Depletion Reagent (cat. no. 
18170). Following RBC depletion, cells were counted and loaded onto the 10X Chromium 
Platform for single-cell RNA-sequencing.  
 
Adult human islets were isolated from cadaveric donor tissue by the UCSF Islet Production Core 
with approval from the UCSF ethical committee. Consented cadaver donor pancreata were 
provided by the nationally recognized organization UNOS via local organ procurement 
agencies. The identifiers were maintained at the source only, and the investigators received de-
identified specimens.  
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Informed consent was obtained for all human (fetal and adult) tissue collection, and protocols 
were approved by the Human Research Protection Program Committee on Human Research of 
UCSF. 
 
Embryonic stem cell culture and differentiation 
The hESC line HUES8 was obtained from Harvard University and used for the generation of 
hESC-derived beta-like cells (BLCs). Pluripotent HUES8 cells were maintained as spherical 
clusters in suspension in mTeSR-1 (StemCell Technologies) in 500 mL spinner flasks (Corning, 
VWR) on a magnetic stir plate (Dura-Mag) within a 37°C incubator at 5% CO2, 100% humidity, 
and a rotation rate of 70 rpm. Cells were screened for mycoplasma contamination using the 
MycoProbe Mycoplasma Detection Kit (R&D Systems), according to the manufacturer’s 
instructions.  
BLCs were generated as previously described (Pagliuca et al., 2014), with additional 
modifications (Millman et al., 2016). In brief, HUES8 cells were seeded into a spinner flask at a 
concentration of 8e5 cells/mL in mTeSR1 media with 10 μM Rock inhibitor Y-27632 (STEMCELL 
Technologies) to allow formation of spherical clusters. Differentiation was initiated 72 h later. 
Differentiation was achieved in a step-wise fashion using the following growth factors and/or 
small molecules: definitive endoderm (Stage 1) (1 day of 100 ng/mL Activin A (R&D Systems) 
and 14 μg/mL of CHIR99021 (Stemgent); 2 days of 100 ng/mL Activin A); gut tube endoderm 
(Stage 2) (3 days of 50 ng/mL KGF (Peprotech)); early pancreatic progenitors (Stage 3) (1 day 
of 200 nM LDN193189 (Fisher Scientific), 50 ng/mL KGF, 0.25 μM SANT-1 (Sigma), 2 μM 
Retinoic Acid (Sigma), 500 nM PdbU (EMD Biosciences), and 10 μM Rock inhibitor Y-27632 
(STEMCELL Technologies); 1 day of 50 ng/mL KGF, 0.25 μM SANT-1, 2 μM Retinoic Acid, 
500 nM PdbU); later pancreatic progenitors (Stage 4) (5 days of 50 ng/mL KGF, 0.25 μM SANT-
1, 0.1 μM Retinoic Acid, and 10 μM Rock inhibitor Y-27632); endocrine progenitors (Stage 5) (4 
days of 0.25 μM SANT-1, 0.1 μM Retinoic Acid, 1 μM XXI (EMD Millipore), 10 μM Alk5i (Axxora), 
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1 μM T3 (EMD Biosciences), 20 ng/mL Betacellulin (Fisher Scientific); 3 days of 25 nM Retinoic 
Acid, 1 μM XXI, 10 μM Alk5i, 1 μM T3, 20 ng/mL Betacellulin); BLCs (Stage 6) (6-11 days of 
10 μM Alk5i; 1 μM T3). Successful differentiation was assessed at the completion of Stages 1, 3, 
4, 5, and 6 via immunofluorescence or FACS for stage-specific marker genes. hESC-derived 
cells used for single-cell RNA-sequencing were taken at ES4 (End of Stage 4), S5D4 (Stage 5, 
Day 4), S5D7, S6D4, and S6D10. Cells for single-cell RNA-sequencing were dissociated with 
Accumax for 15-25 mins in a 37°C water bath. The dissociated cell suspension was neutralized 
with stage-specific media and filtered through a 37um filter. Cells were counted and then loaded 
onto the 10X Chromium Platform for single-cell RNA-sequencing. 
 
In situ hybridization and immunofluorescence of hESC-derived clusters 
hESC-derived cell clusters were fixed in 4% PFA in 1X PBS for 15 mins at RT. Fixed clusters 
were washed with 1X PBS and cryoprotected overnight at 4°C in 30% sucrose. Clusters were 
then embedded in OCT, and sections measuring 8 µm sections were cut.  
 
In situ hybridization was performed on 8 µm sections using RNAscope technology (Advanced 
Cell Diagnostics) according to the manufacturer’s instructions. An in situ probe against human 
FEV (cat. no. 471421-C3) was used in combination with the RNAscope Multiplex Fluorescent 
Reagent Kit v2 for target detection. Following signal amplification of the target probes, sections 
were washed in 1X PBS three times and blocked in 5% normal donkey serum (NDS, Rockland 
Immunochemicals) in 0.1% Triton X-100 in PBS for 1 hr at RT. Tissue sections were then 
stained with a primary antibody against PDX1 (1:100, R&D Systems). The next day, sections 
were washed three times in 0.1% Tween 20 in 1X PBS and then incubated with species-specific 
Alexa Fluor 488-secondary antibodies (1:500, Jackson ImmunoResearch) and DAPI in 5% NDS 
in 0.2% PBT for 1 hr at RT. Sections were washed three times in 0.1% Tween 20 in 1X PBS, 
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rinsed in 1X PBS, and then mounted in ProLong Gold Mounting Medium. Slides were stored at 
4 °C. 
 
Images were captured on a Leica confocal laser scanning SP8 microscope. Maximum intensity 
z-projections were then prepared using ImageJ, where brightness, contrast, and pseudo-
coloring adjustments were applied equally across all images in a given series. 
 
Quantitative RT-PCR 
hESC-derived cells at various stages of directed differentiation were collected in Trizol, and 
RNA was extracted with the Direct-zol RNA Miniprep kit (Zymo Research). Adult human islets 
were also processed this same manner for RNA extraction. Reverse transcription was 
performed with the Superscript IV First-Strand Synthesis System (Thermo Fisher Scientific, cat. 
no. 18091050) using Oligo d(T) primers and random hexamers. RT-PCR was run on an ABI 
Real-Time PCR System (Applied Biosystems, 384-well format) with Taqman probes 
for FEV (assay ID: Hs00232733_m1) and GAPDH (assay ID: Hs02758991_g1) in triplicate. 
Data were normalized to GAPDH.  
 
Single-cell capture and sequencing 
To capture individual cells, we utilized the Chromium Single Cell 3' Reagent Version 3 Kit (10X 
Genomics) (Zheng et al., 2017). Only our 15.5wpc sample was processed with the Chromium 
Single Cell 3' Reagent Version 2 Kit. For all samples, 25,000 cells were loaded onto one or two 
wells of the 10X chip to produce Gel Bead-in-Emulsions (GEMs). GEMs underwent reverse 
transcription to barcode RNA before cleanup and cDNA amplification. Libraries were prepared 
with the Chromium Single Cell 3' Reagent Kit. Each sample was sequenced on the NovaSeq 
(Illumina) in Rapid Run Mode with paired-end sequencing parameters: Read1, 98 cycles; 
Index1, 14 cycles; Index2, 8 cycles; and Read2, 10 cycles. 
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Single-cell analysis 
We utilized CellRanger v3.0.2 software for all single-cell RNA-sequencing datasets with default 
settings for de-multiplexing, aligning reads to the human genome (10X Genomics pre-built hg38 
reference genome) with STAR (Dobin et al., 2012) and counting unique molecular identifiers 
(UMIs) to build transcriptomic profiles of individual cells. Gene-barcode matrices were analyzed 
with the R package Seurat v3.0.1 (Stuart et al., 2019). We first performed a filtering step, 
retaining only the cells that expressed a minimum and maximum number of genes and did not 
exceed a specified percentage of reads that map to the mitochondrial genome. The following 
quality control metrics for each dataset are outlined in Table 3.1. 
Table 3.1. Quality control metrics for human single-cell sequencing analyses. Sample 
name is listed along with the minimum and maximum number of genes and maximum 
percentage of mitochondrial genes used for quality control thresholds. 
 
Sample Name Minimum number of genes 
Maximum number 
of genes 
Maximum 
percentage of 
mitochondrial 
genes 
12wpc_1 200 4,000 15 
12wpc_2 200 5,000 15 
15.5wpc 200 4,000 7.5 
16wpc 200 6,000 15 
ES4 200 6,000 10 
S5D4 200 6,000 12.5 
S5D7 200 6,000 15 
S6D4 200 6,000 15 
S6D10 200 6,000 15 
 
Data were then normalized with the Seurat3 function NormalizeData with default settings. This 
employs a global-scaling normalization that normalizes gene expression measurements for 
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each cell by the total expression. Genes that exhibit high cell-to-cell variation were then 
identified using FindVariableFeatures. The highly variable genes from this analysis were then 
used in downstream analysis to highlight biological signal from background noise in single-cell 
datasets. Data then underwent linear transformation (“scaling”), which is required prior to 
dimensional reduction with PCA, and this scaling was done with ScaleData. PCA (Principal 
Component Analysis) was performed on the scaled data with RunPCA. Significant PCs 
(principal components) were determined with ElbowPlot, which plots principal components 
based on the percentage of variance exhibited by each one. These significant PCs were utilized 
in Seurat3’s graph-based clustering algorithms, FindNeighbors and FindClusters. The resolution 
parameter of FindClusters was adjusted to vary the number of clusters found by the algorithm. 
Clusters were visualized by UMAP with Seurat3’s RunUMAP and DimPlot functions. 
Differentially expressed genes were determined with the FindAllMarkers function. Seurat3’s 
VlnPlot, DotPlot, and FeaturePlot functions were used to visualize of expression of genes of 
interest across cells and clusters.  
 
Sub-clustering and merging datasets 
Sub-clustering was performed by isolating clusters of interest with the Seurat3 function Subset 
and reanalyzing as outlined above (finding variable genes, scaling data, and identification of 
significant PCs). Cells were classified as endocrine based on the expression of Chromogranin A 
(CHGA). 
 
Merging of all human fetal datasets was accomplished with Seurat3’s Integration workflow. This 
integration workflow in Seurat3 identifies “anchors” across disparate single-cell datasets in order 
to construct harmonized references for better merging of the data and minimization of batch 
effect (Stuart et al., 2019). In the integration workflow, all datasets were merged into a single 
Seurat object and processed to the step encompassing identification of variable genes 
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(FindVariableFeatures). Integration anchors were then identified using the 
FindIntegrationAnchors and used to integrate all human fetal datasets through the IntegrateData 
function. Following integration, data were scaled (ScaleData), significant PCs were identified 
(RunPCA), and UMAP-based clustering was performed (RunUMAP, FindNeighbors, 
FindClusters). Gene expression of specific genes were visualized by using read levels from the 
“RNA” slot of the integrated Seurat object (accessed by inputting “rna_gene” into gene 
parameter).  
 
Pseudotemporal ordering 
For the pseudotemporal ordering analysis of our 12wpc_1 sample, we utilized Monocle v2.99.3 
(named Monocle 3 alpha). Variable genes from the Seurat3 analysis of our 12wpc_1 samples 
(resolution 0.8) were used as input into Monocle, utilizing the VGAM::negbinomial.size 
expressionFamily, and clusters were projected onto the minimum spanning tree after ordering. 
The beginning of pseudotime was assigned using the function orderCells based on NGN3 
expression.  
 
To conduct alpha and beta branch analysis, clusters along each branch were isolated and 
loaded into Monocle separately. Genes that changed significantly as a function of pseudotime 
were identified with Monocle’s differentialGenetest function, and those that displayed a q-value 
less than 0.001 were selected for downstream analysis. These genes were then plotted as a 
heatmap (using plot_pseudotime_heatmap) that clustered genes based on similarities in 
expression patterns along pseudotime. The expression of individual genes was plotted using 
Monocle’s plot_genes_in_pseudotime function.  
 
For the pseudotemporal ordering analysis of our merged human fetal and hESC-derived cell 
datasets, we utilized Monocle3 v0.1.0 (named Monocle 3 beta). We used this version of 
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Monocle3 given its internal batch correction capabilities. For our merged human fetal 
pseudotemporal ordering analysis, variable genes from the Seurat3 integration analysis were 
used as input into Monocle. Clusters were projected onto the minimum spanning tree after 
ordering.  
 
For our merged hESC-derived analysis, variable genes from CHGA+ sub-clustering were used 
as input into Monocle. To batch correct based on sample type, the residual_model_formula_str 
was set to "~ orig.ident” during the pre-process_cds step. To conduct branch-specific analyses, 
the choose_cells function was used to manually select the branches of interest in Monocle’s 
graphical user interface. Once branches were selected, genes that changed significantly along 
pseudotime were identified using the graph_test function. Genes of interest were plotted along 
the Monocle trajectory using the plot_cells function.  
 
Genetic engineering of the FEV-KO hESC line 
The HUES8 hESC line was used to generate our FEV-KO line. For the FEV-KO hESC line, the 
FEV-KO gRNA (5’-CTGATCAACATGTACCTGCC-3’) was designed on Benchling software and 
ordered from Dharmacon in a lyophilized format. The gRNA was suspended nuclease-free 
10mM Tris-HCl Buffer (pH 7.4) ordered from Dharmacon (cat. no. B-006000-100) and stored as 
aliquots in -80C. HUES8 hESCs were grown on Matrigel-coated tissue culture plates, and on 
the morning of nucleofection, media was changed to mTeSR1 + 10 μM Rock inhibitor Y-27632 
for 2 hours prior to nucleofection. Following this incubation step, hESCs were lifted from 
Matrigel plates and dissociated into a single-cell suspension using TrypLE Express. Cells were 
incubated in TrypLE Express dissociation reagent for 6 mins at RT. mTeSR1 + 10 μM Rock 
inhibitor Y-27632 was used to neutralize the dissociation, and cell suspension was filtered 
through a 37um filter.  
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To carry out the nucleofection, we mixed 2.75uL of tracrRNA (160uM) and 2.75uL of our FEV-
KO gRNA (160uM) (to make the “RNA-complex”) in a PCR strip tube and incubated for 30 mins 
in the 37°C cell culture incubator. After 30 mins, 5.5uL of purified Cas9-NLS protein (QB3 UC 
Berkeley MacroLab) was added to the RNA complex, gently mixed to make the RNP 
(ribonucleoprotein), and incubated at 37°C for exactly 15 mins. After exactly 15 mins, previously 
dissociated cells were resuspended in Lonza’s P3 buffer from the P3 Primary Cell 4D-
Nucleofector X Kit S (V4XP-3032). 10uL of cell suspension containing 400K cells were pipeted 
into one well of the Lonza nucleofection strip, and 10uL of the RNP was added. The 
nucleofection strip was then inserted into the Lonza 4D-Nucelofector (Lonza, AAF-1002B) and 
nucleofected with the CA137 setting compatible with the P3 buffer. Nucleofected cells were then 
transferred to a 15mL conical with 3mL of mTeSR1 containing 10 μM Rock inhibitor Y-27632 
and pen/strep. Cell viability was determined via Moxiflow, and cells were plated in one well of a 
6-well plate coated with Matrigel. Cells were grown for 2-3 passages in mTeSR1 containing 
10 μM Rock inhibitor Y-27632 and pen/strep to allow for recovery from nucleofection.  
 
To determine genomic editing efficiency of the FEV-KO nucleofection experiment, genomic DNA 
from nucleofected cells was harvested in QuickExtract DNA Extraction (Lucigen, QE09050) and 
then used for PCR amplification. The following forward and reverse primers targeting the FEV-
KO editing site were used to produce a 491-bp amplicon: 5’-CCGTCTTCTCCTCCTTGTCACC-
3’ and 5’-CTCGGCCACAGAGTACTCCAC-3’. This amplicon is GC-rich, requiring use of a PCR 
polymerase capable of handling GC-rich amplicons (PrimeSTAR GXL Premix, Clontech). This 
DNA amplicon (and a wildtype DNA amplicon) was sent to Quintarabio for Sanger sequencing. 
The chromatographs of each sequencing run were used for TIDE (Tracking of Indels by 
Decomposition) analysis, which estimates the frequency of insertions and deletions (indels) in a 
pool of cells that has undergone genomic editing (https://tide.deskgen.com) (Brinkman et al., 
2014). Cutting efficiency of hESCs nucleofected with FEV-KO gRNA was then determined.  
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To derive a clonal FEV-KO line from this heterogeneous pool of hESCs that have no mutation in 
the FEV locus, a mutation(s) in one FEV allele, or mutations on both FEV alleles, we clonally 
plated these cells on Matrigel-coated plates. Approximately 1.5K cells were dispersed onto a 10 
cm Matrigel-coated plate and allowed to grow for 9-10 days in mTeSR1. For the first 4-5 days of 
culture, cells were cultured in mTeSR1 containing 10 μM Rock inhibitor Y-27632. Clonal 
colonies were then hand-picked under a colony-picking microscope under sterile conditions. 
These hand-picked colonies were each transferred into one well of a 96-well plate, allowed to 
grow for 2-3 days, and then successively passaged into large plate formats (96-well to 24-well 
to 6-well to 10cm dish). Clonality was first determined through TIDE analysis as outlined above 
and confirmed with TOPO cloning of the FEV-KO PCR amplicon.  
 
Genetic engineering of the FEV-KI hESC lines 
The HUES8 hESC line was used to generate our FEV-MYC, FEV-GFP, and FEV-tNGFR lines. 
The MYC, GFP, and tNGFR inserts were all commercially synthesized as gene blocks from 
Integrated DNA Technologies. 5’ and 3’ FEV locus homology arms that were 400bp in length 
were then added to each of the MYC, GFP, and tNGFR gene blocks using In-Fusion HD 
Cloning (Clontech, 638920). These homology arms flanked the cut site targeted by our FEV-KI 
gRNA. The result of In-Fusion HD cloning was a pUC19 plasmid containing a MYC, GFP, or 
tNGFR insert flanked by 5’ and 3’ FEV homology arms. These plasmids were transformed into 
Stellar Competent Cell (Clontech, 636766), and PCR amplification off of these isolated plasmids 
generated a PCR amplicon for use as our targeting template to knock in MYC, GFP, and tNGFR 
into the FEV locus. The following forward and reverse primers were used in PCR to generate 
each targeting template from each plasmid: 5’-TGAACTACGACAAGCTGAGCCG-3’ and 5’-
TCCTTGGGGAAGAGCAAAAGTG-3’.  
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For knock-in of MYC, GFP, and tNGFR into the FEV locus, a FEV-KI gRNA 
(GCCATTACCACTAGACGGGG) was designed using Benchling software and targeted the end 
of exon 3 of the FEV locus. This FEV-KI gRNA cut immediately preceding the FEV stop codon 
found at the end of exon 3 and would facilitate the knock-in of each insert in-frame with the FEV 
locus. On the morning of nucleofection, HUES8 hESCs were fed with mTeSR1 + 10 μM Rock 
inhibitor Y-27632 for 2 hours. Following this incubation step, hESCs were lifted from Matrigel-
coated plates and dissociated into a single-cell suspension using TrypLE Express. Cells were 
incubated in TrypLE Express dissociation reagent for 6 mins at RT. mTeSR1 + 10 μM Rock 
inhibitor Y-27632 was used to neutralize the dissociation, and cell suspension was filtered 
through a 37um filter.  
 
To carry out the nucleofection, we mixed 1.25uL of tracrRNA (160uM), 1.25uL of our FEV-KI 
gRNA (160uM), and 1ug of either the MYC, GFP, or tNGFR targeting templates in a PCR strip 
tube and incubated for 30 minutes in the 37C cell culture incubator. After 30 mins, 2.5uL of 
purified Cas9-NLS protein (QB3 UC Berkeley MacroLab) was added, gently mixed to make the 
RNP complex, and incubated at 37C for exactly 15 minutes. Dissociated cells were pelleted at 
1000rpm for 3 mins and resuspended in Lonza P3 buffer (Lonza, V4XP-3032). 10uL of cell 
suspension containing 400K cells were then pipeted into a Lonza cuvette, and 10uL of the RNP 
complex + targeting template was added. The cuvette was then inserted into the Lonza 4D-
Nucelofector (Lonza, AAF-1002B) and nucleofected with the CA137 setting compatible with the 
P3 buffer. Nucleofected cells were then transferred to a 15mL conical with 3mL of mTESR 
containing 10 μM Rock inhibitor Y-27632 and pen/strep. Cell viability was determined via 
Moxiflow, and cells were plated in one well of a 6-well plate coated in Matrigel. Cells were grown 
for 2 passages to allow for recovery from nucleofection.  
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To determine if the MYC, GFP, and tNGFR inserts were successfully knocked-in, genomic DNA 
from nucleofected cells was harvested in QuickExtract DNA Extraction (Lucigen, QE09050) and 
used for PCR amplification. The following forward and reverse primers were used:  
MYC: 5’-AGATCCAGCTGTGGCAGTTTCT-3’ and 5’-ACCAGACAAGGATTGAGGGAGC-3’ 
GFP: 5’-CGTGCATCTGGAAAGCTACGTG-3’ and 5’-CTTGAAGAAGTCGTGGCGCTTC-3’ 
tNGFR: 5’-TGAACTACGACAAGCTGAGCCG-3’ and 5’-TCCTTGGGGAAGAGCAAAAGTG-3’ 
Presence of a knock-in band that was larger than the FEV wildtype band was indicative that a 
subset of nucleofected cells carried the insert. 
 
To derive clonal FEV-KI lines from a heterogeneous pool of hESCs that either had the knock-in 
insert or not, we clonally plated these cells on Matrigel-coated plates. Approximately 1.5K cells 
were dispersed onto a 10cm Matrigel plate and allowed to grow for 9-10 days in mTeSR1. For 
the first 4-5 days of culture, cells were cultured in mTeSR1 containing 10 μM Rock inhibitor Y-
27632. These hand-picked colonies were each transferred into one well of a 96-well plate, 
allowed to grow for 2-3 days, and then successively passaged into large plate formats (96-well 
to 24-well to 6-well to 10cm dish). Genomic DNA was isolated from each clonal line and the 
insert was confirmed through PCR using same primers as indicated above. Sanger sequencing 
of the genomic FEV locus confirmed that the MYC, GFP, and tNGFR had no mutations and was 
in-frame with the endogenous FEV locus.  
 
Generation of gene KOs during directed differentiation of hESCs 
Approximately 100-150e6 End Stage 4 (ES4) cells from our directed differentiation protocol 
were dissociated in Accumax for 15-25 mins in a 37°C water bath. The dissociated cell 
suspension was passed through a 37um filter. Cell count and viability were determined with a 
Moxiflow cell counter. Cells were pelleted at 1000rpm for 3 mins and kept in ES4 media until 
nucleofection. 
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For nucleofection, we used the large format of Lonza’s nucleofection kits (P3 Primary Cell 4D-
Nucleofector X Kit L, V4XP-3024), which accommodates nucleofection of up to 20e6 cells per 
nucleofection vessel. Four conditions were typically included in these experiments: non-
nucleofected control, scramble control, hAAVS1 control, and KO of gene of interest. The non-
nucleofected control group contained ES4 cells that did not go through nucleofection. The 
scramble control group contained ES4 cells that were nucleofected with a scramble gRNA 
(GGTTCTTGACTACCGTAATT) that is not predicted to cut anywhere in the human genome. 
The hAAVS1 control included ES4 cells that were nucleofected with a gRNA targeting a safe 
harbor locus in the human genome AAVS1 (GGGGCCACTAGGGACAGGAT). The KO of gene 
of interest group contained ES4 cells that were nucleofected with a gRNA targeting the gene of 
interest we wished to knock out. All gRNAs were ordered from Dharmacon. 
 
For each nucleofection set of 10-20e6 ES4 cells, we mixed 9.5uL of tracrRNA (160uM), 9.5uL of 
our FEV-KI gRNA (160uM) in a PCR tube and incubated for 30 minutes in the 37°C cell culture 
incubator. After 30 mins, 19uL of purified Cas9-NLS protein (QB3 UC Berkeley MacroLab) was 
added, gently mixed to make the RNP complex, and incubated at 37°C for exactly 15 minutes. 
Dissociated ES4 cells were pelleted at 1000rpm for 3 mins, and each set of 10-20e6 ES4 cells 
were resuspended in 64uL of Lonza P3 buffer (from V4XP-3024). Each set of cells were then 
pipetted into a large Lonza nucleofection vessel, and 36uL of the RNP were added. 
Nucleofection vessel was then inserted into the Lonza 4D-Nucelofector (Lonza, AAF-1002B) 
and nucleofected with the CA137 setting compatible with the P3 buffer. Nucleofected cells were 
then transferred to a 15mL conical with 10mL of S5D1 media. Cell viability was determined via 
Moxiflow. 
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Following nucleofection, cells were immediately re-aggregated into clusters using AggreWell 
400 plates (STEMCELL Technologies, 34415). Wells in the AggreWell 400 plates were washed 
with an Anti-Adherence Rinsing Solutions (STEMCELL Technologies, 07010) and centrifuged in 
a swinging bucket rotor at 1300 x g for 5 mins. Rinsing solution was removed, and S5D1 media 
was used to rinse wells. S5D1 media was aspirated, and 1.2e6 cells were then pipeted into each 
well of an AggreWell 400 plate. Plates were spun at 100 x g for 3 mins to facilitate re-
aggregation of cells in each microwell and then were observed under microscope to verify even 
distribution of cells among microwells. Plates were placed in the 37°C cell culture incubator, and 
spheroids formed by 48 hours (by S5D3). On S5D3, clusters were removed from the AggreWell 
plates and cultured in either miniature spinner flasks called Biotts (BWV-S03A) set at a 70rpm 
rotation speed or in 6-well ultra low-attachment plates (5mL of media with approximately 5e6 
cells per well) placed on an orbital shaker set to 100rpm. Directed differentiation of these 
nucleofected clusters was continued either in Biotts or in a 6-well ultra low-attachment plate. 
 
FACS of hESC-derived cells 
BLC clusters were dissociated in Accumax for 15-25 mins in a 37°C water bath. The dissociated 
cell suspension was passed through a 37um filter. Cells were pelleted at 1000rpm for 3 mins 
and fixed in 4% PFA for 12 mins at RT. Cells were washed in 1X PBS, pelleted again, and 
resuspended in 1X PBS. Fixed cells were stored in 4°C prior to staining for FACS. 
 
For FACS staining, cells were permeabilized using 1X Permeabilization Buffer (Invitrogen, 00-
8333-56) for 5 mins at RT. Cells were then incubated in primary antibody diluted in Blocking 
reagent (0.2% Triton X-100, 5% NDS, 1% Bovine Serum Albumin (BSA) in 1X PBS) overnight at 
4C. Primary antibodies used were anti-Chromogranin A (1:500, Abcam ab15160) and anti-C-
Peptide (1:200, EMD Millipore 05-1109). The next day, cells were washed in 1X 
Permeabilization Buffer for 5 mins at RT and incubated in species-specific Alexa Fluor 488- and 
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555-conjugated secondary antibodies (1:500, Jackson ImmunoResearch) for 30 mins at RT. 
Cells were then washed in 1X Permeabilization Buffer, pelleted, resuspended in 1X PBS, and 
analyzed with BD Fortessa Analyzer. 
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Figure 3.1. Single-cell RNA-sequencing identifies diverse cellular compartments in 12wpc 
human fetal pancreas. (a) UMAP-based clustering of single cells organized into 22 distinct 
clusters from one 12wpc human fetal pancreas. Each dot represents a single cell and is colored 
based on its assigned cluster identity. Plot to the left represents UMAP-based clustering of cells 
from each of two technical replicate samples run on two different wells of the 10X Chromium 
single-cell sequencing chip. Each technical replicate shows even contribution of cells to each 
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cluster within the merged UMAP. (b) Expression patterns of known marker genes of epithelial 
cells (CHD1+), ductal cells (SOX9+), acinar cells (CPA1+), endocrine cells (CHGA+), 
mesenchymal cells (COLA1A+), endothelial cells (PECAM1+), immune cells (PTPRC+), and 
nerve (SOX10+) cells, revealing the identities of all 22 clusters from UMAP-based clustering. 
Intensity of color indicates level of gene expression. (c) Heatmap showing the top 50 
differentially-expressed genes in each cluster compared to all other clusters. Individual cells are 
represented in each column, and columns of cells derived from the same cluster are grouped 
together. Cluster numbers are consistent with cluster numbering system as shown in (a). Genes 
are represented by rows.  
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Figure 3.2. Endocrine sub-clustering identifies known and novel cell populations in 
12wpc human fetal pancreas. (a) UMAP-based sub-clustering of CHGA+ clusters, as defined 
in Figure 17b, organized into 10 distinct populations. Inset shows CHGA+ clusters from Fig. 
3.1b. (b) Known markers of the endocrine lineage, including NGN3, INS, GCG, SST, and 
GHRL, identifies NGN3+ endocrine progenitors, INS+ beta cells, GCG+ alpha cells, SST+ delta 
cells, and GHRL+ epsilon cells, respectively. FEV expression is also plotted to highlight novel 
populations previously uncharacterized in human pancreatic development. (c) Dot plot 
displaying the top five differentially-expressed genes from each cluster and their expression 
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levels across all 10 endocrine lineage clusters. Size of each dot represents the proportion of 
each population that expresses each specified gene. Color intensity reflects average level of 
gene expression. Genes highlighted in red are referred to in the body of the results section.  
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Figure 3.3. Identification of pre-beta and pre-alpha progenitors in 12wpc human fetal 
pancreas. (a) Violin plots depicting distribution of expression of NGN3, FEV, INS, and GCG, in 
single cells from clusters 6 (common endocrine progenitors), 8 (pre-beta progenitors), 0 (beta 
population #1), 2 (beta population #2), 4 (beta population #3), 9 (pre-alpha progenitors), and 1 
(alpha population). Each dot represents the gene expression of a single cell, and the colored 
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distributions (“violins”) represent the spread of gene expression within each cluster. (b) 
Pseudotemporal ordering using Monocle 3 of common endocrine progenitors, pre-beta 
progenitors, pre-alpha progenitors, beta cells, and alpha cells (defined as clusters 6, 8, 9, 0, 2, 
and 1). Pseudotime begins at the vertex of the trajectory with common endocrine progenitors 
(cluster 6). Two differentiation arcs emanate from this cluster, leading to alpha and beta linages. 
Pre-beta progenitors (cluster 8) are placed immediately before differentiation into beta cells 
along pseudotime, and pre-alpha progenitors (cluster 9) are positioned immediately before 
differentiation into the alpha cell lineage. Second plot represents pseudotemporal ordering using 
the third beta cell population (Beta 3) as an additional input. Third plot represents 
pseudotemporal ordering of all endocrine lineages found in our 12wpc human fetal pancreas. (c) 
Gene expression intensity plots depicting gene expression in individual cells placed along 
pseudotime. Color intensity reflects level of gene expression.  
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Figure 3.4. Transcriptomic profile comparison among pre-beta, pre-alpha, and common 
endocrine progenitors. (a) Pseudotemporal ordering highlighting cell populations (common 
endocrine progenitors, pre-beta progenitors, and pre-alpha progenitors) used for pairwise 
comparisons. (b-d) Pairwise comparisons among clusters 6 (common endocrine progenitors), 8 
(pre-beta progenitors), and 9 (pre-alpha progenitors). Heatmaps depict the genes expressed 2-
fold or greater in each comparison. 
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Figure 3.5. Identification of candidate regulators of beta lineage allocation in human 
endocrine cell development. (a) Heatmap depicting gene expression of cells (represented by 
columns) as a function of pseudotime across beta cell differentiation. Pseudotime begins with 
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common endocrine progenitors (cell cluster 6), followed by pre-beta progenitors (cell cluster 8), 
and ends with beta cell populations (cell clusters 0 and 2). Each individual row on the heatmap 
represents a gene, and the color intensity represents its expression along pseudotime. Genes 
that change significantly as a function of pseudotime are grouped in 7 main gene clusters: those 
that are highly expressed at the beginning of pseudotime (gene clusters 2, 3, and 4), genes that 
are upregulated during the pre-beta progenitor stage but taper in expression as beta cell identity 
is acquired (gene clusters 6 and 7), and genes that are upregulated during the pre-beta 
progenitor stage and remain expressed in the differentiated beta cell stage (gene clusters 1 and 
5). (b-e) Pseudotime gene expression plots highlighting genes known to be downregulated as 
differentiation into the beta lineage occurs (b), genes known to be upregulated during beta cell 
differentiation (c), novel candidate regulators of beta cell lineage allocation that are imprinted 
(d), genes previously identified in the development and function of the nervous system (e), and 
those have known functions as a DNA-binding protein or in canonical signaling pathways, such 
as Activin A signaling (e). In (b-e), each dot represents the gene expression a single cell placed 
along pseudotime, and the color of the dot denotes its original cluster identity, which 
corresponds to the cell differentiation scheme outlined in (a). The black curve maps the average 
gene expression as a function of pseudotime. (f) Model for beta cell differentiation in human 
fetal pancreatic development.  
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Figure 3.6. Identification of candidate regulators of alpha lineage allocation in human 
endocrine cell development. (a) Heatmap depicting average gene expression of cells as a 
function of pseudotime during alpha cell differentiation. Pseudotime begins with common 
endocrine progenitors (cluster 6), followed by pre-alpha progenitors (cluster 9), and ends with 
differentiated alpha cells (cluster 1). Each individual row on the heatmap represents a gene, and 
the color intensity represents its expression along pseudotime. Genes that change significantly 
as a function of pseudotime are grouped in 6 main gene clusters: those that are highly 
expressed at the beginning of pseudotime (gene clusters 2 and 3), genes that are upregulated 
during the pre-alpha progenitor stage but taper in expression as alpha cell identity is acquired 
(gene cluster 5), and genes that are upregulated during the pre-alpha progenitor stage and 
remain expressed in the differentiated alpha cell stage (gene clusters 1, 4, and 6). (b-e) 
Pseudotime gene expressions plots highlighting genes known to be expressed by the adult 
alpha cell lineage (b), genes known to be upregulated specifically during alpha cell 
differentiation (c), and novel candidate regulators of alpha cell lineage allocation that have 
previously been identified in the development and function of the nervous system (d) or are cell 
surface markers and channels (e). In (b-e), each dot represents the gene expression a single 
cell placed along pseudotime, and the color of the dot denotes its original cluster identity, which 
corresponds to the cell differentiation scheme outlined in (a). The black curve maps the average 
gene expression as a function of pseudotime. (f) Model for alpha cell differentiation in human 
fetal pancreatic development.  
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Figure 3.7. Human fetal pancreatic populations over developmental time. (a) UMAP-based 
clustering of merged cell populations from 12wpc_1, 12wpc_2, 15.5wpc, and 16wpc samples. 
Merging of these four datasets was accomplished using Seurat 3’s Integration method. (b) 
UMAP clustering of each sample and technical replicate (if any) showing contribution of 
designated sample to overall merged UMAP clustering shown in (a). The 12wpc_1, 12wpc_2, 
and 16wpc samples were each run on two lanes of the 10X Chromium single-cell sequencing 
 141	
chip, while the 15.5wpc sample, which was enriched for EPCAM+ cells, was run on only one 
lane of the 10X chip. (c) Known marker genes of epithelial cells (EPCAM+), ductal cells 
(SOX9+), acinar cells (CPA1+), endocrine cells (CHGA+), mesenchymal cells (COLA1A+), 
endothelial cells (PECAM1+), immune cells (PTPRC+), and nerves (SOX10+), showing the 
identities of all 31 clusters from UMAP-based clustering. Color indicates level of gene 
expression. 
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Figure 3.8. Human fetal endocrine populations over developmental time. (a) UMAP-based 
clustering resulting from endocrine sub-clustering of CHGA+ clusters from merged dataset (Fig. 
3.7a) organized into 16 distinct populations. (b) Sample ID mapped onto UMAP depicts 
contribution of each timepoint (and associated technical replicate, if any) to each merged 
cluster. (c) Gene expression intensity plots highlighting NGN3+ progenitors, FEV+ cells, INS+ 
beta cells, GCG+ alpha cells, SST+ delta cells, and GHRL+ epsilon cells. (d) Dot plot displaying 
the top three differentially-expressed genes from each cluster and their expression levels across 
all 16 endocrine lineage clusters. Size of each dot represents the proportion of each population 
that expresses each specified gene. Color intensity reflects average level of gene expression. 
(e) Pseudotime ordering with Monocle 3 using endocrine progenitors and the alpha and beta 
lineages as input. Both the sample ID and mitochondrial content are mapped onto the 
pseudotime ordering trajectory, highlighting significant batch effect that is not corrected due to 
inclusion of 15.5wpc sample. 15.5wpc sample displays significantly lower mitochondrial content, 
which drives batch effect.  
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Figure 3.9. Single-cell RNA-sequencing identifies heterogeneous cellular compartments 
in hESC-derived endocrine progenitor populations. (a) Schematic depicting the six stages of 
the protocol for in vitro beta cell differentiation, highlighting End Stage 4 pancreatic progenitors 
and Stage 5 endocrine progenitors taken for single-cell RNA-sequencing. (b) UMAP-based 
clustering of ES4 (end stage 4), S5D4, and S5D7 cells. (c-e) Blended expression plots highlight 
cells that express either both PDX1 and NKX6-1 or NEURDO1 and CHGA. Gene expression 
plots of NGN3, TOP2A, CDX2, INS, and GCG highlight endocrine progenitors, replicating cells, 
cells that mis-differentiated into a CDX2+ intestinal lineage, and hormone-expressing 
populations, respectively.  
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Figure 3.10. Single-cell RNA-sequencing identifies heterogeneous cellular compartments 
in hESC-derived beta-like stage cells. (a) Schematic depicting the six stages of our in vitro 
beta cell differentiation, highlighting Stage 6 beta-like cells taken for single-cell RNA-
sequencing. (b) UMAP-based clustering of S6D4 and S6D10 beta-like stage cells organized into 
distinct clusters. (c, d) Blended expression plots highlight cells that express either both PDX1 
and NKX6-1 or NEURDO1 and CHGA. Gene expression plots of CDX2, INS, and GCG cells 
that represent cells mis-differentiated into a CDX2+ intestinal lineage or hormone-expressing 
populations, respectively.  
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Figure 3.11. Emergence of FEV+ cells during in vitro beta cell differentiation. (a) qPCR 
(Taqman) data depicting FEV expression throughout the directed differentiation of hESCs 
towards the beta lineage. FEV expression in isolated adult human islets shown as a 
comparator. (b) Dual in situ hybridization and immunofluorescence on S5D3 and S6D11 hESC-
derived clusters. FEV transcript is represented in red, and DAPI staining is in blue. For S5D3 
clusters, green represents PDX1. For S6D11 clusters, green represents CHGA. (c) FEV 
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expression plots from ES4, S5D4, S5D7, S6D4, and S6D10 single-cell RNA-sequencing. (d) 
Heatmaps depicting the results of a Pearson’s correlation analysis comparing FEV+ progenitors 
from 12wpc_1 and 12wpc_2 human fetal datasets with FEV+ clusters found in each sampled 
timepoint of directed differentiation. Color denotes level of correlation with FEV+ progenitors 
from 12wpc_1 and 12wpc_2 human fetal datasets, where shades of red reflect high 
transcriptional correlation.  
 
  
 148	
 
Figure 3.12. Reconstruction of lineage relationships among hESC-derived endocrine 
cells during in vitro beta cell differentiation. (a) UMAP-based clustering of merged CHGA+ 
clusters from ES4, S5D4, S5D7, S6D4, and S6D10 timepoints. (b) Timepoint IDs are mapped 
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onto UMAP clusters to illustrate the contribution of each timepoint to each resulting merged 
cluster. (c) Pseudotemporal ordering of the merged dataset using Monocle 3 depicts one main 
differentiation trajectory. Timepoint IDs mapped onto the trajectory reveals a cluster of ES4 cells 
at one end of the trajectory, which we designate as the beginning of our pseudotime ordering 
analysis. (d) Monocle trajectory with highlighted clusters labeled by their cluster identity as 
found in (a). (e) Gene expression intensity plots depicting INS, GCG, and SST expression in 
individual cells placed along pseudotime highlight the poly-hormonal and INS+ beta cell 
branches in the differentiation trajectory. FEV gene expression intensity plot depicts uniform 
FEV expression throughout the majority of pseudotime. (f) Gene expression intensity plots 
depicting PHOX2A, TLX2, and TBX2 expression in individual cells placed along pseudotime 
highlight the restriction of these genes in the hormone-negative branch that contains the hESC-
derived cells that are predicted to have mis-differentiated. (g) PHOX2A, TLX2, and TBX2 
expression plots from merged, endocrine sub-clustered UMAP from Fig. 3.8a. (h) Model of a 
bifurcation event of PDX1+/NKX6.1+ progenitors into a mis-differentiated FEV+ lineage and 
hormone-expressing endocrine lineages. 
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Figure 3.13. Assessing the function of FEV in beta cell differentiation and maturation. (a, 
b) Schematic illustrating the FEV locus and the use of CRISPR/Cas9-mediated genomic editing 
to generate a FEV-KO hESC clonal line. A FEV-KO gRNA was designed to target exon 1. 
Genomic editing with this FEV-KO gRNA led to the generation of a FEV-KO hESC clonal line 
with a 1-bp deletion in one allele and a 1-bp insertion in the second allele, leading a 
homozygous mutation in the FEV locus. (c) Illustration of the directed differentiation of FEV-KO 
hESCs towards a beta lineage. (d) FACS analysis of wildtype and FEV-KO pluripotent cells 
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quantifies percentage of cells with pluripotency markers OCT4 and TRA-1-60. FACS analysis of 
wildtype and FEV-KO cells at the completion of Stage 1 of the directed differentiation quantifies 
percentage of cells that have entered into the SOX17+/FOXA2+ definitive endoderm stage. 
FACS analysis of wildtype and FEV-KO cells at Stage 6, Day 11 (S6D11) determines the 
percentage of CHGA+/CPEP+ beta cells present.  
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Figure 3.14. Strategy for identifying transcriptional targets of FEV. (a) Schematic 
illustrating the use of CRISPR/Cas9-mediated genomic editing to generate a FEV-MYC hESC 
line. A FEV-KI (knock-in) gRNA was designed to target the 3’ end of exon 3 of the FEV locus. A 
targeting template containing a 3xMYC sequence flanked by homology arms was also designed 
and commercially synthesized. Through use of genomic editing and homology-directed repair, 
the 3xMYC sequence was knocked-in in frame with the endogenous FEV locus, leading to the 
expression of a FEV-MYC fusion protein to be used for ChIP-seq. (b) Illustration of future plans 
for the directed differentiation of FEV-MYC hESCs towards a beta lineage. Endocrine 
progenitor-stage cells will be harvested and ChIP-seq will be performed using an antibody 
against MYC. The MYC antibody will pull down FEV transcription factor bound to DNA, and 
sequencing of bound DNA will identify transcriptional targets of FEV specifically during this 
endocrine progenitor stage prior to beta cell lineage determination.  
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Figure 3.15. Identifying and isolating FEV-expressing cells during in vitro beta cell 
differentiation. (a) Schematic illustrating the use of CRISPR/Cas9-mediated genomic editing to 
generate two FEV reporter hESC lines: a FEV-GFP and a FEV-tNFGR line. A FEV-KI gRNA 
targets the 3’ end of exon 3 of the FEV locus, and a targeting template containing either a T2A-
GFP or T2A-tNGFR sequence flanked by homology arms was also designed and commercially 
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synthesized. Through use of genomic editing and homology-directed repair, the T2A-GFP or 
T2A-tNGFR sequence was knocked-in in frame with the endogenous FEV locus, leading to 
bicistronic translation of the FEV transcription factor and reporter protein (GFP or tNGFR). (b) 
Illustration depicting future use of our FEV reporter lines, such as our FEV-GFP line, to perform 
small molecule library screens to identify signaling compounds that induce FEV+ progenitor 
replication or enhance beta cell differentiation from FEV+ progenitors. (c) Illustration showing 
future use of our FEV reporter lines to sort and isolate different FEV+ populations, such as a 
predicted mis-differentiated FEV+ cell population, throughout in vitro beta cell differentiation.  
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Figure 3.16. Development of a platform to functionally validate candidate beta lineage 
regulators. (a) Illustration depicting isolation of endocrine progenitor-stage cells for gene-
knockdown via CRISPR/Cas9 genomic editing. Endocrine progenitor-stage clusters will be 
dissociated and nucleofected with Cas9 and a gRNA targeting a candidate beta lineage 
regulator. These edited endocrine progenitor-stage cells will then be re-aggregated and 
differentiated towards the beta lineage to determine if knockdown of specific candidate beta 
lineage regulators result in reduced beta cell differentiation.  
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Chapter 4 
Conclusions and Future Directions 
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In this work, we have constructed a roadmap of murine pancreatic development by 
generating transcriptional profiles of known and novel cell populations in both the epithelial and 
mesenchymal compartments and inferring lineage relationships across developmental time 
(Chapter 2). Our discovery of a novel endocrine progenitor population defined by high Fev 
expression in mouse prompted us to examine human pancreatic development and uncover 
previously underappreciated heterogeneity in the endocrine compartment during differentiation 
(Chapter 3). We extended our findings from mouse to human and identified FEV-expressing 
endocrine progenitor populations in human pancreatic development. Using in silico modeling to 
construct lineage relationships, we mapped the transcriptional dynamics of human endocrine 
cell differentiation and identified candidate lineage regulators of human alpha and beta lineage 
allocation. We subsequently identified major differences present between human endocrine cell 
differentiation in vivo during development versus current in vitro methods to produce beta cells 
from hESCs. Our analyses identified a potential mis-differentiated lineage that formed as hESC-
derived pancreatic progenitors differentiated towards a beta lineage. Blocking the generation of 
this mis-differentiated lineage during in vitro beta cell differentiation may be powerful approach 
to making in vitro beta cell differentiation more efficient and more reflective of in vivo beta cell 
development. Thus, our work forms a foundation on which improvements to in vitro beta cell 
differentiation can be made to more closely reflect proper endocrine cell development in vivo, to 
ideally increase both the yield and functionality of beta-like cells that are generated at the 
completion of the directed differentiation protocol. 
 
Transcriptional stages and regulators of endocrine lineage allocation 
 
 How a seemingly homogenous endocrine progenitor population marked by Ngn3 
expression gives rise to a diversity of hormone-expressing lineages in the pancreas has been a 
subject of intense research. Our single-cell transcriptional dataset strengthened our 
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understanding of the events that occur following Ngn3 downregulation and before endocrine cell 
specification in both mouse and human. In mouse, the time between Ngn3 downregulation and 
hormone acquisition is reported to be only on the order of 12 hours (Beucher et al., 2012b). This 
short time window is also thought to be preserved in human cells but has not been 
experimentally determined (Jennings et al., 2015). It is possible that endocrine lineage 
commitment to a specific hormone-expressing cell type has already been made at the Ngn3-
expressing stage and occurs prior to Ngn3 downregulation. However, our analyses in both 
mouse and human pancreatic development suggested that commitment to a specific hormone 
lineage may occur at a stage following Ngn3 expression. In our in silico reconstruction of 
endocrine cell differentiation, we observed Fev/FEV-expressing progenitors that appeared to 
become specified towards one hormone lineage over the other. This observation was not made 
in the common Ngn3/NGN3-expressing progenitor population present in both mouse and 
human, suggesting that commitment to a hormone lineage does not occur in this Ngn3/NGN3-
expressing stage. One possible mechanism through which these pre-fated endocrine progenitor 
and differentiated hormone-expressing lineages are compartmentalized is via Wnt signaling. 
Inhibition of Wnt signaling promotes beta cell differentiation from hESC-derived endocrine 
progenitors in vitro (Sharon et al., 2019b). Wnt signaling may serve as a key regulator that 
ensures that post-Ngn3/NGN3+ endocrine progenitors have enough time to become specified 
towards a specific hormone-expressing lineage. Future work should focus on elucidating the 
precise cellular stages of endocrine lineage commitment. 
 Our work has uncovered candidate transcriptional regulators of alpha and beta lineage 
allocation in both murine and human endocrine cell development. Validation of their functional 
significance should be performed next. For candidate alpha lineage regulators, genetic knockout 
mice can be generated and studied for alpha cell differentiation defects. Mouse pancreatic 
explants also represents another method with which these candidate alpha regulators can be 
knocked down via viral transduction of gene-specific shRNA. This strategy can also be 
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leveraged in the directed differentiation of hESCs to glucagon-expressing alpha cells to validate 
the human alpha lineage regulators we have identified (Rezania et al., 2011). Similarly, our in 
vitro beta cell differentiation platform represents a method for validating the function of 
candidate beta lineage regulators. Using the CRISPR/Cas9-mediated gene knockdown system 
that we have developed, candidate beta lineage regulators can be specifically knocked down in 
endocrine progenitors to determine if differentiation to the beta lineage is impaired. Use of a 
human fetal pancreatic explant system may also represent an alternative system to functionally 
test these beta lineage regulators in a non-artificial, non-hESC-based system. 
 
The role of the epigenome in endocrine lineage specification 
 
 Application of a recently developed technique called single-cell Assay for Transposase-
Accessible Chromatin using sequencing (scATAC-seq) to endocrine progenitors could identify 
endocrine progenitor heterogeneity at the epigenetic level. Although transcriptionally similar, 
certain subsets of NGN3+ and FEV+ progenitors may differ dramatically in their potential to give 
rise to a specific hormone lineage. Specifically, are there NGN3+ or FEV+ progenitors present 
in pancreatic development that are differentially primed to express specific combinations of 
alpha or beta-specific genes? This technology can also be applied to PDX1+ pancreatic 
progenitors to determine if hormone-lineage specification extends even before the NGN3-
expressing endocrine progenitor stage.  
 
Function of FEV in human endocrine cell development 
The transcription factor FEV was expressed at multiple stages of human endocrine cell 
development. FEV expression was one defining feature of pre-alpha and pre-beta progenitors 
found in our single-cell transcriptomic profiling of 12wpc pancreas. In our in silico reconstruction 
of lineage relationships, these FEV-expressing pre-alpha and pre-beta progenitors emerged 
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after the NGN3-expressing common progenitor population, which is concordant with Fev being 
a transcriptional target of Ngn3 in mouse pancreatic development (Ohta et al., 2011). Unlike in 
the murine pancreas, however, FEV was only observed to be expressed in differentiated alpha 
cells and not beta cells in human fetal pancreas, suggesting that beta cells downregulate FEV 
upon differentiation into the beta lineage from pre-beta, FEV-expressing progenitors. In the 
human beta lineage, given that FEV was expressed in the pre-beta progenitor stage and 
appeared to be an important transcription factor for human beta cell differentiation, elucidation 
of its transcriptional targets will enhance our understanding of beta cell differentiation. This can 
be done either with human fetal tissue, using a FEV antibody suitable for ChIP-seq, or with cells 
from in vitro beta cell differentiation, leveraging the FEV-MYC hESC line whose construction we 
have described in this work. Identifying the transcriptional targets of FEV along the alpha 
lineage will also yield new insights into the transcriptional regulation of alpha cell differentiation. 
Identification of transcriptional targets along alpha cell differentiation and how they differ from 
those along beta cell differentiation will further our understanding of the transcriptional networks 
that regulate fate restriction of endocrine progenitors as they differentiate into distinct lineages. 
Given that FEV expression was retained in differentiated alpha cells, future work should also 
determine the role of FEV in alpha cell function.  
Possible functions of FEV in human endocrine cell development may also be gleaned 
from known transcriptional targets of Fev in mouse serotonergic neurons and beta cells. In 
serotonergic neurons, Fev activates genes required for the acquisition of serotonin transmitter 
identity and for the functional maturation of serotonergic neurons into excitable cells in the brain 
(Wyler et al., 2016). In mouse insulinoma cells, Fev binds to the Insulin1 and Insulin2 promoters 
and regulates their transcription (Ohta et al., 2011). A comparison between Fev targets in the 
brain compared to those of the pancreas may offer insight into shared transcriptional circuitry 
that regulates both differentiation and function of serotonergic neurons and beta cells. These 
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insights can then be applied to future work investigating the targets of FEV along the process of 
human endocrine cell differentiation.  
 
The role of the changing microenvironment during endocrine cell differentiation 
 In addition to intrinsic programs that dictate endocrine lineage allocation, the surrounding 
microenvironment may play a significant role in shaping these decisions. In both our murine and 
human studies, we have identified significant heterogeneity in multiple compartments of the 
surrounding microenvironment, including the mesenchyme, vasculature, nerves, and immune 
system. Several subpopulations within each of these compartments may influence endocrine 
cell development by promoting one hormone-expressing lineage over others. In mouse, we 
classified the developing mesenchyme into different cell populations across developmental time 
based on transcriptional heterogeneity. For instance, the mesothelium, a mesenchymal 
population within the developing pancreas, formed as the pancreatic epithelium developed. As 
the mesothelium matured, the profile of the factors it secreted changed, and the shift of 
mesothelium-derived secreted factors may provide critical cues that drive endocrine cell 
development. Similar to in mouse, several mesenchymal populations emerged in human 
pancreatic development, and the impact that these different mesenchymal cells have on the 
endocrine cell compartment is relatively unexplored in human pancreatic development. Multiple 
endothelial, neural, and immune populations also emerged across human development. 
Mapping how these non-epithelial populations change throughout the course of pancreatic 
development may yield new insight into how these populations influence endocrine cell 
development at discrete developmental times through secreted factors or direct physical 
interaction.  
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Improving strategies to generate beta-like cells in vitro  
 The ability to generate the insulin-producing, beta lineage from hESCs stems from 
knowledge of how beta cells form in vivo. With new insight gained from our mouse and human 
studies on endocrine cell development, we can implement modifications to the existing methods 
of in vitro beta cell differentiation. From our in vivo human fetal single-cell datasets, we can 
determine which transcriptional regulators are upregulated during proper beta cell 
differentiation. Following validation of these candidate beta lineage regulators, we can then 
determine if any of these transcriptional regulators fail to become expressed in existing in vitro 
beta cell differentiation protocols. If so, the addition of specific exogenous growth factors can be 
utilized to specifically activate gene expression of fundamental regulators of beta cell 
differentiation. Properly mimicking the transcriptional beta cell differentiation program may not 
only improve efficiency of beta cell differentiation in vitro but may also produce beta cells that 
display improved function and maintain this function over time.  
Inhibition of mis-differentiation will also improve current methods of beta cell 
differentiation in vitro. In our in vitro beta cell differentiation platform, we uncovered a mis-
differentiated lineage that resembled cells of the noradrenergic lineage defined by PHOX2A 
expression. Additionally, the generation of an enterochromaffin (EC) lineage from the same 
endocrine progenitor stage that gives rise to the beta lineage was observed (Veres et al., 2019). 
Effectively suppressing the emergence of these lineages during the process of generating beta 
cells from hESCs is expected to improve yield outcomes, which is an important consideration 
when there is a need to generate enough beta cells for eventual human clinical transplantation. 
For instance, use of BMP and cAMP inhibitors may prevent the emergence of the PHOX2A+ 
noradrenergic lineage, and use of small molecules that suppress EC differentiation may inhibit 
the formation of ECs during beta cell differentiation.  
Finally, since beta cell development does not occur in isolation, the addition of specific 
cell types and/or their secreted factors to defined stages along beta cell differentiation may also 
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improve efficiency of in vitro beta cell differentiation or function of the resulting hESC-derived 
beta cells. For instance, the pancreatic or endocrine progenitor cell stages of in vitro beta cell 
differentiation may benefit from the additional of specific mesenchymal, endothelial, or nerve 
cells that are observed to interact with endocrine progenitors in vivo. With the transcriptomic 
data we have at single-cell resolution of these populations present through human pancreatic 
development, future work can isolate specific populations and perform co-culture studies in 
conjunction with in vitro beta cell differentiation. Isolation of these cells can also enable 
generation of primary cell lines that can be stably maintained in culture for use in co-culture 
studies. Alternatively, deeper analysis of the transcriptomic profiles of these niche populations 
present in human endocrine cell development can reveal specific combinations of secreted 
factors that can be added in vitro to support beta cell development in lieu of adding the niche 
cells themselves.  
 
In vitro generation of other pancreatic hormone-expressing lineages from FEV+ 
progenitors  
 Although generating beta cells from hESCs is a main focus of the field given their direct 
relevance to diabetes, we must also think beyond the beta cell and towards other islet lineages 
if we wish to assemble hESC-derived beta cells into pseudo-islets that resemble islets in vivo. 
Our murine study of endocrine cell development revealed that the alpha, beta, delta, epsilon, 
and gamma lineages of the pancreas transit through a Fev-expressing cell stage, likely through 
a Fev+ endocrine progenitor stage. Through examining human endocrine cell development, we 
observed that both alpha and beta lineages also are derived from a FEV+ progenitor stage. 
Higher resolution of human endocrine cell differentiation will benefit from increased numbers of 
the delta, epsilon, and gamma cells. Finally, in our in vitro model of beta cell differentiation, cells 
that express SST also appear to transit through a FEV-expressing cell stage, suggesting that 
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human differentiation into at least SST-expressing cells involves transit through a FEV+ 
progenitor.  
Given our findings in murine and human endocrine cell differentiation, it is possible that 
FEV+ progenitors serve as a common endocrine stage that precedes differentiation into all five 
hormone-expressing islet lineages in human. Additional single-cell RNA-sequencing of cells 
enriched in the endocrine lineage will increase the numbers of delta, epsilon, and gamma cells 
that will enable in silico lineage tracing for these lineages. This additional transcriptomic data 
can also identify candidate regulators of delta, epsilon, and gamma lineages. The transcriptional 
drivers of these endocrine lineages have been largely unexplored in both mouse and human, as 
efforts have been mainly focused on the alpha and beta lineages. The FEV+ endocrine 
progenitors we identify in in vitro beta cell differentiation may serve as a launch point for 
generating other non-beta endocrine lineages in vitro. Future work can leverage our FEV 
reporter lines, enrich for FEV+ cells at the endocrine progenitor cell stage, and screen for the 
generation of non-beta endocrine lineages using different cocktails of exogenous growth factors. 
 
Modeling human pancreatic development in a dish 
 This work greatly augments our ability to model human pancreatic development in vitro. 
By applying single-cell RNA-sequencing to both mouse and human pancreatic development, we 
have uncovered novel stages of endocrine cell development that better inform our goal of 
differentiating beta cells from hESCs. Single-cell RNA-sequencing is a valuable tool to learn 
new differentiation trajectories in which genetic lineage tracing in vivo is not possible, such as in 
human fetal development. Applying this tool also enabled the identification of a mis-
differentiated lineage that emerged during in vitro beta cell differentiation. This mis-differentiated 
lineage greatly diminishes the efficiency of generating hESC-derived beta cells. By combining 
the findings from our single-cell sequencing of murine and human pancreatic development and 
of in vitro beta cell differentiation, we can now begin implementing improvements to the current 
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process of the directed differentiation of beta cells such that we can soon generate functional 
beta cells more efficiently for cellular replacement therapy for individuals with diabetes mellitus.  
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